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Abstract 
Cancer is a serious health problem in the world, both in terms of morbidity and mortality. 
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading 
cause of cancer death among men in Western countries. Currently, prostate serum 
antigen (PSA) is the most used biomarker for PCa diagnostic. However, the PSA 
screening has limited sensitivity and specificity and PSA is not able to differentiate 
aggressive from indolent PCa.  
Metabolomics is a powerful analytical tool with which biomarkers and therapeutic targets 
can likely be discovered because cancer cells have the capacity to modify many 
homeostatic systems within the body and consequently change the production, the use 
and consequently the levels of many metabolites. Metabolomics allows the discovery of 
biochemical signatures and with these signatures it is possible to investigate several 
metabolic pathways, and the differences between cancer and healthy metabolic 
phenotypes.  
In this work a GC-MS was used as analytical platform to prove the concept that metabolic 
alterations were able to discriminate PCa cell lines (22RV1; PC3; DU145; LNCaP) from 
normal prostate cell line (PNT2). For that, in the first part of the work, we evaluated 
alteration in the volatiloma (extracellular metabolites) obtained at pH 7 and pH 2. In both 
approach, volatiloma revealed to be able to differentiate PCa cell lines from normal 
prostate cell line. The altered VOCs (volatile organic compounds) include ketones, 
aldehydes and organic acids. In the second part of the work, we evaluated alteration in 
intracellular metabolites and for that a derivatization protocol was used before GC-MS 
analysis. Once again the results reveal that metabolic alterations were able to differentiate 
PCa cell lines from normal prostate cell line. The altered metabolites include amino acids, 
sugars, steroids, and fatty acids. By evaluating the altered metabolites it was also possible 
to conclude that the main disrupted metabolic pathways, in consequence of neoplastic 
progression, were linked to the energetic metabolism, protein metabolism and lipid 
metabolism.  
 
Key words: Prostate cancer; Metabolomics; Cell Lines; Volatile Carbonyl Compounds; 
Gas Chromatography /Mass Spectrometry. 
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Resumo 
      
O cancro é um grave problema de saúde, em todo o mundo, tanto em termos de 
morbilidade como de mortalidade. O cancro da próstata (PCa) é o cancro mais 
frequentemente diagnosticado nos homens e o segundo cancro mais mortal para os 
homens nos países Ocidentais. Atualmente, o biomarcador mais usado para o 
diagnóstico desta doença é o antigénio específico da próstata (PSA). Contudo, este 
biomarcador tem uma sensibilidade e uma especificidade limitadas para o rastreio do 
cancro da próstata e, além disso, o PSA não é capaz de diferenciar cancros da próstata 
agressivos de cancros da próstata indolentes.     
 A metabolómica é uma poderosa ferramenta analítica, que pode ser usada para a 
descoberta de novos biomarcadores mas também de novos alvos terapêuticos. Isto é 
possível uma vez que as células cancerígenas têm a capacidade de modificar vários 
sistemas homeostáticos do organismo e consequentemente alterar a produção, o uso e 
os níveis de diversos metabolitos. A metabolómica permite descobrir a assinatura 
metabólica e, assim, utilizando esta assinatura é possível investigar várias vias 
metabólicas e as diferenças entre o fenótipo cancerígeno e o fenótipo saudável.   
Neste trabalho foi usada a técnica de GC-MS como plataforma analítica, como prova de 
conceito de que as alterações metabólicas são capazes de discriminar linhas celulares de 
cancro da próstata (22RV1; PC3; DU145; LNCaP) da linha celular de próstata normal 
(PNT2). Para isso, na primeira parte do nosso trabalho, avaliamos as alterações no 
volatiloma (metabolitos extracelulares) at pH 7 e a pH 2. Em ambas as abordagens, o 
volatiloma mostrou ser capaz de diferenciar as linhas celulares de cancro da próstata da 
linha celular normal. Os compostos orgânicos voláteis (VOCs) alterados incluem cetonas, 
aldeídos, e ácidos orgânicos. Na segunda parte do trabalho, avaliamos alterações nos 
metabolitos intracelulares, usando um protocolo de derivatização, prévio á análise por 
GC-MS. Mais uma vez, os resultados revelaram que as alterações metabólicas foram 
capazes de diferenciar as linhas celulares cancerígenas da linha celular normal. Os 
metabolitos alterados incluem aminoácidos, açúcares, esteróides e ácidos gordos. A 
avaliação dos metabolitos alterados permite concluir que as principais vias metabólicas 
alteradas, em consequência da progressão neoplásica, são o metabolismo energético, o 
metabolismo proteico e o metabolismo lipídico.    
Palavras-chave: Cancro da próstata; Metabolómica; Linhas celulares; Compostos 
carbonílicos voláteis; Cromatografia gasosa/espetroscopia de massa. 
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Abstract
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer death
among men in Western countries. Current screening techniques are based on the measurement of serum prostate
specific antigen (PSA) levels and digital rectal examination. A decisive diagnosis of PCa is based on prostate
biopsies; however, this approach can lead to false-positive and false-negative results. Therefore, it is important to
discover new biomarkers for the diagnosis of PCa, preferably noninvasive ones. Metabolomics is an approach that
allows the analysis of the entire metabolic profile of a biological system. As neoplastic cells have a unique
metabolic phenotype related to cancer development and progression, the identification of dysfunctional metabolic
pathways using metabolomics can be used to discover cancer biomarkers and therapeutic targets. In this study,
we review several metabolomics studies performed in prostatic fluid, blood plasma/serum, urine, tissues and
immortalized cultured cell lines with the objective of discovering alterations in the metabolic phenotype of PCa and
thus discovering new biomarkers for the diagnosis of PCa. Encouraging results using metabolomics have been
reported for PCa, with sarcosine being one of the most promising biomarkers identified to date. However, the use
of sarcosine as a PCa biomarker in the clinic remains a controversial issue within the scientific community. Beyond
sarcosine, other metabolites are considered to be biomarkers for PCa, but they still need clinical validation.
Despite the lack of metabolomics biomarkers reaching clinical practice, metabolomics proved to be a powerful
tool in the discovery of new biomarkers for PCa detection.
Translational Oncology (2016) 9, 357–370
Introduction
Systems biology applied to cancer research encompasses the “omics”
tools, including genomics, transcriptomics, proteomics, and metabo-
lomics, which complement each other and are capable of measuring
changes in several entities (genes, transcripts, proteins, or metabolites,
respectively) simultaneously, providing an overview of various
physiological or pathological conditions [1–3].
Metabolomics can provide an idea of the physiological status of a
biological system, and therefore, alterations in the “normal”
metabolome may be indicative of disease. These alterations in the
“normal” metabolome have the potential to deliver new diagnostic
markers for the detection and prognosis of diseases and to monitor the
response to therapeutic interventions [4]. Metabolomics also has the
potential to give new understanding of the phenotypic changes
resultant from genetic alterations, environmental influence, and
toxicological influence [5].
The term metabolomics includes the assessment of all the
endogenous metabolites produced by the organism including small
molecule intermediates and end products of biochemical reactions in
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a cell (approximately ≤1500 Da), as well as exogenous metabolites,
such as drugs, products from the body flora, and food. Instead of genes
and proteins that participate in these biological processes, the
metabolites produced are indicators of what is happening in the
metabolism of a cell in physiological or pathophysiological conditions.
Thus, metabolites can be altered in such diseases as cancer [1,6–9].
As neoplastic cells have a unique metabolic phenotype related to
cancer development and progression, the identification of dysfunc-
tional metabolic pathways through metabolomics can be used to
identify cancer biomarkers and discover therapeutic targets [5,6,10].
Prostate Cancer
Prostate cancer (PCa) is the second most diagnosed cancer in men
[11], principally affecting men over 50 years old [12], and is the fifth
leading cause of cancer-related deaths in men worldwide [11].
Statistically, in 25% of men worldwide with PCa that develop
metastatic disease [13], the bones are the principal targets of PCa
metastasis [14]. Given that PCa has a long latency period and is
potentially curable, it is essential to develop efficient and precocious
screening methods for its early detection and characterization [12].
The quantification of prostate serum antigen (PSA) and the digital
rectal examination are the most common screening techniques used
for PCa diagnosis. However, performing a prostate biopsy is
mandatory for a final diagnosis [12]. Serum PSA levels higher than
4.0 ng/ml are a sign of PCa [14], although PSA is not able to
differentiate patients with aggressive PCa from those with indolent
disease [15]. The value of PSA screening is also controversial because
of its limited sensitivity and specificity [1,16]. Recent studies
suggested that certain PCa patients may present with PSA levels
below 4.0 ng/ml [14]. This fact leads to false negatives, as no reliable
cutoff values exist to demonstrate the unequivocal presence of PCa
[16,17]. Furthermore, PSA levels may be affected by several other
factors, such as age, prostatitis, urinary tract infection, and benign
prostate hyperplasia, leading inevitably to false-positive results
[14,16,18,19].
The biopsy analysis can also provide false-negative results when the
tumor is small; when the cancer cells are distributed heterogeneously;
and in early PCa stage when, histologically, the tumor appears benign
[20–22]. Thus, samples obtained during the biopsy for histopatho-
logic analysis may not be representative of the cancer [23].
The lack of a consistent biomarker for PCa diagnosis and
monitoring highlights the need for novel, specific, sensitive, and
cost-effective biomarkers to implement the best treatment approach
in a precocious state of the disease [14].
Altered Metabolism of PCa Cells
In 1920, Otto Warburg discovered that cancer cells, unlike
nonmalignant cells, preferentially produce ATP through the
glycolytic pathway (anaerobic pathway) instead of the Krebs cycle,
even in the presence of oxygen. This capability of cancer cells to
sustain high rates of glycolysis for ATP generation is known as the
Warburg effect [24–26].
Despite the relevance of the Warburg effect in cancer cells, the
Krebs cycle and oxidative phosphorylation also play an important role
in many types of cancer, including PCa. Recent evidence suggests that
increased citrate oxidation is an important metabolic characteristic in
PCa that supports the high cellular energy demand [27]. One of the
major functions of prostate cells is the production of citrate, PSA, and
polyamines, such as spermine, which are the major components of
prostatic fluid. Therefore, prostate cells have a distinct metabolic profile as
they produce specific compounds [1,16]. The production of citrate by
prostate cells is very high in comparison with other organs [28]. Unlike
other cells in the organism, prostate cell metabolism significantly favors
citrate synthesis over citrate utilization, which makes the prostate
peripheral zone epitheliumunique among human cells [29]. Usually, cells
degrade citrate in aerobic ATP production, with citrate being oxidized
during the Krebs cycle as part of the intermediary metabolism of glucose.
However, nonmalignant prostate cells accumulate and secrete citrate. The
oxidation of citrate is catalyzed by mitochondrial aconitase (m-aconitase).
In normal prostate cells, m-aconitase is inhibited by the high intracellular
concentrations of zinc, leading to citrate accumulation (Figure 1) [28,29].
Extensive metabolic alterations occur when prostate cells experience
neoplastic transformation. One of the most relevant alterations is citrate
oxidation, because cancer cells are unable to accumulate zinc, andwithout
elevated levels of zinc, m-aconitase is no longer inhibited and can catalyze
citrate oxidation [2,4,27,28,30]. This transformation of citrate accumu-
lation in healthy prostate cells to oxidized citrate in malignant prostate
cells results in more efficient energy production. This is probably an early
event in the progression tomalignancy and precedes the histopathological
identification of malignant cells [27,31,32].
For citrate synthesis, oxaloacetate and acetyl-coenzyme A (acetyl-
CoA) are essential, but whereas oxaloacetate is regenerated in the
Krebs cycle, acetyl-CoA is consumed. To ensure that cancer cells have
the needed energy for rapid proliferation, it is necessary to maintain
elevated rates of citrate oxidation, and thus, the availability of
acetyl-CoA is required. Some studies suggested that to maintain this
accelerated citrate oxidation, alterations in fatty acid metabolism are
needed to provide both ATP and acetyl-CoA [27,33,34] (Figure 1).
Beyond the Krebs cycle and glycolysis, glucose also can be degraded
by the pentose phosphate pathway. This metabolic pathway provides
NADPH and ribose-5-phosphate (important for the synthesis of
nucleic acids and nucleotides), thus promoting anabolic reactions and
redox homeostasis. In a recent study, Tsouko et al. (2014)
demonstrated that androgen receptor (AR) signaling augmented the
levels of glucose-6-phosphate dehydrogenase (G6PD) (key enzyme
for pentose phosphate pathway), NADPH, and ribose synthesis in
hormone-sensitive PCa cells and castrate-resistant PCa (CRPC) cells.
After inhibition of mammalian target of rapamycin with rapamycin,
the upregulation of G6PD is abolished. Hence, these studies revealed
a relationship between the upregulation of G6PD via AR and
mammalian target of rapamycin. These results suggested the
importance of pentose phosphate pathway for PCa growth [35].
Cell proliferation and intercellular signaling are dependent on
increased lipid biosynthesis. Acetyl-CoA also plays an important role
in this metabolic alteration because it is a precursor for lipogenesis and
cholesterogenesis and can be produced by transformation of citrate in
the cytosol [1]. Sterol regulatory element-binding protein–1, an
essential transcription factor for lipogenesis, is also implicated in AR
transcriptional regulation. Beyond increased lipogenesis, sterol regula-
tory element-binding protein–1 also increased reactive oxygen species
production and the expression of NADPH oxidase, which leads to
proliferation, migration, and invasion of PCa cells [36–38]. In PCa
cells, the levels of choline and creatine are increased because there is an
augmentation of membrane synthesis for cell proliferation [16].
Glutamine also has an important role in the maintenance of
lipogenesis, as well as to provide intermediates for the Krebs cycle
through glutaminolysis (where glutamine is transformed into glutamate
by glutaminase and then glutamate is transformed into
Translational Oncology Vol. 9, No. 4, 2016 Biomarker Discovery in Human Prostate Cancer Lima et al. 363
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α-ketoglutarate). The observation that the glutamine transporter and
glutaminase are both overexpressed in PCa cells was proof of the
importance of this mechanism in PCa [38–40]. The α-ketoglutarate
derivate from glutamine can contribute to the formation of citrate when
incorporated into the Krebs cycle (oxidation pathway); however,
α-ketoglutarate can also be transformed into citrate by the reversal of the
tricarboxylic acid cycle through reductive carboxylation. This alteration
of oxidation to reductive carboxylation is promoted by hypoxia and
leads to lipid synthesis and tumor growth [41]. The tumor-stromal
interactions also have an important role in PCa development. The
myofibroblastic microenvironment, formed from the interaction of
cancer cells with “cancer-associated fibroblasts”, is important for the
reverse Warburg effect. Cancer-associated fibroblasts in the myofibro-
blastic microenvironment undergo the Warburg effect, induced by
epithelial cancer cells, and secrete lactate and pyruvate. The lactate and
pyruvate are taken up by the PCa cells and used for the Krebs cycle,
anabolic metabolism, and cell proliferation [38,42,43].
Metabolomics Studies in PCaModel Systems and Biological Fluids
The most common models and biological fluids used to perform
metabolomics studies are tissue and cultured cell lines and human
urine, serum/plasma, prostatic fluid/seminal fluid, respectively.
The use of urine as a sample for metabolomics studies has many
advantages compared with serum: urine is easier to obtain and handle,
needs less sample preparation, and has higher amounts of metabolites
and a lower protein content [12,44,45]. Blood plasma/serum has
some advantages compared with urine, as the diurnal variation and
the intra- and intervariability are lower. However, serum and plasma
are more complex matrices than urine, having a higher concentration
of proteins, and sample collection is more invasive [5].
Seminal fluids, obtained by ejaculation, come from the seminal
vesicles, prostate, and epididymis. Prostatic fluid is collected after
prostate massage, and the composition of this biofluid is simpler than
seminal fluid [46,47]. The use of seminal/prostatic fluids has some
advantages compared with the use of other biofluids, as these samples
are richer in prostatic metabolites because the metabolites do not
need to cross blood-tissue barriers once they are naturally secreted
into the seminal/prostatic fluid. Thus, seminal/prostatic fluids are
less affected by confounding factors. However, these biofluids may
be difficult to collect in men with erectile dysfunction, and a portion
of men may have personal or ethical problems with giving these types
of samples [48].
The collection of tissue samples is more invasive than the collection
of other matrices; however, the use of matched malignant and normal
Figure 1. Schematic illustration of the most significantly altered metabolic pathways in PCa cells. Dashed lines = downregulated
pathway; continuous line = upregulated pathway. Metabolites overexpressed in PCa cells are shown in bold. TCA, tricarboxylic acid
(cycle); AAs, amino acids; DNA, deoxyribonucleic acid; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; G6P,
glucose-6-phosphate; 6P, 6-phosphate; 3PG, 3-phosphoglycerate; CoA, coenzyme A.
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adjacent prostate tissue is a good strategy to reduce intraindividual
variability in metabolomics studies [49].
In vitro models are increasingly used because of interindividual
variability, and difficulties enrolling patients in these models are
nonexistent. In addition, cell lines have a perfectly defined cell state
which allows the analysis of a targeted metabolic status [2,50,51].
However, they do not efficiently simulate the complex cell-cell and
cell-matrix interactions occurring within an organism [2,52].
There are two different metabolomics approaches to discover
biomarkers for cancer: the top-down approach and the bottom-up
approach. Both approaches have advantages and disadvantages. The
top-down approach has the advantage of starting the metabolome
Table 1. Metabolomic Studies Performed in Urines from PCa Patients
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/Discrimina-
t i v e Me t abo l i t e s
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 13 n= 24 GS-MS Binary strings,
Similarity
coefficients
91/21 Butyrolactone, methyl vinyl ketone,
methylamine, N-ethylformamide,
acetonitrile dimethylamino, pyridine,
N-methyl-formamide, acetaldehyde,
acetamide, 1-methyl-piperidine,
1-piperidineacetonitrile, dimethylamine,
pyrrole, methacrolein, N-N-dimethylamine,
3-methyl-pyridine, 2-methyl-1H-pyrrole,
2-octanone, 1-ethyl-1H-pyrrole,
2-n-butylacrolein and methyl propyl disulfide
NS [65]
n= 59 n= 51 LC-MS
GS-MS
Wilcoxon P test,
hierarchical
clustering,
nonparametric
tests
583/34 Sarcosine (+) Alterations in glycine synthesis
and degradation
[53]
n= 106 n= 57
(33 patients with
no evidence of
malignancy plus 24 HC)
GC-MS Nonparametric
statistical tests
and ROC
NS/0 No relevant differences in sarcosine levels
between patients with and without PCa
[61]
n= 3 n= 5 LC-MS NS NS/5 1.Sarcosine
2.Proline
3.Kynurenine (+)
4.Uracil (+)
5.Glycerol 3-phosphate (+)
1. Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
2. Alteration in amino acids metabolism
3. Alteration in kynurenine pathway
4. Alteration in pyrimidine metabolism
5. Alteration in energetic metabolism
[55]
n= 25 PCa patients
developing
biochemical
recurrence
n= 29 PCa patients
who remained
recurrence-free
GC-MS ROC 8/2 Sarcosine (+)
Cysteine (+)
(in the group developing
biochemical recurrence)
Alterations in glycine synthesis
and degradation
[56]
n= 33 n= 23
(13 HC plus 10
patients with BPH)
GC-MS Nonparametric
statistical tests
and ROC
NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[57]
n= 86 n= 45 LC-MS ROC NS/1 Diagnostic value of sarcosine was modest;
relationship with clinicopathologic
parameters was not found
Alterations in glycine synthesis
and degradation
[58]
n= 20 n= 28 (8 patients with
BPH plus 20 HC)
GC-MS PCA
ROC
81/5 Dihydroxybutanoic acid (+), xylonic acid (+),
pyrimidine (−), ribofuranoside(−),
and xylopyranose(−)
Alterations in carbohydrate and
energy metabolism
[60]
n= 211 n= 134 GC-MS ROC NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
[59]
n= 32 n= 32 LC-MS
GC-MS
PCA
PLS-DA
1132/15 1. Glycine (−), serine(−), threonine (−),
alanine (−)
2. Glutamine (−), citrate (−), aconitate (−),
succinate (−)
3. Sucrose (−), sorbose (−), arabinose (−),
arabitol (−), inositol (−), galactaric acid (−)
4.Carnitines (−)
1. Alteration in amino acids metabolism
2. Disturbance in energy metabolism
3. Dysregulation in carbohydrates
degradation
4. Alteration in long-chain fatty
acids metabolism
[63]
n= 59 n= 43 GC-MS RF
LDA
196/4 1. 2,6-dimethyl-7-octen-2-ol (−),
3-octanone (−), 2-octanone (−)
2. Pentanal (+)
1. Increase of utilization of these
metabolites for increased
energy consumption
2. Inflammatory conditions via
the excessive production of
reactive oxygen species, known
to induce lipid peroxidation
[64]
BPH, benign prostatic hypertrophy; GS-MS, Gas chromatography–mass spectrometry; HC, healthy controls; LDA, linear discriminant analysis; LC-MS, Liquid chromatography–mass spectrometry; NS,
not specified; PCA, Principal component analysis; PLS-DA,Partial least squares discriminant analysis RF, random forest; ROC, receiver-operator characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
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Table 2. Metabolic Studies in Serum/Plasma from PCa patients
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
n= 962 n= 1061 HC GC-MS Conditional
logistic
regression
NS/5 Palmitic acid (+), stearic acid (−),
myristic acid (+), linolenic acid (+),
eicosapentaenoic
acids (+)
Alteration in lipid metabolism [70]
n= 85 HG
plus n= 120
LG
n= 114 HC F I A - M S / M S
LC-MS/MS
ROC and
logistic
regression
model
112/5 1. Lysophosphatidyl-choline
(C16:0 and C18:0) (−)
2. Serotonin (−)
3. Aspartic acid (+)
4. Ornithine (−)
1. Alteration in lipid
metabolism
2. Alteration in growth
inhibition and induction
of apoptosis
3. Alteration in protein
biosynthesis
4. Ornithine decarboxylase
overexpression
[75]
n= 561 n= 1034 HC GC-MS
LC-MS
Wilcoxon
signed rank
tests and
χ2 tests
7/3 Choline (+), vitamin B2 (+),
methylmalonic acid (−)
Alteration in membrane
phospholipidic metabolism
[71]
n= 134 n= 666 HC LC-MS ROC 19/7 Glutamine (−), alanine (+),
valine (−), isoleucine (+),
tryptophan (−), ornithine (+),
lysine (+)
Alteration in free amino
acid metabolism
[73]
n= 28
Serum from
patients developing
biochemical
recurrence
n= 30
Serum from
patients with
recurrence free
5 years after
prostatectomy
LC-MS
GC-MS
ROC 9/3 Cystathionine (+),
homocysteine (+), cysteine (+)
Alteration in methionine
metabolism
[56]
n= 36
Fasting plasma
from PCa patients
3 months after
the therapy
initiation
n= 36
Fasting plasma
from PCa before
starting androgen
deprivation therapy
LC-MS
GC-MS
t tests 504/56 1. DHEAS (−), epiandrosterone
sulfate (−), androsterone sulfate (−),
cortisol (−), 4-androsten-3β (−),
17β-diol disulfates 1 & 2 (−),
5α-androstan-3β (−) 17β-diol
disulfate (−), pregnen-diol disulfate (−),
pregn steroid monosulfate (−) and
andro steroid monosulfates 1 & 2 (−).
2. Cholate (+), glycocholate (+),
taurocholate (+), chenodeoxycholate (+),
taurochenodeoxycholate (+),
ursodeoxycholate (+),
hyodeoxycholate (+), deoxycholate (+),
taurodeoxycholate glycodeoxycholate (+),
glycochenodeoxycholate (+),
7-ketodeoxycholate (+)
glycochenodeoxycholate (+),
glycolithocholate sulfate (+),
taurolithocholate 3-sulfate (+),
glycocholenate sulfate (−), and
taurocholenate sulfate (−)
3. Carnitines (−), ketone bodies (−),
dicarboxylic acids
4. 2-hydroxybutyrate (−) and
branched-chain keto-acid
dehydrogenase complex products (−)
1. Steroids metabolism
2. Bile acids and intermediates
of bile acid metabolism
3. Lipid oxidation
4. Markers of insulin resistance
[78]
n= 290 n= 312 Fluorometric assay ROC 1/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[66]
n= 105 n= 36 ESI-MS/MS PCA and
HCA
390/35 Phosphatidylethano-lamine (+),
ether-linked phosphatidylethanola
mine (+), ether-linked
phosphatidylcholine (+)
Alteration in lipid metabolism [72]
n= 1122
(813 serum
from patients with
nonaggressive PCa
plus 309 serum
from patients with
aggressive PCa
(Gleason score 8))
n= 1112 LC-MS ROC NS/1 Sarcosine (+) Alterations in glycine synthesis
and degradation
[67]
n= 25 n= 100 HC Immunoassay NS 4/1 Insulin (+) Alteration in energetic
metabolism
[76]
n= 64 n= 50 HC LC-MS PCA 480/49 Azelaic acid, uric acid, tryptophan, lysoPC Alteration in fatty acids [69]
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evaluation using a real sample (urine or plasma) that could be used in a
clinical practice. However, urine and plasma are complex biological
matrices and have metabolites from different origins, and the
metabolites may be more diluted. The advantage of the bottom-up
approach (starts with the metabolic analyses of cell lines) is that cultured
cell lines are a simpler biological system with less interference factors. In
fact, studies with immortalized cultured cells are important to eliminate
confounding factors, such as the age of patients, smoking habits, diet,
and other diseases that influence the intervariability in plasma and urine.
Nevertheless, the findings in cultured cell lines may not be directly
extrapolated to the real disease as it is practically impossible to simulate
complex cell–cell and cell–matrix interactions in cell cultures of PCa.
Both approaches used together can be useful tools to obtain metabolic
information that can discriminate the metabolic pathways in PCa cells.
Studies with Human Fluids and Model Systems
Urine Studies. Table 1 summarizes the major metabolites and
metabolic pathways that have been found to be dysregulated in
metabolomics studies performed on urine samples from PCa patients.
One of the most relevant metabolomics studies was performed by
Seekumar et al. (2009), where sarcosine (N-methylglycine)was discovered
as possible biomarker in urine for PCa. Sarcosine, an intermediate
product in the synthesis and degradation of glycine, was found to be
highly elevated during PCa progression tometastasis andwas not detected
or was presented at very low concentrations in the urine of healthy
individuals [53]. Carcinogenesis alters the biosynthesis of sarcosine,
although the importance of sarcosine in carcinogenesis remains unknown.
It is known that glycineN-methyltransferase (GNMT) has a significant role
in the metabolism of PCa tissues. This enzyme catalyzes the conversion of
glycine to sarcosine and also participates both in the metabolism of
methionine and in gluconeogenesis [54]. Similar results were achieved in
other studies performed with different analytical platforms using urine as
the matrix (Table 1) [55–59]. However, other studies concluded that
urinary sarcosine levels were not significantly different between PCa
patients and healthy controls (Table 1) [60,61]. According to Issaq and
Veenstra (2011), several causes for such divergences can be associated to
different study design andmethods, which can have diverse specificities and
sensitivities, and also to interindividual differences [62].
Others common metabolic alterations detected in urine from PCa
patients are alterations in amino acids, organic acids, sphingolipids,
fatty acids, and carbohydrates. Dysregulation of carbohydrate
degradation occurs because carbohydrates can be used by cancer
TABLE 2 (continued)
PCa Subject
Group
Control Group Analytical
Platform
Statistical
Methods
Total Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
PLS (18:0/0:0), 3-oxo-9,11-tridecadienoic acid,
3-hydroxy-tetradecanedioic acid,
6-hydroxy-pentadecanedioic acid,
5-(2-methylpropyl)-2-oxooxolane-3-carboxylic
acid, 5-butyl-2-oxooxolane-3-carboxylic acid,
lysoPE (0:0/18:2), LysoPE (18:2/0:0),
lysoPC (18:2/0:0), cortolone-3-glucuronide,
pregnanetriol glucuronide, androstenedione,
decanoic acid, menthol glucuronide,
citronellol glucuronide,
l-α-amino-1H-pyrrole-1-hexanoic acid,
lysoPC (0:0/18:2), phenylalanyl phenylalanine
3β,16α-dihydroxyandrostenone sulfate,
2-tert-butyl-1,4-benzenediol sulfate, indoxyl
sulfuric acid,10-dihydroxy-12Z,15Z-
octadecadienoic acid,12,13-dihydroxy-9Z,
15Z-octadecadienoic acid, 5,16-dihydroxy-
9Z,12Z-octadecadienoic acid, 27-nor-
5β-cholestane-3α,7α,12α,24,25-pentol glucuronide,
hexadecanedioic acid phenylacetylglutamine,
heptadecanoic acid, n-[(3α,5β,7β)-7-hydroxy-24-oxo-
3-(sulfooxy)cholan-24-yl]-glycine, n-[(3α,5β,7α)-
3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-glycine,
glycochenodeoxycholate-3-sulfate, 5-isopropyl-2-
methylphenol, sulfate, 5-carboxy-α-chromanol glucuronide,
indole-3-carboxaldehyde, androsterone sulfate,
5α-dihydrotestosterone sulfate and etiocholanolone sulfate
metabolism, amino acids
metabolism, lysophospholipids
metabolism, and bile acids
metabolism and alteration in
steroid hormone biosynthesis
pathway
n= 70
40 LG PCa plus
30 HG PCa
n= 32 HC 1H-NMR PCA,
OPLS-DA
and ROC
NS/4 1.Alanine (+), pyruvate(+)
2.Sarcosine (+) glycine (−)
1. Alteration in energetic
metabolism and lipogenesis
2. Alterations in glycine
synthesis and degradation
[68]
n= 29 n= 21 BPH NMR
LC-MS
GC-MS
PCA and
ROC
348/53 1. Acylcarnitines
2. Choline (glycerol-phospholipids)
3. Arginine
1. Alteration in fatty acids
metabolism
2. Alteration in membrane
phospholipidic metabolism
3. Alteration in amino acids
metabolism
[74]
BPH, Benign prostatic hypertrophy; DHEAS, dehydroepiandrosterone sulfate; HC, Healthy Controls; HCA, hierarchical clustering analysis; GS-MS, Gas chromatography–mass spectrometry; HG, high
grade; LC-MS, Liquid chromatography–mass spectrometry; LG, low grade; NS, Not specified; OPLS-DA, orthogonal partial least squares discriminant analysis; PCA, principal component analysis; PLS,
Partial least squares; ROC, Receiver-Operator Characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
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cells for energy production. Alterations in carnitine profiles were also
detected; carnitines and their derivatives are important for conserva-
tion of regular mitochondrial function as well as the transport of
activated long-chain fatty acids from the cytoplasm to the
mitochondrial compartment. The results also suggested disturbances
in energy metabolism, including the Krebs cycle, which were expected
given the Warburg effect and the alteration of the activity of
m-aconitase, as previously explained (Table 1) [60,63].
Potentiality of urinary volatile organic compounds to discriminate
between PCa samples and controls was also evaluated in several
different studies. In these studies, volatile organic compounds were
able to differentiate urine from PCa patients and from control
individuals (Table 1) [64,65].
Plasma and Serum Studies. A summary of metabolomics studies
performed on serum and plasma samples can be found in Table 2.
Studies evaluating sarcosine as a biomarker for PCa were performed
in serum samples using different analytical platforms [fluorometric
assay, liquid chromatography–mass spectrometry (LC-MS), and
1H-nuclear magnetic resonance (NMR)]. The results showed that
PCa samples had elevated levels of sarcosine and could distinguish
low-grade from high-grade PCa, suggesting plasmatic level of
sarcosine as a good biomarker for PCa (Table 2) [66–68].
Beyond the alteration in sarcosine levels, metabolomics studies of
serum/plasma from PCa patients also revealed alterations in fatty acids,
amino acids, lysophospholipids, bile acids, and metabolites related to the
steroid hormone biosynthesis pathway. The alteration in fatty acids is
related to changes in lipid β-oxidation necessary to provide energy for
abnormal cell proliferation (Table 2) [69,68,70–75]. Alterations in
energetic metabolism are also common [68,76] (Table 2), and increased
levels of glucose in serum samples at the time of PCa diagnosis were
associated with an increased risk of recurrences after therapy with radical
prostatectomy or radiation therapy [77].
Serum and plasma metabolomics studies can also be used to assess
alterations in the metabolic profile caused by medical treatment. The
metabolic profile of fasting plasma from PCa patients before starting
androgen deprivation therapy and 3 months after the therapy
initiation was analyzed [78]. As expected, steroid levels decreased
during androgen deprivation therapy, whereas the levels of most bile
acids and their metabolites increased with therapy. Bile acids have an
important role in the control of serum lipids, glycemic regulation, and
energy homeostasis. Lower levels of metabolites related to lipid
metabolism after 3 months of treatment were also observed. Carnitines,
ketones, dicarboxylic acids, and the levels of 2-hydroxybutyrate and
branched-chain keto-acid dehydrogenase complex products (bio-
markers of insulin resistance) were also present in lower levels after
the therapy, indicating a reduction in the catabolic state [78].
Prostatic Fluid and Seminal Fluid Studies. Table 3 presents a
summary of metabolomics studies performed in prostatic fluid and
seminal fluid from PCa patients.
Prostatic and seminal fluids are other biofluids that may be used to
perform PCa metabolomics studies to discover alterations in cancer
cell metabolism and noninvasive biomarkers for PCa detection.
As explained previously, normal prostate cells have the ability to
accumulate zinc and consequently accumulate citrate. However, PCa
cells lose this ability. Several metabolomics studies support this
theory. The analysis of prostatic and seminal fluid using different
analytical platforms (fluorescence technique and NMR) revealed
reduced levels of zinc and citrate in PCa groups when compared with
the controls (Table 3) [46,79–82]. Kline et al. (2006) also concluded
that citrate level tests outperform the PSA test in PCa detection.
Additionally, the analysis of citrate in semen has the same efficacy as
the analysis of citrate in prostatic secretion for detecting PCa [81].
Another important function of normal prostate cells is the synthesis
of polyamines, such as spermine and myo-inositol. The analysis of
prostatic and seminal fluid from PCa patients showed significantly
decreased levels of spermine and myo-inositol (Table 3) [80,82]. Serkova
et al. (2008) also demonstrated that the reduction in citrate, spermine,
and myo-inositol levels is independent of the patient’s age [82].
Ex Vivo Tissue Studies. Table 4 presents a summary of
metabolomics studies performed in PCa tissues.
The value of sarcosine as a PCa biomarker was also evaluated in
prostate tissue samples using different analytical platforms. The levels of
sarcosine were increased in PCa samples (Table 4) [15,53,59,83]. Results
also revealed that sarcosine levels were significantly elevated in metastatic
PCa and clinically localized PCa tissue samples, whereas in benign
samples, sarcosine was not detected. These results indicate that sarcosine
may be a good biomarker for monitoring disease progression and
aggressiveness [53].
Other metabolites, namely citrate, lactate, and alanine, were
frequently altered in PCa tissue samples. These results suggest
alterations in citrate synthesis (Krebs cycle) and in energetic
metabolism. As previously explained, the PCa cells switch from
Table 3. Metabolomic Studies in Prostatic and Seminal Fluid from PCa Patients
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discriminative
Metabolites Found
Discriminatory
Metabolites/Biomarkers
Metabolic Pathways Dysregulated Ref.
n= 13 (prostatic fluid) n= 28 chronic prostatitis,
n= 28 adenoma n= 22 HC
Fluorescence Student’s t test and
Kolmogorov-
Smirnov test
1/1 Zinc (−) Lose capability to accumulated zinc [79]
n= 4 (prostatic fluid) n= 10 BPH
n= 12
NMR Multiple regression NS/3 1. Citrate (−)
2. Spermine (−) and
myo-inositol (−)
1. Alteration in energetic metabolism
2. Alteration in polyamines synthesis
[80]
n= 3 (seminal fluid) n= 3
n= 1 BPH
NMR NS NS/1 Citrate (−) Alteration in energetic metabolism [46]
n= 21 (seminal fluid)
n= 7
(prostatic fluid)
n= 16 (seminal fluid)
n= 17 (prostatic fluid)
NMR ROC NS/1 Citrate (−) Alteration in energetic metabolism [81]
n= 52
(prostatic fluid)
n= 26 NMR LR and ROC 9/3 1. Citrate(−)
2. Myo-inositol (−)
and spermine (−)
1. Alteration in energetic metabolism
2. Alteration in polyamines synthesis
[82]
BPH, Benign prostatic hypertrophy; LR, logistic regression; NMR, Nuclear magnetic resonance; NS, Not specified; ROC, Receiver-operator characteristic.
(+): levels increased in PCa; (−): levels decreased in PCa.
368 Biomarker Discovery in Human Prostate Cancer Lima et al. Translational Oncology Vol. 9, No. 4, 2016
 
	12	
	
Table 4. Metabolomic Studies in Prostate Cancer Tissue
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discrimi-
native Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 21 n= 66
Benign
prostate tissue
MRS LDA NS/6 1. Citrate (−)
2. Taurine (+), glutamate (+)
1. Reduced citrate synthesis
(Krebs cycle)
2. Alteration in energy metabolism
[85]
n= 10
Malignant
human
prostate tissue
n= 10
BPH
1H-NMR Nonparametric test
of Kruskal-Wallis
NS/3 1. Citrate (−)
2. Choline (+)
3. Myo-inositol (+)
1. Reduced citrate synthesis
(Krebs cycle)
2. Increased membrane turnover
3. Altered membrane metabolism
[86]
n= 15
Adenocarcinoma
n= 1
HC
1H-NMR Linear regression analysis NS/2 1. Citrate (−)
2. Spermine (−)
1. Reduced citrate synthesis
2. Reduced spermine synthesis
(amino acid synthesis)
[87]
n= 27
Adenocarcinoma
n= 44
BPH
MRS NS 22/3 1. Citrate (−)
2. Choline (+)
3. Lipid/lysine ratio (+)
1. Reduced citrate synthesis
2. Increased membrane turnover
3. Increased cellular proliferation
[88]
n= 20 n= 33
Benign tissue
1H-NMR Nonparametric
Spearman correlation
coefficients
NS/8 1. Choline (+), phosphocholine (+),
glycerophospho-choline (+)
2. Taurine (+)
3. Myo-inositol (+), scyllo-inositol (+)
4. Citrate (−), polyamines (−)
1. Alteration in phospholipid
membrane synthesis and hydrolysis
2. Alteration in energy metabolism
3. Altered membrane metabolism
4. Reduced citrate and polyamines synthesis
[89]
n= 15 n= 32
Benign
prostatic tissue
1H-NMR Z statistics NS/5 Phosphocholine (+), glycerol-
phosphocholine (+),
phosphor-ethanolamine (+),
glycerophospho-ethanolamine (+),
ethanolamine (−)
Alterations on phospholipid
membrane assembly and catabolism
[92]
n= 16 n= 82
Benign
prostate biopsies
1H-NMR NS NS/2 1. Lactate (+)
2. Alanine (+)
1. “Warburg effect”
2. Intensification in glycolytic
flux and increased protein
synthesis in cancer cells
[90]
n= 18 n= 30 1H-NMR LR NS/7 tCho/Cit (+), Cho/Cr (+),
GPC + PC)/Cr (+), Lac/Al (+) Cit/Cr (−)
Alterations in citrate synthesis
(Krebs cycle), in membrane
turnover, and in energetic
metabolism
[84]
n= 12 Localized
PCa n= 14
metastatic PCa
n= 16 Benign
tissue
adjacent to PCa
LC-MS
GC-MS
Wilcoxon P test,
hierarchical clustering,
nonparametric tests
626/60 1. Sarcosine (+)
2. Uracil (+)
3.Kynurenine (+)
4. Glycerol-3-phosphate (+),
5. Leucine (+), proline (+)
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the metabolism
of choline.
2. Alterartion in pyrimidine
metabolism
3.Alteration in Kynurenine pathway
4. Alteration in energetic metabolism
5. Alteration in amino acids metabolism
[53]
n= 27 n= 54 NMR NS NS/NS Omega-6 PUFA (+) Alteration in lipid metabolism [95]
n= 16
patients with
chemical failure
n= 32
Patients without
recurrence after
prostatectomy
1H-NMR PCA NS/6 1. Spermine
2. Myo-inositol, phosphoryl, scyllo-inositol
3. Choline
4. Glutamate, glutamine
1. Reduced spermine synthesis
(amino acid synthesis)
2. Altered membrane metabolism
3. Alteration in phospholipid
membrane synthesis and hydrolysis
4.Alteration in energy metabolism
[93]
n= 41 n= 108
Benign adjacent
prostate tissue
1H-NMR Binary logistic regression
and multivariate
linear regression
13/6 1. Choline compounds (+)
2. Myo-inositol (−), scyllo-inosito (+)
1. Alteration in phospholipid
membrane synthesis and hydrolysis
2. Altered membrane metabolism
[94]
n= 92 n= 92 GC-MS Nonparametric statistical
tests and ROC
NS/1 Sarcosine (+)
(sarcosine levels were not related with
tumor stage, grade or
biochemical recurrence)
Alterations in glycine synthesis
and degradation. Sarcosine is an
intermediate compound in the
metabolism of choline.
[83]
n= 331 n= 178 GC-MS
LC-MS
ROC 469/200 1. Sarcosine (+)
2. Kynurenine (+)
3. Proline (+)
4. Uracil (+)
5.Glycerol-3-phosphate (+), threonine (+)
citrate (−) ADP-ribose (−)
15-hydroxyeicosatetraenoic acid(−)
6.Polyanines (−)
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
2. Alteration in kynurenine pathway
3.Alteration in amino acids metabolism
4.Alterartion in pyrimidine metabolism
5.Alteration in energetic metabolism
6.Reduced polyamines synthesis
[15]
n= 11
Localized PCa
plus n= 10
metastatic PCa
n= 11
Benign adjacent
prostate samples
GC-MS ROC NS/1 Sarcosine (+) (progressive elevation from
benign tissue to localized tumors and
metastatic disease)
Alterations in glycine synthesis
and degradation
Sarcosine is an intermediate
compound in the metabolism of choline.
[59]
(continued on next page)
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citrate accumulation to citrate oxidation when becoming malignant.
PCa cells also undergo the Warburg effect, all of which explain these
alterations (Table 4) [15,84–91].
It is also well established that cancer cells have elevated
proliferation rates, and this is reflected in alterations in membrane
metabolism. Several metabolomics studies performed in PCa tissue
revealed an increase of choline levels in PCa samples, which indicates
alterations in phospholipid membrane synthesis and hydrolysis
(Table 4) [84,86,88,89,92–94]. Because this elevated proliferation
rate also increases cell energy requirements, PCa samples also have
alterations in lipid metabolism (as lipids may be used by the cells to
produce energy) (Table 4) [49,95].
Beyond the study of the metabolic pathways involved in cancer
development, it is also important to assess which metabolic pathways
are involved in the growth of bone metastases. The results obtained
from a study [78] revealed a significant increase in cholesterol levels in
bone metastases tissues from PCa patients. The metabolic profile
from PCa bone metastases indicates high energy metabolism, which
may be related to highly proliferating cells. This conclusion was based
on the elevated levels of certain metabolites, such as threonine,
glutamate, phenylalanine, citrate, fumarate, glycerol-3-phosphate,
and fatty acids. Another relevant metabolic alteration in PCa bone
metastases tissue was the elevated levels of myo-inositol-1-phosphate,
which may indicate active cell signaling involving inositol-based
compounds as second messengers. Inositol-based molecules are
related to the activation of protein kinase C, and the activation of
this molecule is important for cell proliferation, apoptosis, differen-
tiation, invasion, and angiogenesis. The concentration of sarcosine
was increased in bone metastases from PCa and from other cancers,
which reveals that sarcosine may not be specific to PCa. Metabolites
such as threonine, asparagine, fumarate, and linoleic acid are present
in high levels in samples from bone metastases. The levels of these
metabolites were also increased in samples of primary prostate tissues
from patients with confirmed bone metastases. Linoleic acid, an
essential fatty acid, was associated with PCa progression. Further-
more, linoleic acid may also be associated with the inflammatory
response because linoleic acid is transformed into arachidonic acid.
Arachidonic acid is a precursor for prostaglandins, which have an
important role in inflammation [96].
In Vitro Studies. Table 5 summarizes general information on in
vitro metabolomics studies in PCa-derived cell lines.
The biological relevance of sarcosine was evaluated in four
immortalized PCa cell lines, in primary benign prostate epithelial
cells, and in an immortalized benign prostate epithelial cell line.
Sarcosine levels were increased in malignant cell lines when compared
with benign cell lines [53,97]. Furthermore, alterations in the
expression of the enzymes involved in sarcosine metabolism influence
cell proliferation, invasion, and cell death, which suggest the
importance of sarcosine in PCa metabolism (Table 5) [53,59]. In
an effort to understand the role of sarcosine in PCa progression,
Sreekumar et al. (2009) evaluated the role of androgen signaling and
the genes ERG and ETV1 (important mediators of PCa progression).
The results showed that after treatment with androgens, cell lines that
were ERG positive and ETV1 positive had increased GNMT
expression and decreased sarcosine dehydrogenase (SARDH)
expression [53].
In agreement with the results from metabolomics studies
performed in other matrices (urine, plasma/serum, and tissues),
presented here previously, alterations in amino acid metabolism were
also observed in the studies performed in PCa cell lines. PCa cells lines
revealed alterations in the levels of certain amino acids, such as
leucine, valine, or isoleucine (Table 5) [97–99].
The increase of lactate and alanine levels in PCa cell lines is
frequently observed in metabolomics studies. These alterations
suggest changes in cellular energy metabolism (Table 5) [97–100].
As reported for other matrices, metabolomics studies in PCa also
revealed that PCa cells experience alterations in membrane
metabolism with changes, for example, in choline metabolite levels
(Table 5) [98,101]. Androgen signaling has an important role in the
development and progression of PCa. In fact, one current therapy for
metastatic PCa is the use of antiandrogen agents; however, with the
progression of the disease, patients normally develop resistance to this
therapy, and it is currently impossible to predict if the cancer will
progress into a castration-resistant state. The androgen-responsive cell
lines can be characterized by increased levels of spermine, N-acetyl-
spermine, serine, threonine, lysine, homocysteine, asparagine,
alanine, and glutamic acid, as well as decreased levels of
S-adenosylmethionine, with a simultaneous increase in levels of its
breakdown product, homocysteine. These findings indicate that
androgen-responsive cell lines have an elevated methylation activity.
Androgen treatment resulted in further perturbations in amino acid
metabolism and in a shift toward increased methylation.
TABLE 4 (continued)
PCa Subject Group Control Group Analytical
Platform
Statistical Methods Total Metabolites
Found/Discrimi-
native Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways Dysregulated Ref.
n= 95 n= 95
Normal adjacent
prostate tissue
GC-MS
LC-MS
ROC,
Univariate Cox regression,
Kaplan-Meier analyses,
and multivariate Cox
regression analyses
820/9 1. Gluconic acid (−), maltotriose (−)
2. Aminoadipic acid (+)
3. Cerebronic acid (+),
glycerophosphoethanol-amine (+),
2-hydroxybehenic acid (+), tricosanoic acid (+)
4. Isopentenyl pyrophosphate (+)
5. 7-methylguanine (+)
1. Alteration in carbohydrate metabolism
2. Increased fatty acid synthesis
3. Alteration in lipid metabolism
4. Intermediate in the steroid
synthesis pathway, indicates
an increase of cholesterol levels
5. DNA damage
[49]
n= 30 LG PCa plus
n= 81 HG PCa
n= 47
Normal
adjacent tissue
MRS PCA, PLS and PLS-DA 23/2 1. Citrate (−)
2. Spermine (−)
1. Reduced citrate synthesis
2. Reduced spermine synthesis
[91]
BPH, Benign prostatic hypertrophy; Cho/Cr, choline/creatinine; Cit/Cr, citrate/creatinine; GS-MS, Gas chromatography–mass spectrometry; (GPC + PC)/Cr, (glycerol-phosphocholine +
phosphoryl-choline)/creatinine; HC, Healthy Controls; HG, High grade; Lac/Al, lactate/alanine; LC-MS, Liquid chromatography–mass spectrometry; LDA, Linear discriminant analysis; LG, Low
grade; LR, Linear regressionMRS, magnetic resonance spectroscopy; NMR, Nuclear magnetic resonance; NS, Not specified; PCA, Principal component analysis; PLS, partial least squares; PLS-DA, partial
least squares discriminant analysis; tCho/Cit, total choline/citrate.
(+): levels increased in PCa; (−): levels decreased in PCa.
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Table 5. Metabolomic Studies Performed in Human PCa-Derived Cell Lines
Cancer Cell Lines Control Group Analytical
Platform
Statistical
Methods
Total
Metabolites
Found/
Discriminative
Metabolites
Found
Discriminatory Metabolites/Biomarkers Metabolic Pathways
Dysregulated
Ref.
AD prostate carcinoma
LNCaP cell line
Androgen-independent
prostate carcinoma
PC-3 cell line
MRS NS 3/2 Uptake of ethanolamine and
N,N′-dimethylethanolamine (+)
(principally in AD cells in
presence of androgens)
Alteration in membrane
lipid synthesis
[101]
VCaP, DU145,
22RV1, and LNCaP
PrEC and RWPE LC-MS
GC-MS
Wilcoxon
P test,
hierarchical
clustering,
nonparametric
tests
1/1 Sarcosine (+) Alterations in glycine
synthesis and degradation
[53]
Androgen-nonresponsive
PC3 and DU145 cell lines
Androgen-responsive
VCaP (treated with
synthetic androgen)
and LNCaP cell lines
RWPE LC-MS HCA 1553/674 Malignant cell lines
1. Sarcosine (+)
2. Threonine (+), phenylalanine (+),
alanine (+), creatine (+),creatinine (+),
citrulline (+), tryptophan (−),
1-methyl tryptophan (−) and
kyneuric acid (−)
Androgen-responsive cell lines
3. Serine (+), threonine (+), lysine (+),
homocysteine (+), asparagine (+),
alanine (+), glutamic acid (+)
4. S-adenosylmethionine (−), homocysteine (+)
Androgen treatment resulted in further
perturbations in amino acid metabolism
and increased methylation.
1. Alterations in glycine
synthesis and degradation
Sarcosine is an intermediate
compound in the
metabolism of choline.
2. Alteration in amino
acids metabolism
3. Alteration in amino
acids metabolism
4. Elevated methylation
activity
[97]
PC3 and LNCaP treated
with LY294002
(inhibitor of the PI3K
signaling pathway) or
17AAG (inhibitor of
the HSP90 protein chaperone)
PC3 and LNCaP
untreated
MRS PCA NS/24 After both treatments: lactate (−),
alanine (−), fumarate (−)
LY294002 treatment: phosphocholine (−),
glutathione (−), glutamine (+), valine (+),
leucine (+), isoleucine (+)
17AAG treatment: phosphocholine (+),
citrate (+), glutamine (−), valine (+),
leucine (+), isoleucine (+), myo-inositol (+),
taurine (+)
PI3K and HSP90 inhibition [102]
Low-invasiveness
WPE1-NB14 and
high-invasiveness
WPE1-NB11 cell lines
RWPE-1 1H-NMR PLS-DA NS/10 1. Leucine (−), valine (−), isoleucine (−),
glutamine (−), glutamate (−),
β-hydroxyisovalerate (−)
2. Glycine (−)
3. Lactate, alanine
4. Phosphocholine (+)
1. Increased protein
synthesis and amino
acid catabolism
2. Alterations in methylation
and synthesis and
degradation of sarcosine
3. Alteration in energetic
metabolism;
4. Alteration in choline
metabolism
[98]
Androgen-nonresponsive
PC3 and androgen-
responsive LNCaP cell lines
PNT1A 1H-NMR Two-way
analysis of
variance
followed by
Bonferroni
posttest
NS/3 Glucose consumption (+)
PC3 cells:
Lactate (+)
Alanine (+)
Lactate/alanine ratio (+)
Increased levels of oxidative
stress in PC3 cells.
Androgen-responsive and
-nonresponsive PCa cells
showed different glycolytic
metabolism profiles.
[100]
DU145, PC3, and LNCaP
(knockdown of GNMT,
SARDH, or PIPOX and
overexpression of GNMT,
SARDH, or PIPOX
(convert sarcosine
back to glycine)
RWPE GC-MS ROC NS/1 Overexpression of GNMT: sarcosine (+)
(increase in invasion).
Knockdown of GNMT: sarcosine (−)
(reduction in cell proliferation, invasion,
and greater percentage of cell death)
Overexpression of SARDH or PIPOX:
sarcosine (−) (reduced invasion)
Knockdown of SARDH: sarcosine (+)
(increase proliferation and invasion)
Knockdown of PIPOX: sarcosine (+)
(increased invasion)
Alteration in glycine
synthesis and degradation
[59]
CRPC cell C4-2, 22Rv1
and LNCaP-abl
Androgen receptor
positive LNCaP
and MDA-PCa-2a
and
MDA-PCa-2b
LC-MS HCA 150/38 CRPC cells:
1. Sugars and intermediates associated
with energy metabolism and signaling (+)
AD cells
2. Carnitines, amino acids, and their
methylated derivatives (+)
1. Alteration in energy
metabolism and signaling
2. Alteration in amino
acid metabolism
[99]
(continued on next page)
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Androgen-nonresponsive cell lines and androgen-responsive cell lines also
have differences in their glycolytic metabolism profiles.
Androgen-dependent PCa cells and androgen-independent PCa cells
also show differences in membrane lipid synthesis (Table 5) [97,100,101].
Metabolomics studies in cell lines may also be used to evaluate the
alterations that occur after a pharmacological therapy. The treatment
of PCa cells appears to lead to changes in energetic metabolism and
choline metabolism (Table 5) [102]. Dichloroacetate (DCA) is an
inhibitor of pyruvate dehydrogenase kinase, and inhibition of this
enzyme has the potential to reverse the Warburg effect due to the
increased pyruvate uptake into mitochondria. After treatment
with this drug, the highly metastatic cells showed significantly
lower levels of lactate/metabolite ratios [Lac/Cr, Lac/Cho, Lac/Al,
and Lac/(Cho + Cr + Al)], whereas in poorly metastatic cells, no
changes in lactate/metabolite ratios were found after the treatment.
These findings suggest that highly metastatic cells are more dependent
on lactate production (Table 5) [103].
Conclusions and Future Directions
The introduction of PSA testing has radically altered how PCa is
diagnosed andmanaged. However, this test may lead to a false-positive or
false-negative diagnosis. This drawback has given rise to serious efforts
toward the discovery of new biomarkers, preferentially noninvasive,
which have better specificity and sensitivity.
Because metabolic alterations are the last step in the cellular
response to diseases, metabolomics can be successfully used to
discover new biomarkers for cancer. In this regard, several studies
have been conducted to characterize the metabolic profile of PCa.
One of the major obstacles in data interpretation is that the
metabolic profile is influenced by various factors, such as age, diet,
drugs, and chronobiological variations, among others. Additional
problems include sample preparation, the analytical procedures, and
the statistical platforms used. Major differences in these conditions
can compromise the comparison of results among different studies
and consequently compromise the discovery of new biomarkers.
Another intrinsic difficulty with metabolomics studies is the massive
amount of data produced that is difficult statistically to analyze.
Despite these difficulties, metabolomics is a powerful tool for the
discovery of new biomarkers for PCa detection, biomarkers indicative
of cancer prognosis, disease progression, and therapeutic response, as
well as identifying new therapeutic targets.
The metabolomics studies described in this review revealed
different results, but almost all studies in urine, plasma/serum,
prostatic fluids, tissues, and cell lines associated PCa with decreased
levels of citrate and polyamines and increased levels of choline, lactate,
and amino acids.
Further studies are still needed to confirm the results of these
studies and identify an inexpensive, noninvasive, sensible, and specific
biomarker for PCa.
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Aims 
 
Prostate cancer is the second most diagnosed cancer in men, with 1.1 million new cases 
diagnosed in all world, in 2012 (1). The quantification of prostate serum antigen (PSA) and 
the digital rectal examination are the most common screening techniques used for PCa 
diagnosis. Nevertheless, to reach a final diagnosis it is mandatory to perform a prostate 
biopsy (PB) (2). However, PSA screening is controversy due to its limited sensitivity and 
specificity. PSA is specific for prostate diseases, in general, but not specific for PCa (3-5). 
Therefore, it is urgent and necessary discover new biomarkers in order to establish a 
confident, rapid, specific, noninvasive and economic methodology for early PCa diagnosis 
and prognosis. In this sense, metabolomics has been increasingly playing an important 
role in the discovery of new biomarkers. Many metabolomic studies have been conducted 
in multiple matrices (cells, tissues and biofluids) in order to improve diagnostic 
approaches, revealing promising results (6-15). However, the studies related with VOCs, 
for this specific pathology, are limited.  
In order to contribute to the discovery of new PCa biomarkers and to better understand 
the prostatic cancer mechanism, the aims of this study are based on the realization of a 
complex metabolomic study, using four different prostatic cancer cell lines and one normal 
prostate cell line. In order to achieve this goal, the present work was subdivided in the 
following tasks: 
1) Application of a metabolomic approach based on HS-SPME/GC-MS analytical 
technique to study the exometabolome (VOCs) of 4 prostate cancer cell lines 
(PC3, 22RV1, LNCaP, DU145 cell lines) with different grades and features and a 
non-tumoral cell line (PNT2 cell line), as well as to search for significant 
differences between them; 
2) Study of the exometabolome at two different pHs (pH 2 and 7) in order to infer 
what is the ideal pH for the extraction of volatile organic compounds and 
discrimination of potential biomarkers; 
3) Screening, identification and statistical analysis of VOCs that contribute for 
separation between cell lines and consequent discovery of potential biomarkers;  
4) Application of a metabolomic approach based on GC-MS technique to reveal the 
endometabolome (intracellular metabolites such as AAs, organic acids; fatty acids, 
sugars and steroids) of the all prostate cell lines (tumorals and non-tumoral), as 
well as to search for significant differences between them; 
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5) Screening, identification and statistical analysis of intracellular compounds (AAs, 
organic acids; fatty acids, sugars and steroids) that contribute for separation 
between cell lines and consequent discovery of potential biomarkers;  
6) Integration of the results obtained through the two GC-MS techniques, in order to 
better understand the metabolic pathways changed in prostate cancer; 
As far as we know, this is the first time that a complex metabolomics study is performed in 
vitro, not having been executed any study of VOCs profiling in in vitro prostate cancer cell 
models. 
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Prostate cancer (PCa) is the second most diagnosed cancer in men, and is the fifth 
leading cause of cancer-related deaths in men worldwide (1). In 2014, in the United 
States, 233 000 men were diagnosed with PCa and 29 480 men died due to this cancer. 
(16). The five-year survival for men with metastatic disease is very low (28%) and this 
occurs because of the development of resistance to castration, nerveless PCa has a long 
latency period and is potentially curable (2).  
Age, diet, genetics, the pre-existence of sexually transmitted infections, the exposure to 
toxic metals, polychlorinated biphenyls and polycyclic aromatic hydrocarbons are some of 
the factors involved in the development of PCa (17-20). 
Currently, prostate serum antigen (PSA) is the most used biomarker for PCa diagnostic. 
However, the PSA screening has limited sensitivity and specificity (17, 21, 22) and PSA is 
not able to differentiate aggressive from indolent PCa (3, 4). Therefore, discovery of new 
biomarkers for PCa diagnostic is urgent and has the potential for substantial public health 
benefit.   
An ideal cancer biomarker must be monitored in biological samples obtained by 
noninvasive procedure and inexpensive to allow frequent measurements, sensitive and 
specific for a particular cancer, and should appear altered in early stages of the disease. 
Additionally, it must be capable to depict the evolution of the tumor and the metastatic 
onset or spread (17).  
Metabolomics is a powerful analytical tool with which biomarkers and therapeutic targets 
can likely be discovered as cancer cells have the capacity to modify many homeostatic 
systems within the body and, consequently, change the production, the use and the levels 
of many metabolites (23, 24). Metabolomics allows the discovery of biochemical 
signatures and with these signatures it is possible to investigate several metabolic 
pathways, and the differences between cancer and healthy metabolic phenotypes (23). 
An early intervention is possible using metabolomics since it is believed that metabolic 
alterations precede neoplastic proliferation. Thus, in theory, it is possible to detect early 
and avoid cancer development and to reduce neoplastic proliferation and invasion of local 
or distant tissues by precocious treatment (3).  
In the design of experimental and analytical models of cancer, it is very important to be 
aware that metabolic profile can be altered by other factors not related to the cancer, like, 
age, diet, drugs, chronobiological variations, among others,  being very important to 
control these effects in order to obtain reliable results, the cell lines are the ideal model to 
overcome these problems (23). The advantages of using cell lines in metabolomics 
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studies are the nonexistence of interindividual variability or difficulties enrolling patient 
controls in the studies. In fact, in cell lines studies there are less confounding factors as, 
for example, age, concurrent pathologies, diet, tabagic habits and influence from different 
tissues. In addition, cell lines have a perfectly defined cell state which allows the analysis 
of a targeted metabolic status. Metabolic alterations that do not appear in studies using 
animal models or human subjects due to sample biological complexity are reveled. Cell 
lines are less complicated to control, less expensive and the results are easier to interpret 
and more reproducible when compared with other samples like biofluids or tissue from 
humans or animal models. Also, ethical problems inherent to the use of animal models or 
human subjects are obviated (25-27). However, none of these models are perfect 
because it is practically impossible to simulate complex cell–cell and cell–matrix 
interactions in cell cultures of prostate cancer and these interactions are very important for 
metabolic alterations that happen with tumor progression (26, 28). 
Volatile organic compounds (VOCs) correspond to a carbon-based chemical group, with 
low molecular weight and high volatility. These compounds are emitted from the human 
body and can reflect the metabolic condition of an individual. VOCs, odorous and non-
odorous, vary in relative abundance with age, gender, health status, lifestyle behaviors, as 
well as, with genetic background (29, 30). VOCs, prove to have a great potential to 
provide new biomarkers of cancer detection. Some works have already focused on the 
application of VOCs analyses to different cancers, namely breast, lung, head and neck, 
esophago-gastric, skin, colorectal, liver and renal (31-38). In these works, several different 
matrices were used to the identification of VOCs, one of the most used matrix was breath, 
however other matrices were used with success, namely, cell lines, urine, plasma, gastric 
content and fecal samples (39-43).VOCs analyses were also applicated in PCa with 
success. In these studies, VOCs were able to differentiate urine from PCa patients and 
control individuals (7, 44). In these works the analytical platform used was GC-MS. For 
GC separation, it is necessary to use elevated temperatures and the metabolites must be 
volatilized in the injector port. For these reasons, GC can only be used in thermally stable 
compounds. GC-MS has the highest resolving power, but can only be used to analyze 
volatile compounds and certain substances, such as fatty acids and organic acids, with 
low molecular weights, being an ideal technique to VOCs analysis (45-47).  GC-MS, 
compared to LC-MS, has higher sensitivity, robustness and reproducibility, and the 
identification of unknown metabolites is possible using the extensive spectrum databases 
available, which is a very important tool to identify unknown compounds (45). 
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Materials and Methods 
 
Chemicals 
All chemicals and reagents were analytical grade. RPMI-1640 medium, and 4-
fluorobenzaldeyde (used as internal standard) were purchased from Sigma-Aldrich Co. 
(St. Louis, MO, USA). The antibiotic mixture penicillin/streptomycin (10000 U/mL/10000 
µg/mL), heat inactivated fetal bovine serum (FBS) and trypsin 0.25%-EDTA were 
purchased from GIBCO Invitrogen (Barcelona, Spain).  Hydrochloric acid (HCl) and 
sodium hydrogencarbonate were obtained from Merck (Darmstadt, Germany). Sodium 
chloride (NaCl) was from VWR (Leuven, Belgium).   
 
Cell Culture 
PCa immortalized cell lines (PC3, 22RV1, DU145 and LNCaP) and normal prostate 
epithelium immortalized cell line (PNT2) were provided by Portuguese Oncology Institute-
Porto (Table 1). All cell lines were grown in RPMI-1640 supplemented with 10% of FBS 
and 1% of penicillin/streptomycin. All cell lines were maintained at 37°C and 5% CO2. 
Cells were grown to 80% confluency, before passage. 
 
Table 1: Characteristics of prostate cell lines used in this study. 
 PNT2 22RV1 PC3 DU145 LNCaP 
Organism Homo 
sapiens 
Homo 
sapiens 
Homo sapiens Homo 
sapiens 
Homo sapiens 
Age 33 years NA 62 years 69 years 50 years 
Ethnicity NA NA Caucasian 
 
Caucasian 
 
Caucasian 
Tissue Prostate Prostate Prostate; 
derived from 
metastatic site: 
bone 
Prostate; 
derived from 
metastatic 
site: brain 
Prostate; 
derived from 
metastatic site: 
left 
supraclavicular 
lymph node 
Morphology Epithelial Epithelial Epithelial Epithelial Epithelial 
Culture 
Properties 
Adherent Adherent Adherent Adherent Adherent 
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 PNT2 22RV1 PC3 DU145 LNCaP 
Disease Healthy 
 
Carcinoma Grade IV, 
adenocarcinoma  
Carcinoma 
 
Carcinoma 
Tumorigenic No Yes Yes Yes Yes 
AR 
expression  
Yes Yes No No Yes 
Metastatic 
potential 
 NA High Moderate Low 
 
 
 
VOCs collection from extracellular medium 
All cell lines were plated in 75 cm2 culture flasks and grown to 100% confluency in RPMI-
1640 medium. After the cells had reached 100% confluency the medium was discarded 
and replaced with 15 mL of fresh RMPI-1640 medium, and left to grow for 48h, together 
with three controls (cellular medium without cells). After the 48h, the extracellular medium 
from flasks with cells and without cells (controls) was collected, centrifuged (2000 x g for 
10 minutes at 4 ⁰C), the supernatant separated in two aliquots (one to use for volatile 
profiling at pH 7 and other to use for volatile profiling at pH 2) and immediately frozen at    
-80 ⁰C until analysis. The same procedure, for all cell lines (four PCa cell lines and one 
normal cell line), was used for the four consecutive passages (passage number 3, 4, 5 
and 6) each passage was performed in triplicate, resulting in a total of 60 experiments.  
 
VOCs extraction from cell lines 
The method used was based on those previously developed by Monteiro et al (2014), with 
some modifications. Briefly, stored samples were thawed slowly at low temperatures, in 
order to minimize the loss of VOCs. All samples were analyzed at the pH of the medium 
culture around pH 7 (pH between 7.395 and 7.956) and at pH 2 (pH between 1.846 and 
2.466). For acidification a fixed volume of 5M HCl was used (2.5 µL for pH 7 controls; 50 
µL for pH 2 samples; and 52 µL for pH 2 controls). For GC–MS analysis 2 mL of sample 
were put into a 10 mL glass vial added with the internal standard (4-fluorobenzaldehyde, 
10 µL with a concentration of 10 µg/mL) and salt (NaCl, 0.59 g). For the extraction a 
DVB/PDMS fiber coating was used, with 9 min of incubation and 24 min of extraction at 
68°C with agitation (38). 
NA: Not available; AR: Androgen receptor  
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GC–MS system and data acquisition 
 
GC–MS analysis 
The GC-MS conditions for VOCs analysis were previously optimized by Monteiro et al. 
(2014). A Scion-436 gas chromatograph coupled to a Bruker SQ (single quadrupole) 
equipped with a SCION SQ ion trap mass detector and a Bruker Daltonics MS workstation 
software version 6.8, with a VF-5 MS (30 m x 0.25 mm x 0.25 µm) column (Varian) was 
used. A CombiPAL automatic autosampler (Varian, Palo Alto, CA) was used and 
experimental conditions were previously described (38). The carrier gas used was helium 
C-60 (Gasin, Portugal) (flow of 1 ml/min) and the injector port was heated to 230 °C. The 
analysis was performed in Full Scan mode. The oven temperature was fixed at 40 °C for 1 
min, then increasing to 250 °C (rate 5 °C/min), held for 5 min, then increasing to 300 °C 
(rate 5 °C/min) and held for 1 min. The transfer line temperature was 280 °C, manifold 
temperature was 50 °C and the trap temperature was 180 °C. The mass range was 40 - 
350 m/z, with a scan rate of 6 scan/s. All samples were injected randomly.  
To ensure reproducibility, quality control samples (QCs) were injected three times per day. 
These QCs were a pool of all samples (the samples from the five cell lines and the 
respective controls) (48), this pool was aliquoted (2 mL vials) and immediately frozen at    
-80 ⁰C until analysis.      
 
Statistical analysis 
Prior to statistical analysis of results, all chromatograms were pre-processed: baseline 
correction (used to the raw data before peak detection to remove random noise and 
baseline shift), peak detection (the aim is to detect all peaks avoiding as possible false 
positives), chromatogram deconvolution (to decompose overlapped chromatographic 
signals), and alignment (to adjust for any minor variation in retention time), for these 
corrections the program MZmine was used (49), the parameters used to accomplish these 
were: RT range 2.8-34.0 min; m/z range 50-250; MS data noise level 1.0´104; m/z 
tolerance 0.5; chromatogram baseline level 1.0´103; peak duration range 0.02-0.30 min. 
Also all ions with a RSD (relative standard deviation) greater than 30% as well as ions 
(m/z) coming from the column, the fiber and responsible for temporal interference were 
removed from the matrix. The obtained data was also normalized for the total area of the 
chromatograms (division of peak area for the sum of the areas of all peaks). The statistical 
treatment includes an unsupervised (PCA) and a supervised analyzes (PLS-DA), after a 
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pareto (Par) scaling, to determine which VOCs were significantly different between PCa 
lines and normal cell line. Model robustness was estimated by R2X (variance explained by 
the X matrix, i.e. GC-MS data), R2Y (variance explained by the Y matrix, i.e., sample 
class) and Q2 (goodness of prediction). All VOCs with VIP (Variable Importance 
Projection) values greater than one were considered potential relevant VOCs for the 
separation among cell lines. For these relevant compounds an univariate analysis was 
performed, using Shapiro-Wilk test (to determine normality distribution of data), and 
unpaired Student’s t-test with Welch correction (for normal distribution) test or unpaired 
Mann-Whitney test (for non-normal distribution) to calculated the p value. In addition the 
percentage of variation, uncertainty of the variation quotient, as well as, the effect size and 
its uncertainty, were calculated (50). Bonferroni correction was used to adjust p-values for 
multiple comparisons by setting the significance cut off to p value (0.05) divided by the 
number of compounds simultaneously tested in univariate statistical analyses. 
Finally, to confirm the robustness of the PLS-DA models, a randomized Monte Carlo 
cross-validation (MCCV) (7 blocks, 500 runs) was performed (using a software developed 
in the University of Aveiro), (51) obtaining the prediction power (Q2) and confusion 
matrices for original and permuted data for all PLS-DA models. When a minimal 
overlapping of the distribution of original and permuted classes was obtained, PLS-DA 
models were considered robust. Classification rates, specificity (spec.) and sensitivity 
(sens.) were also acquired for all PLS-DA models through a receiver operating 
characteristic (ROC) map.   
 
 
Results 
 
VOCs analysis obtained at pH 7 
After data acquisition by GC-MS, the data were used to perform the multivariate analyses, 
namely PCA and PLS-DA. A total of 239 features were detected in the chromatograms 
obtained at pH 7. 
The reproducibility of the analytical method is confirmed by the QCs projection on axis 1 
and 2 (Figure 1) (all QCs samples are grouped (orange color). Furthermore, the 
multivariate analyses prove that VOCs are able to discriminate PCa cell lines from normal 
prostate cell line and between the different PCa cell lines. This discriminant capability is 
observed not only in PLS-DA analysis but also in PCA (Figure 2).  
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Figure 1: PCA with QCs samples (in orange) and VOCs from all cell lines and controls (blue) (R2X 
= 0.357) 
 
 
Figure 2: PCA (A) (R2X = 0.445) and PLS-DA (B) with VOCs from all cells line (R2X = 0.438; R2Y = 
0.459; Q2 = 0.44) (PNT2 (normal cells): green; PC3 (PCa cells): light blue; DU145 (PCa cells): red; 
LNCaP (PCa cells): yellow; 22RV1 (PCa cells): dark blue) 
To evaluate which VOCs were responsible for this separation, each cancer cell line was 
compared separately with the normal cell line, namely 22RV1 vs PNT2, PC3 vs PNT2, 
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DU145 vs PNT2 and LNCaP vs PNT2. An optimal separation between PCa cell lines and 
normal cell line was observed (Figure 3). 
 
 
   
 
 
 
 
 
 
 
 
 
 
All VOCs with VIP (Variable Importance Projection) values greater than one were 
considered potentially relevant for the separation among cell lines. Hence, a total of 23 
VOCs were considered relevant to differentiate 22RV1 from PNT2; 16 VOCs were 
considered relevant to differentiate PC3 from PNT2; 27 VOCs were considered relevant to 
differentiate DU145 from PNT2 and 21 were considered relevant to differentiate LNCaP 
from PNT2. The identification of VOCs selected by the statistical approaches was done by 
using the National Institute of Standards and Technology (NIST 14) data base spectra 
library and by comparing experimental Kovats indexes and kovats indexes from literature. 
To confirm the importance of these metabolites univariate analysis was performed to 
calculate the p value, the variation quotient and the effect size.  
After univariate analysis the VOCs that were taken into account, were those with p<0.05; 
relevant value of variation quotient; and relevant effect size. Therefore, a total of eight 
VOCs proved to be relevant to differentiate 22RV1 from PNT2, eight VOCs proved to be 
relevant to differentiate PC3 from PNT2, seven VOCs proved to be relevant to 
differentiate DU145 from PNT2 and seven proved to be relevant to differentiate LNCaP 
from PNT2. All these results are shown in detail in Table 2 (22RV1 vs PNT2), Table 3 
(PC3 vs PNT2), Table 4 (DU145 vs PNT2) and Table 5 (LNCaP vs PNT2).These VOCs 
Figure 3: PLS-DA from PCa cell line vs normal cell line. A: 22RV1 (PCa cells) (dark blue) vs 
PNT2 (normal cells) (green) (R2X=0.436; R2Y=0.989; Q2=0.967). B: PC3 (PCa cells) (light blue) 
vs PNT2 (normal cells) (green) (R2X=0.667; R2Y=0.985; Q2=0.973). C: DU145 (PCa cells) (red) 
vs PNT2 (normal cells) (green) (R2X=0.401; R2Y=0.959; Q2=0.884). D: LNCaP (PCa cells) 
(yellow) vs PNT2 (normal cells) (green) (R2X=0.486; R2Y=0.97; Q2=0.931). 
A B 
C D 
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include ketones, alcohols, aldehydes, among others. From these VOCs two stand out, 
namely, 1,3-benzothiazole and pentadecan-2-one because they reveal to be important for 
the separation among all PCa cell lines and normal cell line. However, several other 
VOCs were identified and were also able to discriminate between cancer and normal cell 
lines, namely, 3,7-Dimethyloct-7-en-1-ol (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs 
PNT2), 2-methylundecanal, (PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2), 2,7-
dimethyloctan-1-ol  (PC3 vs PNT2), 2-(1-4-Methylcyclohex-3-en-1-yl)propan-2-ol (PC3 vs 
PNT2), decan-1-ol (DU145 vs PNT2), 1-methoxypropan-2-yl acetate (LNCaP vs PNT2), 
and 1,4-xylene  (LNCaP vs PNT2). Some unidentified VOCs were also important for the 
discrimination between cancer and normal cell lines (Table 2; Table 3; Table 4; Table 5) 
(Figure 4; Figure 5; Figure 6; Figure 7).   
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Table 2: List of metabolites selected in PLS-DA of 22RV1 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained at pH 7. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental KI MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
3-Methylbut-3-en-1-ol 3.57 67/68 730 749 881 763-32-6 >0.05    7.3 ± 5.4    
1-Methoxypropan-2-yl 
acetate 
6.47 58/72 850 863 911 108-65-6 >0.05    30.4± 16.7    0.85± 0.81 
Unknown 8.3 58/69 NA 930 NA NA >0.05         
Unknown  10.87 56 NA 1016 NA NA 0.0204    62.5± 47.4     
2,6-Dimethyloct-7-en-
2-ol 
12.5 67 1064 1070 851 18479-
58-8 
>0.05       
Nonan-2-one 13.06 58 1092 1088 900 821-55-6 >0.05         
Unknown 14.21 55 NA 1127 NA NA >0.05   80.1 ± 47.2      1.12± 0.83 
2,7-Dimethyloctan-1-
ol (dihydro citronellol) 
14.26 56 69 1130 1128 727 15250-
22-3 
>0.05         
Naphthalene 15.83 51/102/127 1182 1182 914 91-20-3 0.0011P     49.2 ± 8.8     1.76± 0.92 
6-Ethyl-2-
methyldecane 
16.32 57/71/85 1185 1198 878 62108-
21-8 
>0.05           
3,7-Dimethyloct-7-
en-1-ol (α-citronellol) 
16.71 
 
67/81 
 
1214 
 
1212 
 
791  0.0096   48.8± 20.3    1.26± 0.85 
1,3-Benzothiazole 16.98 
 
135/108 
 
1229 
 
1222 
 
896 95-16-9 <0.000
1P 
   75.0 ±6.8    6.91 ± 2.10 
Unknown 17.03 69/ 67 NA 1224 NA NA 0.0011P    58.3± 22.2    1.46± 0.88 
Unknown 19.51 140/125/57 NA 1313 NA NA 0.0024   14.6± 3.8   1.43± 0.87 
Unknown 20.18 72 NA 1338 NA NA >0.05         
2-Methylpropyl 3-
hydroxy-2,2,4-
trimethylpentanoate 
20.33 56 71 1331 1344 783 NA >0.05         
5-Pentyloxolan-2-one 
or γ-Nonanoic lactone 
20.63 85 1363 1355 818 104-61-0 >0.05         
Unknown 23.12 158 NA 1452 NA NA >0.05         
Unknown 23.34 85 NA 1461 NA NA >0.05         
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental KI MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Unknown 24.1 58 119 NA 1491 NA NA <0.000
1P 
  63.5± 4.7   4.03 ± 1.38 
Hexadecane 26.6 57 85 1600 1596 907 544-76-3 >0.05       
Pentadecan-2-one 28.78 58 59 71 1698 1689 835 2345-28-
0 
<0.000
1P 
  203.5 ± 5.4   7.34 ± 2.22 
Unknown 28.87 57 85 NA 1693 NA NA 0.0003P   58.6 ±10.1   1.76 ± 0.92 
 
 
 
 
 
 
 
 
 
 
 
 
KI: Kovat indices; not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 2.17x10-3 (0.05 divided by 23 
analyzed VOCs); RT: Retention Time.  
	
Figure 4: Boxplots from the metabolites important for the separation between 22RV1 (PCa cells) and 
PNT2 (normal cells), after univariate analysis, obtained at pH 7. 
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Table 3: List of metabolites selected in PLS-DA of PC3 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination 
between PCa and normal cell lines obtained at pH 7. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
1,4-Xylene 6.57 91 865 867 907 106-42-3 >0.05    10.74± 6.87     
Unknown  10.87 56 NA 1016 NA NA >0.05         
2,6-Dimethyloct-7-
en-2-ol 
12.5 67 1064 1070 851 18479-
58-8 
>0.05         
Nonan-2-one 13.06 58 1092 1088 900 821-55-6 >0.05         
Unknown 14.21 55 NA 1127 NA NA >0.05         
2,7-Dimethyloctan-
1-ol 
14.26 56 69 1130 1128 727 15250-
22-3 
<0.0001P    74.48± 7.9    5.91± 1.84 
2-(1-4-
Methylcyclohex-3-
en-1-yl)propan-2-ol 
(α-Terpineol) 
16.14 93/136 1190 1192 869 10482-
56-1 
<0.0001P   58.47± 4.51   7.22± 2.18 
3,7-Dimethyloct-7-
en-1-ol (α-
citronellol) 
16.71 
 
67/81 
 
1212 
 
1212 
 
791 6812-78-
8 
<0.0001P   58± 21.18    1.52± 0.88 
1,3-Benzothiazole 16.98 
 
135/108 
 
1229 
 
1222 
 
896 95-16-9 <0.0001P    70.22 ±7.35   7.03 ± 2.13 
Unknown 17.03 69/67 NA 1224 NA NA >0.05         
2-Methylundecanal 18.86 58/71 1306 1289 810 110-41-8 0.0029P   58.67±11   1.54± 0.89 
Unknown 20.18 72 NA 1338 NA NA >0.05         
2-Methylpropyl 3-
hydroxy-2,2,4-
trimethylpentanoate 
20.33 56/71 1331 1344 783 NA >0.05         
Unknown 24.1 58/119 NA 1491 NA NA <0.0001P   177.78± 
6.14 
  6.03 ± 1.87 
Pentadecan-2-one 28.78 
 
58/59/71 
 
1698 
 
1689 
 
835 2345-28-
0 
<0.0001P   848.29 ± 
6.06 
  10.53 ±3.07 
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Unknown 28.87 57/85 NA 1693 NA NA <0.0001P    181.87 
±4.63 
  8.1 ± 2.42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 3.12x10-3 (0.05 divided by 16 
analyzed VOCs); RT: retention time. 
	
Figure 5: Boxplots from the metabolites important for the separation between PC3 (PCa cells) and PNT2 (normal 
cells), after univariate analysis, obtained at pH 7. 
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Table 4: List of metabolites selected in PLS-DA of DU145 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained at pH 7. 
Chemical name 
(IUPAC) or 
common name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
4-Methylpentan-2-
one 
3.71 57  735 755 862 108-10-1 >0.05   45.57 ±28.50    
4-Methylpent-3-en-
2-one 
4.81 55 83 798 798 869 141-79-7 >0.05   22.18± 13.60     
1-Methoxypropan-
2-yl acetate 
6.47 58 72 850 863 911 108-65-6 >0.05   72.03±8.56   1.11±0.85 
1,4-Xylene 6.57 91 865 867 907 106-42-3 >0.05   89.15±32.29    
Unknown 9.22 59 NA 961 NA NA 0.0414    32.26± 15.95    0.92± 0.83 
Unknown 9.95 58/85 NA 985 NA NA >0.05    20.36± 12.46     
Unknown  10.87 56 NA 1016 NA NA >0.05    62.5± 47.4    0.76± 0.80 
4,6-
Dimethylheptan-2-
one 
11.91 78/84 1045 1050 836 19549-
80-5 
>0.05         
2,6-Dimethyloct-7-
en-2-ol 
12.5 67 1064 1070 851 18479-
58-8 
>0.05   46.05±30.73    
Nonan-2-one 13.06 58 1092 1088 900 821-55-6 >0.05         
Unknown 14.21 55 NA 1127 NA NA >0.05       
2,7-Dimethyloctan-
1-ol 
14.26 56/69 1130 1128 727 15250-
22-3 
>0.05       
Unknown 14.62 55 NA 1141 NA NA >0.05       
3,7-Dimethyloct-7-
en-1-ol 
16.71 
 
67/81 
 
1214 
 
1212 
 
791 6812-78-
8 
<0.001P   73.13± 23.15    1.86± 0.95 
1,3-Benzothiazole 16.98 
 
135/108 
 
1229 
 
1222 
 
896 95-16-9 0.0348   23.35±8.56   1.02±0.84 
Unknown 17.03 69/67 NA 1224 NA NA 0.0010P    23.26±6.27    1.63± 0.91 
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Chemical name 
(IUPAC) or 
common name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Decan-1-ol 18.3 55/69 1257 1269 888 112-30-1 0.0251   18.24±6.65   1.01±0.84 
2-
Methylundecanal 
18.86 58/71 1306 1289 810 110-41-8 0.0037    31.88± 10.31    1.41± 0.88 
Unknown 19.51 140/125/57 NA 1313 NA NA >0.05    9.18±5.37     
2-Methylpropyl 3-
hydroxy-2,2,4-
trimethylpentanoate 
20.33 56/71 1331 1344 783 NA 0.0267   32.07± 16.86    
5-Pentyloxolan-2-
one (γ-Nonanoic 
lactone) 
20.63 85 1363 1355 818 104-61-0 >0.05   65.35± 36.32    
Unknown 23.12 158 NA 1452 NA NA >0.05   64.14± 37.74    
Unknown 23.97 57/69 NA 1486 NA NA 0.0338   20.39± 7.80  0.96± 0.84 
Unknown 24.1 58/119 NA 1491 NA NA >0.05       
Hexadecane 26.6 57/85 1600 1596 907 544-76-3 >0.05   31.52± 18.52    
Pentadecan-2-one 28.78 
 
58/59/71 
 
1698 
 
1689 
 
835 2345-28-
0 
0.0007P   58.66 ±10.04   1.89 ± 0.96 
Unknown 28.87 57/85 NA 1693 NA NA >0.05       
 
 
 
 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 1.85X10-3 (0.05 divided by 27 analyzed 
VOCs); RT: retention time. 
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Figure 6: Boxplots from the metabolites important for the separation between DU145 (PCa cells) and PNT2 (normal 
cells), after univariate analysis, obtained at pH 7. 
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Table 5: List of metabolites selected in PLS-DA of LNCaP (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained at pH 7. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental KI MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
3-Methylbut-3-en-2-
ol 
2.95 58 737 725 724 10473-14-
0 
0.0018P   34.78±7.88   1.48±0.88 
1-Methoxypropan-2-
yl acetate 
6.47 58/72 850 863 911 108-65-6 0.0447   70.57±18.49   1.11±0.83 
1,4-Xylene 6.57 91 865 867 907 106-42-3 0.0011P   182.61± 24.11   1.56±0.89 
Unknown 8.3 58/69 NA 930 NA NA >0.05   11.59±10.16    
Unknown 9.95 58/85 NA 985 NA NA 0.0204   30.56±10.07   1.04±0.83 
Unknown  10.87 56 NA 1016 NA NA >0.05    55.61± 31.41     
4,6-Dimethylheptan-
2-one 
11.91 78/84 1045 1050 836 19549-80-
5 
>0.05   11.34±8.23    
Nonan-2-one 13.06 58 1092 1088 900 821-55-6 >0.05       
Unknown 14.21 55 NA 1127 NA NA >0.05   38.6±26.35    
2,7-Dimethyloctan-1-
ol 
14.26 56/69 1130 1128 727 15250-22-
3 
>0.05   32.61± 28.71    
Benzyl acetate  15.15 150 1164 1159 801 140-11-4 >0.05   159.11± 37.11   0.94± 0.82 
6-Ethyl-2-
methyldecane 
16.32 57/71/85 1185 1198 878 62108-21-
8 
>0.05   20.83± 10.32    
Decanal 16.44 56/57/70 1206 1203 880 112-31-2 0.0068   83.27± 29.23    
3,7-Dimethyloct-7-en-
1-ol 
16.71 
 
67/81 
 
1214 
 
1212 
 
791 6812-78-8 >0.05   137.92± 28.06   1.14± 0.84 
1,3-Benzothiazole 16.98 
 
135/108 
 
1229 
 
1222 
 
896 95-16-9 <0.0001P   69.91± 7.11   5.96±1.86 
Unknown 17.03 69/67 NA 1224 NA NA 0.0023P    34.1±15.37    1.05± 0.83 
2-Methylundecanal 18.86 58/71 1306 1289 810 110-41-8 0.0045   71.77±15.15   1.37±0.86 
Unknown 19.51 140/125/57 NA 1313 NA NA >0.05       
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental KI MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
2-Methylpropyl 3-
hydroxy-2,2,4-
trimethylpentanoate 
20.33 56/71 1331 1344 783 NA >0.05         
Unknown 24.1 58/119 NA 1491 NA NA 0.0016P   36.55±7.49   1.63±0.9 
Pentadecan-2-one 28.78 
 
58/59/71 
 
1698 
 
1689 
 
835 2345-28-0 <0.0001P   73.12 ±9.26   2.27 ±1.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 2.38X10-3 (0.05 divided by 21 
analyzed VOCs); RT: retention time. 
 
	
Figure 7: Boxplots from the metabolites important for the separation between LNCaP (PCa cells) and PNT2 (normal 
cells), after univariate analysis, obtained at pH 7. 
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A new PLS-DA models using only discriminant metabolites (Figure 8) was performed. To 
prove the robustness of the models, a MCCV validation was performed for all 
comparisons, using GC-MS full data but also using just the discriminant metabolites 
described before. The results of this validation prove that all created models are robust for 
the discrimination between PCa cell lines and normal cell line (Table 6 and Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 8: PLS-DA from PCa cell line vs normal cell line with the set of discriminant VOCs. A. 22RV1 (PCa 
cells) (dark blue) vs PNT2 (normal cells) (green) (R2X=0.889; R2Y=0.971; Q2=0.957). B. PC3 (PCa cells) 
(light blue) vs PNT2 (normal cells) (green) (R2X=0.987; R2Y=0.979; Q2=0.974). C. DU145 (PCa cells) (red) 
vs PNT2 (normal cells) (green) (R2X=0.831; R2Y=0.738; Q2=0.66). D. LNCaP (PCa cells) (yellow) vs PNT2 
(normal cells) (green) (R2X=0.891; R2Y=0.94; Q2=0.925). 
 
A B 
C D 
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Figure 9: Q2 distribution and ROC plot of true and permuted classes obtained by Monte Carlo 
cross validation for 22RV1 (PCa cells) vs PNT2 (normal cells) obtained at pH 7. 
 
Table 6: MCCV parameters of true and permuted classes obtained for pH 7 when considering GC-
MS full data and the set of discriminant VOCs.  
Models 
True classes Permuted classes 
LV Q2 
CR 
(%) 
Sens
. (%) 
Spec
. (%) 
LV Q2 
CR 
(%) 
Sen
s. 
(%) 
Spec
. (%) 
GC-MS full data  
22RV1 vs PNT2 5 0.91 100 100 100 1 -0.28 47 47 47 
PC3 vs PNT2 2 0.99 100 100 100 1 -0.29 48 49 48 
DU145 vs PNT2 3 0.94 100 99 100 1 -0.42 47 44 50 
LNCaP vs PNT2 4 0.90 100 100 100 1 -0.29 48 48 48 
Set of discriminant VOCs  
22RV1 vs PNT2 1 0.94 100 100 100 1 -0.26 48 48 47 
PC3 vs PNT2 1 0.98 100 100 100 1 -0.14 49 44 54 
DU145 vs PNT2 1 0.72 87 100 75 1 -0.34 47 42 51 
LNCaP vs PNT2 2 0.96 100 100 100 1 -0.32 45 45 45 
 
 
 
 
 
 
LV:  no. of latent variables; Q2:  median predictive power; CR: classification rate; sens.: sensitivity, 
spec.: specificity. 
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VOCs analysis obtained at pH 2 
The same samples analyzed at pH 7 were also analyzed at pH 2. It is important to use 
two different pH levels because variations of pH can lead to the alteration of the VOCs 
ionization state, consequently VOCs that are undetected at pH 7, can be detected at pH 
2. Despite the alteration of pH, the analytical procedure and the statistical treatment used 
for VOCs obtained at pH 2 were the same used for pH 7. A total of 221 features were 
detected in the chromatograms from pH 2 samples. 
The multivariate analysis of chromatograms obtained at pH 2, shows that the analytical 
method is reproducible, which can be seen in Figure 10 (all QCs samples are projected 
together in the space formed by the first three PCA axes). Furthermore, the multivariate 
analyses prove that VOCs obtained at pH 2 are also able to discriminate PCa cell lines 
from normal prostate cell line and between the different PCa cell lines, this discriminant 
capability is observed not only in PLS-DA analysis but also in PCA (Figure 11). 
 
   
 
Figure 10: PCA with QCs samples (in orange) and VOCs from all cell lines and controls (blue) 
obtained  at pH 2 (R2X = 0.562). 
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Figure 11:  PCA (A) (R2X = 0.582) and PLS-DA (B) (R2X = 0.526; R2Y = 0.457; Q2 = 0.437) with 
VOCs from all cells line obtained at pH 2 (PNT2 (normal cells): green; 22RV1 (PCa cells): dark 
blue; PC3 (PCa cells): light blue; DU145 (PCa cells): red; LNCaP (PCa cells): yellow).  
 
To evaluate which were the VOCs responsible for this separation all cancer cell lines were 
compared with the normal cell line, namely 22RV1 vs PNT2, PC3 vs PNT2, DU145 vs 
PNT2 and LNCaP vs PNT2. An optimal separation between PCa cell lines and normal cell 
line was observed (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
D 
A 
C 
B 
Figure 12: PLS-DA from PCa vs PNT2 obtained at pH 2. A. 22RV1 (PCa cells) (dark blue) vs 
PNT2 (normal cells) (green) (R2X=0.586; R2Y=0.976; Q2=0.956). B. PC3 (PCa cells) (light blue) 
vs PNT2 (normal cells) (green) (R2X=0.721; R2Y=0.976; Q2=0.957). C. DU145 (PCa cells) (red) 
vs PNT2 (normal cells) (green) (R2X=0.788; R2Y=0.987; Q2=0.969). D. LNCaP (PCa cells) 
(yellow) vs PNT2 (normal cells) (green) (R2X=0.729; R2Y=0.989; Q2=0.983). 
B A 
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Despite some VOCs detected at pH 2 are the same detected at pH 7, as expected, the pH 
alteration promoted the detection of different VOCs that were not detected at pH 7, 
principally organic acids. As previously explained all VOCs with VIP values greater than 
one were considered potentially relevant for the separation among cell lines (a total of 32 
VOCs for 22RV1 vs PNT2, 25 VOCs for PC3 vs PNT2, 21 VOCs for DU145 vs PNT2 and 
24 for LNCaP vs PNT2). To confirm the importance of these metabolites univariate 
analysis was performed to calculate the p value, the variation quotient and the effect size. 
In Table 7 (22RV1 vs PNT2), Table 8 (PC3 vs PNT2), Table 9 (DU145 vs PNT2) and 
Table 10 (LNCaP vs PNT2) are shown, in detail, all these results.  
After univariate analysis the VOCs that were taken into account, were those with p<0.05; 
relevant value of variation quotient; and relevant effect size. Therefore, a total of 11 VOCs 
proved to be relevant to differentiate 22RV1 from PNT2, 19 VOCs proved to be relevant to 
differentiate PC3 from PNT2, 13 VOCs proved to be relevant to differentiate DU145 from 
PNT2 and 13 proved to be relevant to differentiate LNCaP from PNT2. Comparing to pH 
7, the statistical analyses of results of pH 2, revealed more discriminant VOCs. From 
these VOCs eight stand out, namely, cyclohexanone, 4-methylheptan-2-one, 2-
methylpentane-1,3-diol, 4-methylbenzaldehyde, 1-(3,5-dimethylfuran-2-yl) ethanone, 
methyl benzoate, nonanoic acid and decanoic acid because they reveal to be important 
for the separation between all PCa cell lines and normal cell line. Other VOCs revealed to 
be more specific of each cell line, only allowing discrimination between some cell lines, 
namely, 4-methylpent-3-en-2-one (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs PNT2), 5-
methylheptan-2-one (PC3 vs PNT2, DU145 vs PNT2 and LNCaP vs PNT2), 
phenylethanol (22RV1 vs PNT2, PC3 vs PNT2, DU145 vs PNT2), 4-methylnonanoic acid 
(22RV1 vs PNT2 and LNCaP vs PNT2), benzyl acetate (22RV1 vs PNT2 and LNCaP vs 
PNT2), 5-methyl-2-propan-2-ylcyclohexan-1-ol (PC3 vs PNT2 and LNCaP vs PNT2), 1-
ethoxypentane (DU145 vs PNT2 and LNCaP vs PNT2), methyl nonanoate (22RV1 vs 
PNT2),  2-ethoxy-2-methylbutane (PC3 vs PNT2), hexanoic acid (PC3 vs PNT2), 
phenylmethanol (PC3 vs PNT2), 2,4-dimethylheptan-1-ol (PC3 vs PNT2), benzoic acid 
(PC3 vs PNT2), 6-pentyloxan-2-one (PC3 vs PNT2). Some unidentified VOCs were also 
important for the discrimination between cancer and normal cell lines (Table 7; Table 8; 
Table 9; Table 10) (Figure 13; Figure 14; Figure 15; Figure 16) 
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Table 7: List of metabolites selected in PLS-DA of 22RV1 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained  at pH 2. 
Chemical name 
(IUPAC) or 
common name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
2-Ethoxy-2-
methylbutane  
2.49 59 728 707 683 919-94-8  >0.05    26.6± 19.9     
Unknown 4.18 
 
70 NA 773 NA NA >0.05       
4-Methylpent-3-en-
2-one 
4.81 55/83/98 798 798 855 141-79-7  <0.0001P    47.2± 7.1    3.44± 1.24 
Cyclohexanone 7.2 98/70 894 891 904 108-94-1  <0.0001P    81.1± 7.0    7.72±2.32 
2-Methylheptan-2-ol 7.25 59 885 893 748 625-25-2  >0.05       
4-Methylheptan-2-
one 
8.44 58/59 943 934 928 6137-06-
0 
<0.0001P    28.6±6.3    2.10±0.97 
Hexanoic acid 10 87 990 987 959 142-62-1  >0.05         
2-Methylpentane-
1,3-diol 
10.65 57/89 1005 1009 682 149-31-5 0.0105    10.7± 3.8    1.17± 0.84 
Phenylmethanol 11.33 77 1036 1031 799 100-51-6  >0.05   35.5±19.6    
2,4-Dimethylheptan-
1-ol  
11.91 57 1030 1050 731 18450-
73-2  
>0.05   32.7±20.1    
Phenylethanol 12.14 77/122 1055 1058 847 1517-69-
7  
<0.0001P    38.1 ±7.9    2.36 ±1.02 
4-Methyl-
benzaldehyde  
12.82 91/119/120 1095 1080 953 104-87-0  0.0022    10.6±3.0    1.47± 0.88 
1-(3,5-
Dimethylfuran-2-yl) 
ethanone 
12.99 123/138 1057 1086 760 22940-
86-9 
<0.0001P    47.8± 5.3    4.79± 1.56 
Methyl benzoate 13.15 77/105/136 1094 1091 921 93-58-3 <0.0001P    42.2± 3.9    5.51± 1.74 
Benzyl acetate 15.15 90/135 1164 1159 770 140-11-4 <0.0001P    35.17±6.1    2.75±1.10 
Benzoic acid 15.33 122 1170 1165 837 65-85-0 >0.05         
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Chemical name 
(IUPAC) or 
common name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
5-Methyl-2-propan-
2-ylcyclohexan-1-ol 
(DL-menthol) 
15.66 71/75/81 1175 1176 914 2216-51-
5  
>0.05         
Methyl nonanoate 17.09 87/129 1225 1226 745 1731-84-
6  
<0.0001P   366.0± 7.9   6.46±1.98 
4-Methyloctanoic 
acid  
17.22 99 1208 1231 882 54947-
74-9  
0.0447    30.4± 20.7     
Ethyl 2-
phenylacetate 
17.44 164 1246 1238 918 101-97-3  >0.05    31.9± 19.8     
Unknown 17.52 96 NA 1241 NA NA >0.05         
Unknown 17.71 81 NA 1248 NA NA >0.05         
5-Butyloxolan-2-one 
(γ-octalactone) 
17.79 85 1261 1251 866 104-50-7  >0.05    18.1± 15.2     
Nonanoic acid 18.33 73/115 1273 1279 909 112-05-0  <0.0001P    55.6± 8.8    3.47± 1.25 
Unknown 18.55 66/117 NA 1278 NA NA <0.0001P    94.9± 11.8    6.05± 1.88 
4-Methylnonanoic 
acid 
19.5 60/113 1308 1313 798 45019-28 <0.0001P   1217.1±11.7   5.79± 1.81 
5-Pentyloxolan-2-
one (γ-Nonanoic 
lactone) 
20.63 85 1363 1355 890 104-61-0  >0.05         
Decanoic acid 20.94 60/73/129 1373 1367 931 334-48-5  0.0027   71.1± 14.0   1.47± 0.88 
Unknown 22.2 73 NA 1416 NA NA >0.05    20.9± 17.1     
5-hexyloxolan-2-one 
(γ-decalactone) 
23.32 85 1470 1460 909 706-14-9  >0.05       
Undec-2-enoic acid 23.83 99 1479 1481 635 15790-
94-0  
>0.05      
6-Pentyloxan-2-one 
(δ-decalactone) 
 
23.97 99 1496 1486 863 705-86-2  >0.05         
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 1.56X10-3 (0.05 divided by 32 
analyzed VOCs). 
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Figure 13: Boxplots from the metabolites important for the separation between 22RV1 (PCa cells) and 
PNT2 (normal cells), after univariate analysis, at pH 2. 
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Table 8: List of metabolites selected in PLS-DA of PC3 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between PCa 
and normal cell lines obtained at pH 2. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
2-Ethoxy-2-
methylbutane 
2.49 59 728 707 683 919-94-8  0.0342   38.26± 19.77    0.94±0.81 
1-Ethoxypentane 3.63 59/70 760 752 786 17952-
11-3 
0.0056       
Unknown 4.18 70 NA 773 NA NA >0.05   34.73± 20.54     
4-Methylpent-3-en-2-
one 
4.81 55/83/98 798 798 855 141-79-7  <0.0001P    62.38± 7.88    4.54± 1.5 
Cyclohexanone 7.2 98/70 894 891 904 108-94-1  <0.0001P    50.48± 5.88    4.53±1.5 
4-Methylheptan-2-one 8.44 58/59 943 934 928 6137-06-
0 
0.0003P    38.37±8.84    2.11±0.98 
5-Methylheptan-2-one 9.35 58/71 971 965 714 18217-
12-4 
<0.0001P    51.58± 6.11    4.48± 1.48 
Hexanoic acid 10 87 990 987 959 142-62-1  0.0092   40 ±16.66    1.18±0.84 
2-Methylpentane-1,3-
diol 
10.65 57/89 1005 1009 682 149-31-5 <0.0001P    45.1± 5.81    3.95± 1.36 
Phenylmethanol 
 
11.33 77 1036 1031 799 100-51-6  0.0189    33.69± 15.3    1.04± 0.83 
2,4-Dimethylheptan-1-
ol 
 
11.91 57 1030 1050 731 18450-
73-2  
0.0210    35.32 ±16.5    1.02 ±0.83 
Phenylethanol 12.14 77/122 1055 1058 847 1517-69-
7  
<0.0001P    69.81 ±8.12    5.2 ±1.66 
4-
Methylbenzaldehyde 
12.82 91/119/120 1095 1080 953 104-87-0  <0.0001P    38.0±2.98    6.20± 1.92 
1-(3,5-Dimethylfuran-
2-yl) ethanone 
12.99 123/138 1057 1086 760 22940-
86-9 
<0.0001P    41.51± 5.09    4.06± 1.38 
Methyl benzoate 13.15 77/105/136 1094 1091 921 93-58-3 <0.0001P    53.12± 4.1    6.95± 2.11 
Benzoic acid 15.33 122 1170 1165 837 65-85-0 0.0331    37.17±17.66    1.01±0.82 
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
5-Methyl-2-propan-2-
ylcyclohexan-1-ol 
(DL-menthol) 
15.66 71/75/81 1175 1176 914 2216-51-
5  
0.0068    45.82±18.48    1.27±0.85 
Unknown 17.52 96 NA 1241 NA NA 0.0321    30.2±14.74    0.95±0.82 
5-Butyloxolan-2-one (γ-
Octalactone) 
17.79 85 1261 1251 866 104-50-7  >0.05    28.49± 17.02     
Nonanoic acid 18.33 73/115 1273 1279 909 112-05-0  <0.0001P    59.85± 7.41    4.54± 1.5 
Unknown 18.55 66/117 NA 1278 NA NA <0.0001P    91.07± 11.48    5.74± 1.8 
Decanoic acid 20.94 60/73/129 1373 1367 931 334-48-5  <0.0001P   250.44± 18.1    2.42± 1.03 
Unknown 22.2 73 NA 1416 NA NA 0.0004P    38.38± 10.98    1.71±0.91 
5-hexyloxolan-2-one 23.32 85 1470 1460 909 706-14-9  >0.05       
6-Pentyloxan-2-one 
(δ-decalactone) 
23.97 99 1496 1486 863 705-86-2  0.0006P    39.93±11.98    1.64±0.9 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 2.00X10-3 (0.05 divided by 25 
analyzed VOCs); RT: retention time. 
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Figure 14: Boxplots from the metabolites important for the separation between PC3 (PCa cells) and PNT2 (normal cells), after univariate analysis, at pH 2. 
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Table 9: List of metabolites selected in PLS-DA of DU145 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained at pH 2. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
1-Ethoxypentane 3.63 59/70 760 752 786 17952-
11-3 
0.0010p    31.16± 9.21   1.58±0.89 
4-Methylpent-3-en-2-
one 
4.81 55/83/98 798 798 855 141-79-7  <0.0001p    48.54± 9.03   2.8±1.11 
Cyclohexanone 7.2 98/70 894 891 904 108-94-1  <0.0001p    82.41± 7.28   7.59±2.28 
4-Methylheptan-2-
one 
8.44 58/59 943 934 928 6137-06-
0 
<0.0001p    36.06±6.93   2.51±1.05 
5-Methylheptan-2-
one 
9.35 58/71 971 965 714 18217-
12-4  
<0.0001p    27.47±5.97   2.1±0.97 
Hexanoic acid 10 87 990 987 959 142-62-1  >0.05         
2-Methylpentane-1,3-
diol 
10.65 57/89 1005 1009 682 149-31-5 <0.0001p    25.79± 3.95   2.95± 1.14 
Phenylmethanol 11.33 77 1036 1031 799 100-51-6  >0.05       
2,4-Dimethylheptan-1-
ol 
 
11.91 57 1030 1050 731 18450-
73-2  
>0.05        82.41± 
7.28 
Phenylethanol 12.14 77/122 1055 1058 847 1517-69-
7  
<0.0001p    38.79 ±8.76    2.16 ±0.99 
4-
Methylbenzaldehyde 
12.82 91/119/120 1095 1080 953 104-87-0  <0.0001p    32.04±2.39    6.29± 1.94 
1-(3,5-Dimethylfuran-
2-yl)ethanone 
12.99 123/138 1057 1086 760 22940-
86-9 
<0.0001p    46.45± 6.01    3.96± 1.36 
Methyl benzoate 13.15 77/105/136 1094 1091 921 93-58-3 <0.0001p    51.06± 5.58    4.84± 1.57 
Benzoic acid 15.33 122 1170 1165 837 65-85-0 >0.05         
5-methyl-2-propan-2-
ylcyclohexan-1-ol 
(DL-menthol) 
15.66 71/75/81 1175 1176 914 2216-51-
5  
0.0447    27.4±14.89    0.84±0.81 
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Nonanoic acid 18.33 73/115 1273 1279 909 112-05-0  <0.0001p    31.32± 6.29    2.33± 1.02 
5-Pentyloxolan-2-one 20.63 85 1363 1355 890 104-61-0  >0.05   13.92±11.08     
Decanoic acid 20.94 60/73/129 1373 1367 931 334-48-5  <0.0001p   268.37± 8.66   5.21±1.67 
Unknown 22.2 73 NA 1416 NA NA >0.05         
5-hexyloxolan-2-one  
(γ - Decalactone) 
23.32 85 1470 1460 909 706-14-9  >0.05       
6-Pentyloxan-2-one (δ-
decalactone) 
 
23.97 99 1496 1486 863 705-86-2  >0.05         
 
 
 
 
 
 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cut off p value of 2.38x10-3 (0.05 divided by 21 analyzed 
VOCs); RT: retention time. 
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Figure 15: Boxplots from the metabolites important for the separation between DU145 (PCa cells) and PNT2 (normal cells), after 
univariate analysis, obtained at pH 2. 
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Table 10: List of metabolites selected in PLS-DA of LNCaP (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines obtained at pH 2. 
Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
2-Ethoxy-2-
methylbutane 
 
2.49 59 728 707 683 919-94-8  >0.05         
1-Ethoxypentane 3.63 59/70 760 752 786 17952-
11-3 
0.0001p    35.34± 8.69    1.95± 0.95 
4-Methylpentan-2-one 3.71 58 735 755 907 108-10-1  >0.05       
Cyclohexanone 7.2 98/70 894 891 904 108-94-1  <0.0001P    80.15± 7.33    7.19±2.18 
4-Methylheptan-2-
one 
8.44 58/59 943 934 928 6137-06-
0 
0.0014p    26.3±7.86    1.52±0.88 
5-Methylheptan-2-
one 
9.35 58/71 971 965 714 18217-
12-4 
0.0014p    20.36±5.95    1.5±0.88 
Hexanoic acid 10 87 990 987 959 142-62-1  >0.05       
2-Methylpentane-1,3-
diol 
10.65 57/89 1005 1009 682 149-31-5 <0.0001p    24.26±5.53    1.97± 0.95 
Phenylmethanol 11.33 77 1036 1031 799 100-51-6  >0.05       
2,4-Dimethylheptan-1-
ol 
 
11.91 57 1030 1050 731 18450-
73-2  
>0.05       
4-
Methylbenzaldehyde 
12.82 91/119/120 1095 1080 953 104-87-0  0.0005p    18.39±4.31    1.85± 0.93 
1-(3,5-Dimethylfuran-
2-yl) ethanone 
12.99 123/138 1057 1086 760 22940-
86-9 
0.0003p    21.78± 5.5    1.75± 0.91 
Methyl benzoate 13.15 77/105/136 1094 1091 921 93-58-3 <0.0001P    22.45± 4.27    2.33± 1.01 
Benzyl acetate 15.15 90/135 1164 1159 770 140-11-4 0.0090   23.73±7.0   1.19±0.84 
Benzoic acid 15.33 122 1170 1165 837 65-85-0 >0.05       
5-methyl-2-propan-2-
ylcyclohexan-1-ol 
(DL-menthol) 
15.66 71/75/81 1175 1176 914 2216-51-
5  
0.0019p    42.1±13.39    1.57±0.89   
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Chemical name 
(IUPAC) or common 
name 
RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Ethyl 2-phenylacetate 17.44 164 1246 1238 918 101-97-3  >0.05       
Nonanoic acid 18.33 73/115 1273 1279 909 112-05-0  <0.0001P    66.28± 7.67    5.09± 1.64 
4-Methylnonanoic 
acid 
19.5 60/113 1308 1313 798 45019-28 <0.0001P   3242.3±10.9  65.79± 2.07 
5-Pentyloxolan-2-one 20.63 85 1363 1355 890 104-61-0  >0.05         
Decanoic acid 20.94 60/73/129 1373 1367 931 334-48-5  0.0122   74.5± 19.0   1.13± 0.83 
Unknown 22.2 73 NA 1416 NA NA >0.05       
5-hexyloxolan-2-one 23.32 85 1470 1460 909 706-14-9  >0.05       
6-Pentyloxan-2-one 23.97 99 1496 1486 863 705-86-2  >0.05       
 
 
 
 
 
 
 
 
 
 
 
 
KI: Kovat indices; NA: not available; P Alterations remaining significant after Bonferroni correction, with cut-off p value of 2.08x10-3 (0.05 divided by 24 
analyzed VOCs) RT: retention time. 
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 Figure 16: Boxplots from the metabolites important for the separation between LNCaP ( PCa cells) and PNT2 (normal cells), after univariate analysis, obtained at pH 2. 
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New PLS-DA models using just these set of discriminant metabolites (Figure 17) were 
performed. To prove the robustness of the models a MCCV validation was performed for 
all comparisons, using GC-MS full data and also using discriminant VOCs obtained at pH 
2 described before. Results of these validations prove that all created models are robust 
for the discrimination between PCa cell lines and normal cell line (Table 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: PLS-DA from PCa cell line vs normal cell line with the set of discriminant VOCs obtained at pH 
2. A. 22RV1 (PCa cells) (dark blue) vs PNT2 (normal cells)(green) (R2X=0.824; R2Y=0.977; Q2=0.945). B. 
PC3 (PCa cells) (light blue) vs PNT2 (normal cells) (green) (R2X=0.924; R2Y=0.945; Q2=0.919). C. DU145 
(PCa cells) (red) vs PNT2 (normal cells) (green) (R2X=0.927; R2Y=0.933; Q2=0.9). D. LNCaP (PCa cells) 
(yellow) vs PNT2 (normal cells) (green) (R2X=0.868; R2Y=0.945; Q2=0.926). 
A B 
C D 
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Table 11: MCCV parameters of true and permuted classes obtained for pH 2 when considering 
GC-MS full data and the set of discriminant VOCs.  
Models 
True classes Permuted classes 
LV Q2 
CR 
(%) 
Sens. 
(%) 
Spec. 
(%) 
LV Q2 
CR 
(%) 
Sens
. (%) 
Spec. 
(%) 
GC-MS full data  
22RV1 vs PNT2 1 0.99 100 100 100 1 -0.34 47 47 47 
PC3 vs PNT2 1 0.98 100 100 100 1 -0.31 49 48 49 
DU145 vs PNT2 1 0.98 100 100 100 1 -0.34 49 49 49 
LNCaP vs PNT2 1 0.98 100 100 100 1 -0.39 47 48 46 
Set of discriminant VOCs  
22RV1 vs PNT2 1 0.97 100 100 100 1 -0.21 48 49 47 
PC3 vs PNT2 1 0.96 100 100 100 1 -0.27 46 47 45 
DU145 vs PNT2 1 0.93 100 100 100 1 -0.24 47 47 46 
LNCaP vs PNT2 2 0.94 100 100 100 1 -0.20 46 46 47 
 
 
 
 
 
Discussion 
 
Comparative analysis of VOCs in PCa and normal cell lines obtained at pH 7 
In this work we showed the potentiality of VOCs at physiological pH to discriminate 
different PCa cell lines from normal prostate cell line, indicating that the volatilome may be 
a valuable source of biomarkers for PCa detection. The results revealed significantly 
altered VOCs in all PCa cell lines when compared with normal cell line, namely 1,3-
benzothiazole (decreased in the extracellular medium of all PCa cell lines except DU145) 
and pentadecan-2-one (increased in all PCa cell lines). However, considering the different 
VOCs it is possible to discriminate PCa with different grades of aggressiveness, for 
example, 2,7-dimethyloctan-1-ol and 2-(1-4-methylcyclohex-3-en-1-yl)propan-2-ol, are 
significantly altered specifically in high metastatic potential cell line (PC3); the significant 
increase of decan-1-ol levels is a characteristic alteration of cell line with moderated 
metastatic potential (DU145); and the significant alteration of 3-methylbut-3-en-2-ol, 1-
methoxypropan-2-yl acetate and 1,4-xylene levels is characteristic of cell line with low 
LV – no. of latent variables, Q2 – median predictive power, CR – classification rate, sens. – 
sensitivity, spec. – specificity. 
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metastatic potential (LNCaP). It is also possible to discriminate between androgen-
responsive cell lines from androgen-nonresponsive cell lines using 3,7-Dimethyloct-7-en-
1-ol, since this metabolite is just significantly decreased in the androgen-nonresponsive 
cell lines (PC3, DU145 and 22RV1). Theoretically 22RV1 is an androgen receptor positive 
cell line, however, since the culture medium was not supplement with androgen we 
theorize that this cell line develop androgen independency for a mechanism similar to 
what happens in clinical practice after hormone deprivation therapy. This phenome was 
already addressed by other work groups (52).      
The integration of VOCs in metabolic pathways is, at the moment hard to performed, 
because volatilomic is a recent study approach, however using the human metabolome 
data base (HMDB), a free use date base that contains 41,993 metabolite entries, it is 
possible to see if some of those metabolites found in our samples were already found by 
other researchers in biological matrices. Table 12 does an interconnection between our 
results (significantly altered identified metabolites) and this date base (53-55). 
 
 
Table 12: Significantly altered metabolites important for the separation between PCa and normal 
cell lines, after univariate analysis, obtained at pH 7. 
Chemical name HMDB number Matrices previously 
found 
Cellular locations 
3-Methylbut-3-en-2-
ol 
HMDB39779 NA Cytoplasm 
Extracellular 
1-Methoxypropan-2-
yl acetate 
NA NA NA 
1,4-Xylene HMDB59924 Feces; Saliva  Membrane 
2,7-Dimethyloctan-
1-ol 
NA NA NA 
2-(1-4-
methylcyclohex-3-
en-1-yl)propan-2-ol 
HMDB37171 NA Extracellular 
Membrane 
Naphthalene HMDB29751 Feces; Salive Membrane 
3,7-Dimethyloct-7-
en-1-ol 
HMDB37171 NA Extracellular 
Membrane 
Decan-1-ol HMDB11624 Feces Extracellular 
Membrane 
1,3-Benzothiazole HMDB32930 NA  Cytoplasm 
Extracellular 
2-Methylundecanal HMDB31734 NA  Membrane 
Pentadecan-2-one HMDB31081 Saliva  Membrane 
    
 
 
NA: not available; HMDB: Human Metabolome Database. 
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From all significantly altered metabolites pentadecan-2-one is the VOCs that changes 
more and is specific for the cells (does not exist in the cellular medium). Pentadecan-2-
one is a ketone, and the increase of ketones levels was previously reported for PCa and 
other cancers (7, 37, 44, 56, 57). The production of pentadecan-2-one may be explained 
by the increased fatty acid oxidation and increased protein metabolism, characteristic of 
cancer which leads to ketones production (58). 
The alteration in aldehydes (e.g. 2-methylundecanal) is also a common alteration related 
with cancer, including PCa (7, 37, 44, 59). The alteration in aldehyde profiling can be 
explained by an alteration in lipid peroxidation, which is induced by the increased of ROS 
levels characteristic of cancer cell metabolism and inflammation. Beyond lipid 
peroxidation, aldehydes can also result from amino acid and carbohydrate catabolism. 
Other possible explanation for the aldehydes levels variation can be related to the 
aldehyde dehydrogenase (responsible for the aldehydes oxidation to carboxylic acids) 
activity (increased activity of these enzyme leads to reduction in aldehydes levels and 
down-regulation of these enzyme leads to increase in aldehydes levels) (7, 58-60).  
The hydrocarbon metabolism is well described in cancer metabolism. In our study, several 
alcohols were altered in PCa cell lines, namely, 3-methylbut-3-en-2-ol 3,7-Dimethyloct-7-
en-1-ol, 2,7-dimethyloctan-1-ol, 2-(1-4-methylcyclohex-3-en-1-yl)propan-2-ol, and decan-
1-ol, this alteration may be due to the alteration in hydrocarbon metabolism once alcohols 
are end-products of this metabolism (61, 62). Other well described characteristic of cancer 
cells is their rapid growth; this rapid growth implies an increase of cellular membrane 
synthesis. The alcohols may be metabolized, by the cell to carboxylic acids and these 
used to the synthesis of cellular membrane precursors (63). 
We also observed an alteration in aromatic hydrocarbon (1,4-xylene) the presence of 
these molecules was previously related with the presence of ROS (58, 64).  Naphthalene, 
a cycloalkane, was significantly altered, the presence of these molecules is also related 
with the presence of ROS and oxidative stress (61).  Significant alteration in 1,4-xylene 
levels was previously detected in  exhaled breath of PCa patients (65). 
Our results were concordant with the results of previously volatiloma analysis of PCa urine 
samples since some compounds significantly altered in this study belong to the same 
classes (ketones, alcohols, aldehydes) of compounds significantly altered in previously 
studies, however since, analytical conditions were different (e. g. different equipment, 
fiber, column and temperature gradient programme) the direct comparison of the results is 
not possible (7, 66).       
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Comparative analysis of VOCs in PCa and normal cell lines obtained at pH 2 
Like VOCs analyzed at physiological pH, the volatilome obtained at pH 2 is also able to 
differentiate PCa cell lines from normal prostate cell line, taking into account the quality of 
the two models (R2X = 0.526; R2Y = 0.457; Q2 = 0.437 for pH 2 vs R2X = 0.445; R2Y = 
0.463; Q2 = 0.446 for pH 7) the discriminant capability of these two models is similar. 
However some of the discriminate metabolites were not the same in the two models, so 
the acidification of the samples markedly influences the detected volatilome (e. g. 
detection of organic acids).  
VOCs namely cyclohexanone, 4-methylheptan-2-one, 2-methylpentane-1,3-diol, 4-
methylbenzaldehyde, 1-(3,5-dimethylfuran-2-yl)ethanone, methyl benzoate, nonanoic acid 
and decanoic acid are significantly altered in all PCa cell lines when compared with 
normal cell line. These VOCs are significantly decreased in extracellular medium of all 
PCa cell lines except decanoic acid that is increased in all PCa cell lines. Also, some 
VOCs namely, 2-ethoxy-2-methylbutane, hexanoic acid, phenylmethanol, 2,4-
Dimethylheptan-1-ol, benzoic acid, and 6-pentyloxan-2-one, can discriminate PCa with 
different aggressiveness, for example, 2-ethoxy-2-methylbutane, hexanoic acid, 
phenylmethanol, 2,4-Dimethylheptan-1-ol, benzoic acid, and 6-pentyloxan-2-one, are 
significantly decreased specifically in high metastatic potential cell line (PC3) and, 1-
ethoxypentane, is significantly decreased specifically in moderated and low metastatic 
potential cell line (DU145 and LNCaP, respectively). 4-Methylpent-3-en-2-one and 
Phenylethanol can discriminate androgen-responsive cell lines from androgen-
nonresponsive cell lines, these metabolites are just significantly decreased in the 
androgen-nonresponsive cell lines (PC3, DU145 and 22RV1).  
Some of the VOCs significantly altered in the comparison PCa vs normal prostate cell 
lines are produced by cells (do not exist in the cellular medium) namely, 4-methylnonanoic 
acid, hexanoic acid and 6-pentyloxan-2-one.       
The majority of the VOCs significantly altered were decreased in cancer cell lines in 
comparison with normal cell line this observation was previously made in other 
metabolomics studies with urine from PCa patients (7, 67). The cancer cells may use 
these metabolites for their metabolic processes more extensively then normal prostate 
cells, converting these VOCs in other metabolites than cannot be analyzed by our 
methodology (7, 67).  
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As performed for pH 7, Table 13, make an interconnection between our results at pH 2 
(significantly altered identified metabolites) and HMDB. As for pH 7 it is possible to see if 
some of those metabolites found in our samples at pH 2 were already found by other 
researchers in biological matrices (53-55).  
 
 
Table 13: Significantly altered metabolites important for the separation between PCa and normal 
cell lines, after univariate analysis, obtained at pH 2. 
Chemical name HMDB number Matrices previously 
found 
Cellular 
locations 
2-Ethoxy-2-
methylbutane 
NA NA NA 
1-Ethoxypentane NA NA NA 
4-Methylpent-3-en-2-one HMDB31563 Feces 
Saliva 
Cytoplasm 
Extracellular 
Cyclohexanone  HMDB03315 Feces NA 
4-Methylheptan-2-one NA NA NA 
5-Methylheptan-2-one NA NA NA 
Hexanoic acid HMDB00535 Blood 
Cerebrospinal Fluid  
Feces 
Saliva 
Urine 
Cytoplasm 
Extracellular 
Membrane 
 
2-Methylpentane-1,3-diol NA NA NA 
2,4-Dimethylheptan-1-ol NA NA NA 
Phenylethanol HMDB32619 Feces 
Saliva 
Cytoplasm 
Extracellular 
4-Methylbenzaldehyde HMDB29638 Feces 
Saliva  
Cytoplasm 
Extracellular 
1-(3,5-Dimethylfuran-2-
yl)ethanone 
HMDB32159 NA Cytoplasm 
Extracellular 
Methyl benzoate HMDB33968 NA Cytoplasm 
Extracellular 
Benzyl acetate HMDB31310 Saliva Cytoplasm 
Extracellular 
	71	
	
Chemical name HMDB number Matrices previously 
found 
Cellular 
locations 
Benzoic acid HMDB01870 Blood 
Feces 
Saliva 
Urine 
Cytoplasm 
Extracellular 
Endoplasmic 
reticulum 
5-methyl-2-propan-2-
ylcyclohexan-1-ol 
HMDB03352 Blood 
Feces 
Saliva 
Urine 
Extracellular  
Membrane 
Methyl nonanoate HMDB31264 NA Extracellular 
Membrane 
Nonanoic acid HMDB00847 Feces 
Saliva 
Extracellular 
Membrane 
4-Methylnonanoic acid HMDB34849 NA Extracellular 
Membrane 
Decanoic acid HMDB00511 Blood 
Breast Milk 
Saliva 
Urine 
Extracellular   
Membrane 
6-Pentyloxan-2-one HMDB37116 NA Membrane 
 
 
Some VOCs previously associated with cancer in other metabolomics studies namely, 
phenylmethanol, nonanoic acid, decanoic acid were also significantly altered in this work 
(68, 69).   
Several VOCs significantly altered in pH 2 belong to the same class of the VOCs 
significantly altered in pH 7, namely ketones (cyclohexanone; 4-methylheptan-2-one; 5-
methylheptan-2-one; 1-(3,5-dimethylfuran-2-yl)ethanone; 6-pentyloxan-2-one;  and 4-
methylpent-3-en-2-one), aldehydes (4-methylbenzaldehyde) and alcohols (2-
methylpentane-1,3-diol; phenylethanol; 5-methyl-2-propan-2-ylcyclohexan-1-ol; 
phenylmethanol; 2,4-dimethylheptan-1-ol). 
Significantly alteration in some ethers (1-ethoxypentane and 2-ethoxy-2-methylbutane) 
and organic acids (methyl benzoate; benzyl acetate; nonanoic acid; 4-methylnonanoic 
acid; decanoic acid; hexanoic acid) were also observed. Ethers can be found naturally in 
NA: not available; HMDB: Human Metabolome Database 
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fats and may be in the origin of acids and alcohols during lipid hydrolysis, which may 
explain the reduction of these VOCs levels, observed in PCa cell lines (62). 
Alteration in organic acids was previously described in urine and serum of PCa patients 
(67, 69). Organic acids can be involved in several biological processes, including cell 
signaling, energy storage, energy source, and cellular membrane integrity, so the 
alteration in these VOCs indicated that cancer cells have alteration in energy and lipid 
metabolism (67).  
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Chapter 4: Analysis of Amino 
Acids, Fatty Acids, Steroids and 
Sugars in PCa and Normal Prostate 
Cell Lines 
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Materials and Methods 
 
Chemicals 
All chemicals and reagents were analytical grade.  
RPMI-1640 medium, phosphate buffered saline 1% (PBS), norvaline, methyl linolelaidate, 
desmosterol and N-Methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) were purchased 
from Sigma-Aldrich Co (St. Louis, MO, USA). The antibiotic mixture penicillin/streptomycin 
(10000 U/mL/10000 µg/mL), heat inactivated fetal bovine serum (FBS) and trypsin 0.25%-
EDTA were purchased from GIBCO Invitrogen (Barcelona, Spain). Sodium 
hydrogencarbonate was obtained from Merck (Darmstadt, Germany) and methanol was 
from VWR (Leuven, Belgium). 
 
Cell Culture 
PCa immortalized cell lines (PC3, 22RV1, DU145 and LNCaP) and normal prostate 
epithelium immortalized cell line (PNT2) were provided by Portuguese Oncology Institute-
Porto (see Table 1, Chapter 3) for detail information about cell lines).  All cell lines were 
grown in RPMI-1640 medium supplemented with 10% of FBS and 1% of penicillin-
streptomycin. All cell lines were maintained at 37°C under 5% CO2. Cells grow to 80% 
confluency, before passage. 
 
Samples collection 
All cell lines were plated and grown to 100% confluency in RPMI-1640 medium. Forty 
eight hours after cells reach 100% confluency the medium was collected for VOCs 
analysis (see Chapter 3) and cells were washed with PBS solution. The PBS is rejected 
and the cells were scrapped with ice cold methanol and transferred to falcons in ice and 
centrifuged at 3000 x g for 10 minutes at 4 ⁰C. After this, the methanol was separated 
from the pellet and immediately frozen at -80 ⁰C until analysis. The same procedure, for all 
cell lines, was used for the four consecutive passages, (passage 3 to 6) each passage 
was performed in triplicate, resulting in a total of 60 experiments.  
 
Metabolites extraction from cell lines 
AA, fatty acids, sugars and steroids may not be analyzed directly by gas chromatography 
because of their low volatility and polarity and need to be previously derivatized. The 
method used was previously developed by Pereira et al. (2012), with some adaptations. 
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Briefly, the samples were centrifuged (3000 x g for 10 minutes at 4 ⁰C) (to ensure the total 
exclusion of any remains pellet) transferred to a glass vial and the internal standards 
(10µL/mL) norvaline, methyl linolelaidate and desmosterol were added. One mL of each 
sample was evaporated under a nitrogen stream and 50 µL of dichloromethane plus 50 µL 
of the derivatization reagent, MSTFA, was added to the residue. The vial was vortexed 
and heated for 30 min at 80 °C. 50 µL of remain residue was transfer to the glass vial 
used for GC–MS analysis (70). All extractions and analysis were performed in triplicate. 
 
GC–MS system and data acquisition 
 
GC–MS analysis 
The GC–MS conditions were based on those previously optimized by Pereira et al. (2012) 
with some adaptations. An EVOQ-436 gas chromatograph equipped with a Bruker Triple 
Quadrupole mass detector and a Bruker MS workstation software version 8.2 were used. 
The chromatographic separation was accomplished using a column Rxi-5Sil MS (30 m x 
0.25 mm x 0.25 µm) column (Restek). A CombiPAL automatic autosampler (Bruker) was 
used for all experiments. One µL of sample was injected using split mode (ratio 1/10), the 
carrier gas used was helium C-60 (Gasin, Portugal) (flow of 1 ml/min) and the injector port 
was heated to 250 °C. The analysis was performed in Full Scan mode. The oven 
temperature was fixed at 70 °C for 2 min, increasing to 250 °C (rate 15 °C/min), held for 2 
min, finally increasing to 300 °C (rate 10 °C/min) and held for 8 min. The transfer line 
temperature was 250 °C and manifold temperature was 40 °C. The mass ranged from 50 
to 1000 m/z. The emission current was 50 µA and the electron multiplier was set in 
relative mode to an auto tune procedure. All mass spectra were acquired in the electron 
impact (EI) mode (70). To ensure reproducibility of the methodology, quality control 
samples (QCs) were injected (48), four times per day. To produce these QCs a pool of all 
samples (from the five cell lines) were made, then this pool was immediately frozen at -80 
⁰C until analysis. 
 
Statistical analysis 
The statistical approach used was the same used for VOCs profiling (see Chapter 3).   
Prior to statistical analysis all chromatograms were pre-processed: baseline correction, 
peak detection, chromatogram deconvolution, and alignment, for these corrections the 
program MZmine was used (49), the parameters used to accomplish these were: RT 
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range 3.60-24.0 min; m/z range 50-500; MS data noise level 1.0´104; m/z tolerance 0.3; 
chromatogram baseline level 2.0´104; peak duration range 0.02-0.30 min. All ions (m/z) 
with a RSD greater than 50% (48), as well as ions (m/z) coming from the column, were 
removed. The obtained data was next normalized for the total area of the chromatograms. 
The statistical treatment included an unsupervised (PCA) and a supervised analysis (PLS-
DA) to determine which compounds were significantly different between PCa cell lines 
and normal cell line. To confirm the results, univariate analysis was performed for all 
metabolites relevant for the separation among cell lines, by calculating the p value, 
percentage of variation and uncertainty of the variation quotient, as well as, the effect size 
and its uncertainty (50). 
Bonferroni correction was used to adjust p-values for multiple comparisons by setting the 
significance cutoff to p value (0.05) divided by the number of compounds simultaneously 
tested in univariate statistical analyses. 
To confirm the robustness of the models, a MCCV was used (51). The identification of 
compounds selected by statistical approaches was done by using the National Institute of 
Standards and Technology (NIST 14) data base spectra library kovat indices and also by 
using standards. 
 
 
Results 
 
After GC-MS analysis, the obtained data were used to perform multivariate analyses, 
namely PCA and PLS-DA. A total of 150 features were detected in the chromatograms. 
The reproducibility of the analytical method is confirmed by the QCs projection on axis 1 
and 2 (Figure 18) (all QCs samples are grouped (orange color). Furthermore, the 
multivariate analyses prove that VOCs are able to discriminate PCa cell lines from normal 
prostate cell line and between the different PCa cell lines. This discriminant capability is 
observed not only in PLS-DA analysis but also in PCA (Figure 19). 
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Figure 18: PCA with QCs samples (orange) and all cell lines samples and controls (blue) (R2X = 
0.652). 
 
 
 
 
 
 
 
 
 
Figure 19: PCA (A) (R2X = 0.314) and PLS-DA (B) (R2X = 0.618; R2Y = 0.386; Q2 = 0.35) with 
metabolites from all cells line (PNT2 (normal cells): dark blue: green; 22RV1 (PCa cells): dark blue; 
PC3 (PCa cells): light blue; DU145 (PCa cells): red; LNCaP(PCa cells): yellow;).  
To evaluate which metabolites were responsible for this separation, all cancer cell lines 
were compared with the normal cell line, namely 22RV1 vs PNT2, PC3 vs PNT2, DU145 
vs PNT2 and LNCaP vs PNT2. An optimal separation between each PCa cell lines and 
normal cell line was observed (Figure 20). 
 
 
 
 
 
A 
B 
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All metabolites with VIP values greater than one were considered potential relevant for the 
separation among cell lines. Hence, a total of 30 metabolites were considered relevant to 
differentiate 22RV1 from PNT2, 37 metabolites were considered relevant to differentiate 
PC3 from PNT2, 46 metabolites were considered relevant to differentiate DU145 from 
PNT2 and 38 were considered relevant to differentiate LNCaP from PNT2. To confirm the 
importance of these metabolites, univariate analysis was performed to calculate the p 
value, the variation quotient and the effect size. After univariate analysis the VOCs that 
were taken into account, were those with p<0.05; relevant value of variation quotient; and 
relevant effect size. Therefore, a total of 22 VOCs proved to be relevant to differentiate 
22RV1 from PNT2, 20 VOCs proved to be relevant to differentiate PC3 from PNT2, 24 
VOCs proved to be relevant to differentiate DU145 from PNT2 and 26 proved to be 
relevant to differentiate LNCaP from PNT2. All these results are shown detail in Table 14 
(22RV1 vs PNT2), Table 15 (PC3 vs PNT2), Table 16 (DU145 vs PNT2) and Table 17 
(LNCaP vs PNT2).  
After univariate analysis, metabolites with p<0.05 and relevant variations quotient and 
effect size values were considered important for the separation among cell lines and 
potential biomarkers for PCa. These metabolites include amino acids, fatty acids, steroids 
and sugars. From these metabolites eight  stand out, namely, ethanolamine, lactic acid, L-
Figura 20: PLS-DA from PCa vs PNT2. A. 22RV1 (PCa cells) (dark blue) vs PNT2 (normal 
cells) (green) (R2X=0.724; R2Y=0.978; Q2=0.964). B. PC3 (PCa cells) (light blue) vs PNT2 
(normal cells) (green) (R2X=0.709; R2Y=0.887; Q2=0.817). C. DU145 (PCa cells) (red) vs 
PNT2 (normal cells) (green) (R2X=0.722; R2Y=0.916; Q2=0.879). D. LNCaP (PCa cells) 
(yellow) vs PNT2 (normal cells) (green) (R2X=0.734; R2Y=0.932; Q2=0.894). 
A 
C D 
B	
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valine, L-leucine, L-threonine, lyxofuranose, and L-tyrosine, because they revealed to be 
important for the separation among all PCa cell lines and normal cell line. However, 
several other metabolites were identified and were also able to discriminate between 
different cancer cell lines and normal cell lines, namely, L-alanine, (PC3 vs PNT2; DU145 
vs PNT2; LNCaP vs PNT2), 3-hydroxyisovaleric acid (PC3 vs PNT2; DU145 vs PNT2; 
LNCaP vs PNT2), urea, (22RV1 vs PNT2; PC3 vs PNT2; DU145 vs PNT2), 
phenylalanine, (22RV1 vs PNT2; PC3 vs PNT2; LNCaP vs PNT2),  ribofuranose, (22RV1 
vs PNT2; PC3 vs PNT2; LNCaP vs PNT2) talofuranose, (22RV1 vs PNT2; DU145 vs 
PNT2; LNCaP vs PNT2), sorbose, (22RV1 vs PNT2; DU145 vs PNT2; LNCaP vs PNT2), 
cholesterol, (22RV1 vs PNT2; PC3 vs PNT2; LNCaP vs PNT2), glycerol, (DU145 vs 
PNT2; LNCaP vs PNT2), 2-hydroxyiminohexanoic acid, (22RV1 vs PNT2; LNCaP vs 
PNT2), palmitoleic acid (22RV1 vs PNT2; DU145 vs PNT2), methyl 2-acetamido-2-deoxy-
3-O-methyl-a-D-galactopyranoside, (DU145 vs PNT2; LNCaP vs PNT2), 2-butenoic acid, 
(DU145 vs PNT2), erythrotetrofuranose, (DU145 vs PNT2), palmitic acid (LNCaP vs 
PNT2), 13-octadecenoic acid (LNCaP vs PNT2). Some unidentified metabolites were also 
important for the discrimination between cancer and normal cell lines (tables 14, 15, 16 
and 17) (figures 21, 22, 23 and 24).             
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Table 14: List of metabolites selected in PLS-DA of 22RV1 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines 
Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Ethanolamine, 2TMS 
derivative 
5.08 102/147 1021 1027 890 17165-
52-5  
<0.0001p  97.18± 18.37   3.8±1.35  
Lactic Acid, 2TMS 
derivative* 
5.43 73/147 1066 1057 927 17596-
96-2  
<0.0001p    84.79± 7.44   7.43±2.29 
Glycine, 2TMS 
derivative 
6.14 102/147/204  S 950 7364-42-
3 
0.0004P    834776.33 ± 
190.83 
  0.46 ± 0.80 
ß-Alanine, 2TMS 
derivative 
6.9 102/176 1190 1186 899 17891-
86-0  
<0.0001p    83.07 ± 21.15      2.52± 1.07 
2-Butenoic acid, 2-
[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
6.96 73/147 1186 1192 793 55590-
70-0 
>0.05    29.61 ± 20.94     
L-Valine, 2TMS 
derivative 
7.17 144/218  S 920 7364-44-
5  
<0.0001p    92.03± 12.16   5.20± 1.7 
Urea, 2TMS derivative 7.43 
 
73/147 1249 
 
1219 
 
921 18297-
63-7  
0.0002p   36.52± 9.04    1.93± 0.97 
L-Leucine, 2TMS 
derivative 
7.94 
 
102/158 
 
 S 931 7364-46-
7 
<0.0001P    72.24± 10.06    4.29 ± 1.47 
L-Proline, 2TMS 
derivative 
8.01 73/142/216  S 909  7364-47-
8  
>0.05    21.11 ± 17.59     
Unknown 8.54 147/204 NA 1277 NA NA  0.0309   55.75±17.47   1.04± 0.84 
L-Threonine, 2TMS 
derivative 
8.77 73/117/130  S 737 7536-82-
5  
0.0187  37.40± 17.94   1.02±0.84   
Glycerol, 3TMS 
derivative 
8.92 103/147/205 1289 1297 789 6787-10-
6 
>0.05    32.43 ± 19.85  
L-Aspartic acid, 3TMS 
derivative 
9.93 100  S 890 55268-
53-6  
>0.05       
L- Glutamine, 3TMS 
derivative 
10.73 73/75/246  S 570 70591-
28-5 
<0.0001P   122.43± 13.48   2.36± 1.04 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Phenylalanine, 2TMS 
derivative 
10.84 73/147/218  S 876  2899-52-
7  
0.0075   29.96 ± 8.45   1.23 ± 0.87 
Unknown 11.77 73 NA 1646 NA NA >0.05  54.68± 39.46      
Ribofuranose, 
tetrakis(trimethylsilyl) 
ether  
12.09 73/147/217 1671 1690 864 NA 0.0011p  37.95± 11.34   1.60±0.91    
Lyxofuranose, 
tetrakis(trimethylsilyl) 
ether 
12.15 73/147/217 1671 1698 859 NA <0.0001P  57.89± 13.12    2.43±1.06    
Talofuranose, 
pentakis(trimethylsilyl) 
ether  
12.87 73/103/147/191 1823 1803 720 NA 0.0003p  47.78± 11.98    2.00±0.98    
Sorbose, 5TMS 
derivative 
13.02 103/217 1867 1826 809 NA <0.0001P  73.09± 10.30    4.22±1.45    
L-Tyrosine, 3TMS 
derivative*  
13.06 73/100/218/280  S 923 51220-
73-6  
0.0002p   43.50 ± 7.52   1.92 ± 0.96 
Allopyranose, 5TMS 
derivative 
13.24 217 1829 1859 862 NA >0.05       
Palmitic Acid, TMS 
derivative 
13.77 73/132/129/313  S 935 55520-
89-3 
>0.05  13.54± 6.80     0.86± 0.83    
Galacturonic acid, 
5TMS derivative 
14.04 75 1943 1924 729 NA >0.05   115.65± 78.05    
Unknown 14.25 73/145/311 NA 1934 NA NA  <0.0001p   222.97± 14.87   3.03± 1.17 
Unknown 14.42 117 NA 1942 NA NA >0.05     
Unknown  14.94 117/129/339 NA 1966 NA NA 0.0106   25.74± 8.04   1.16± 0.85 
Unknown 15.14 117/129/145/341 NA 1975 NA NA  0.0252   24.74± 8.62   1.04± 0.84 
9-Hexadecenoic acid, 
TMS derivative 
(palmitoleic acid) 
15.8 55/75/145 2027 2006 701 NA <0.0001P   284.19± 18.01   2.81± 1.13 
Cholesterol, TMS 
derivative 
23.06 129/329/368  S 912 1856-05-
9  
0.0004P   110.38± 15.40   1.96± 0.97 
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KI: Kovat indices; S: Identified using standards; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value 
of 1.67x10-3 (0.05 divided by 30 analyzed metabolites). 
	
Figure 21: Boxplots from the metabolites important for the separation between 22RV1 (PCa cells) and PNT2 (normal cells), after univariate analysis. 
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Table 15: List of metabolites selected in PLS-DA of PC3 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines 
Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Unknown  4.56 69/140 NA 983 NA NA >0.05    69.1 ± 27.4    0.90± 0.87 
Ethanolamine, 2TMS 
derivative 
5.08 102/147 1021 1027 890 17165-
52-5  
0.0052  54.1± 21.8  1.41±0.93  
Lactic Acid, 2TMS 
derivative 
5.43 73/147  S 927 17596-
96-2  
<0.0001P    31.8± 6.2   2.38±1.10 
L-Alanine, 2TMS 
derivative 
5.94 116/147/190  S 935 27844-
07-1 
0.0034    24.9±8.5    1.18± 0.90 
Glycine, 2TMS 
derivative 
6.14 102/147/204  S 950 7364-
42-3 
0.0015    111.1 ± 27.0    1.35 ± 0.93 
Sarcosine, 2TMS 
derivative 
6.32 73 1161 1134 845 7364-
43-4  
>0.05         
β-Alanine, 2TMS 
derivative 
6.9 102/176 1190 1186 899 17891-
86-0  
0.0066    78.5± 18.5    1.43 ± 0.94 
2-Butenoic acid, 2-
[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
6.96 73/147 1186 1192 793 55590-
70-0 
>0.05    28.8 ± 12.2     
3-Hydroxyisovaleric 
acid, 2TMS derivative 
7.1 73/131 1216 1202 937 55124-
90-8 
<0.0001p    802.1 ± 48.5    1.84± 1.00 
L-Valine, 2TMS 
derivative 
7.17 144/218  S 920 7364-
44-5  
<0.0001p    62.10± 15.2   2.40± 1.10 
Urea, 2TMS 
derivative 
7.43 
 
73/147  S 921 18297-
63-7  
<0.0001p   45.1± 9.4   2.36± 1.09 
L-Leucine, 2TMS 
derivative 
7.94 
 
102/158 
 
 S 931 7364-
46-7 
0.0420    25.2±12.6   1.00 ± 0.88 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
L-Proline, 2TMS 
derivative 
8.01 73/142/216  S 909 7364-
47-8  
>0.05         
Unknown 8.54 147/204 NA 1277 NA NA  0.0006p    44.7±12.7    1.67±0.97 
L-Threonine, 2TMS 
derivative 
8.77 73/117/130  S 737 7536-
82-5  
0.0104   39.3± 16.3   1.18±0.90   
L-Aspartic acid, 3TMS 
derivative 
9.93 100  S NA NA >0.05         
L- Glutamine, 3TMS 
derivative 
10.73 73/75/246  S 570 70591-
28-5 
>0.05   35.7± 19.3   0.73± 0.86 
Phenylalanine, 
2TMS derivative 
10.84 73/147/218  S 876 2899-
52-7  
0.0056 35.6±13.2    1.34±0.92    
1,2-Benzisothiazol-
3-amine, TMS 
derivative 
11.7 207 1605 1637 626 NA >0.05       
Unknown  11.77 73 NA 1646 NA NA >0.05 37.5±36.7      
Ribofuranose, 
tetrakis(trimethylsilyl) 
ether  
12.09 73/147/217 1671 1690 864 NA 0.0028 36.9±12.5   1.41±0.93    
Lyxofuranose, 
tetrakis(trimethylsilyl) 
ether 
12.15 73/147/217 1671 1698 859 NA 0.0017 37.9±12.2    1.53±0.95    
Tridecanoic acid, 
TMS derivative 
12.43 117 1705 1739 688 169597-
14-2  
>0.05       
Sorbose, 5TMS 
derivative 
13.02 103/217 1867 1826 809 NA >0.05 21.2±13.2      
L-Tyrosine, 3TMS 
derivative 
13.06 73/100/218/280  S 923 51220-
73-6  
0.0322   27.8± 10.5   1.04± 0.89 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Allopyranose, 5TMS 
derivative 
13.24 217 1829 1859 862 NA >0.05       
Allofuranose, 
pentakis(trimethylsilyl) 
ether 
13.36 147 1853 1877 785 NA >0.05   93.0± 69.3    
Unknown  13.61 73/117/129 NA 1904 NA NA <0.0001P   182.7± 16.8   2.97± 1.22 
Palmitic Acid, TMS 
derivative 
13.77 73/132/129/313  S 935 55520-
89-3 
>0.05       
Galacturonic acid, 
5TMS derivative 
14.04 75 1943 1924 729 NA >0.05       
Unknown 14.25 73/145/311 NA 1934 NA NA  0.0008p   132.5± 18.4   2.18± 1.06 
Unknown  14.94 117/129/339 NA 1966 NA NA >0.05 16.4±9.5      
Unknown 15.14 117/129/145/341 NA NA NA 18748-
91-9  
0.0032 29.5±9.8    1.48±0.94    
Unknown  16.78 75/129 NA 2051 NA NA <0.0001p 56.5±9.1    3.52±1.35    
Methyl 2-acetamido-
2-deoxy-3-O-methyl-
a-D-
galactopyranoside, 
2TMS 
17.94 73/117 2134 2105 660 56196-
89-5  
>0.05   196.9± 50.0   1.05± 0.89 
Cholesterol, TMS 
derivative 
23.06 129/329/368  S 912 1856-
05-9  
<0.0001p   65.9± 7.6   3.01± 1.23 
 
 
 
 
KI: Kovat indices; S: Identified using standards; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 1.39x10-
3 (0.05 divided by 36 analyzed metabolites). 
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Figure 22: Boxplots from the metabolites important for the separation between PC3 (PCa cells) and PNT2 (normal cells), after univariate analysis 
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Table 16: List of metabolites selected in PLS-DA of DU145 (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines 
Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Ethanolamine, 
2TMS derivative 
5.08 102/147 1021 1027 890 17165-
52-5  
<0.0001p  80.14± 
18.04 
 2.92±1.31  
Lactic Acid, 2TMS 
derivative 
5.43 73/147  S 927 17596-
96-2  
0.0213    18.06±7.62   1.03±0.85 
L-Alanine, 2TMS 
derivative 
5.94 116/147/190  S 935 27844-
07-1 
<0.0001p    53.75±8.88   3.26± 1.20 
Glycine, 2TMS 
derivative 
6.14 102/147/204  S 950 7364-
42-3 
>0.05        
Hydracrylic acid, 
2TMS derivative 
6.41 127 1151 1140 842 55162-
32-8  
>0.05         
ß-Alanine, 2TMS 
derivative 
6.9 102/176 1190 1186 899 17891-
86-0  
<0.0001p    729.64± 
20.99 
   2.95± 1.14 
2-Butenoic acid, 2-
[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
6.96 73/147 1186 1192 793 55590-
70-0 
<0.0001p    130.36 ± 
12.10 
   2.57±1.06 
3-Hydroxyisovaleric 
acid, 2TMS 
derivative 
7.1 73/131 1216 1202 937 55124-
90-8 
<0.0001p    789.83 ± 
18.65 
   3.37± 1.23 
L-Valine, 2TMS 
derivative 
7.17 144/218  S 920 7364-
44-5  
<0.0001p    58.58± 
11.82 
  2.76± 1.10 
Urea, 2TMS 
derivative 
7.43 
 
73/147 1249 
 
1219 
 
921 18297-
63-7  
<0.0001p    47.59± 9.66    2.31± 1.01 
L-Leucine, 2TMS 
derivative 
7.94 
 
102/158 
 
 S 931 7364-
46-7 
<0.0001P    45.52± 
10.07 
   2.97 ± 
1.16 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
L-Proline, 2TMS 
derivative 
8.01 73/142/216  S 909 7364-
47-8  
>0.05         
Unknown 8.54 147/204 NA 1277 NA NA  <0.0001p    56.86± 
15.31 
   2.05± 0.97 
L-Threonine, 2TMS 
derivative 
8.77 73/117/130  S 737 7536-
82-5  
0.0499   26.44± 
13.94  
 0.86±0.81   
Glycerol, 3TMS 
derivative 
8.92 103/147/205 1289 1297 789 6787-
10-6 
0.0005p    60.06± 
18.39 
  1.84±0.93  
Erythrotetrofuranos
e, tris-O-
(trimethylsilyl) 
9.74 73/129217 1326 1387 673 NA 0.0001p    39.31± 9.51    2.03± 0.96 
L-Aspartic acid, 
3TMS derivative 
9.93 100  S NA NA >0.05         
Creatinine, N,N,O-
tris(trimethylsilyl) 
10.2
6 
75 1445 1447 758 NA >0.05    51.11± 46.5  
L- Glutamine, 3TMS 
derivative 
10.7
3 
73/75/246  S 570 70591-
28-5 
>0.05         
Phenylalanine, 
2TMS derivative 
10.8
4 
73/147/218  S 876 2899-
52-7  
0.0447 20.14±10.71      
1,2-Benzisothiazol-
3-amine, TMS 
derivative 
11.7 207 1605 1637 626 NA >0.05         
Unknown  11.7
7 
73 NA 1646 NA NA >0.05     
Lyxofuranose, 
tetrakis(trimethylsilyl) 
ether 
12.1
5 
73/147/217 1671 1898 859 NA 0.0001p 42.84± 10.66    2.01±0.96    
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Tridecanoic acid, 
TMS derivative 
12.4
3 
117 1705 1739 688 169597-
14-2  
>0.05   63.28±58.62    
Talofuranose, 
pentakis(trimethylsilyl
) ether  
12.8
7 
73/103/147/ 
191 
1823 1803 720 NA 0.0224 25.94±11.29    1.04±0.83    
Sorbose, 5TMS 
derivative 
13.0
2 
103/217 1867 1826 809 NA 0.0009p 37.57±11.5    1.59±0.89    
L-Tyrosine, 3TMS 
derivative 
13.0
6 
73/100/218/ 
280 
 S 923 51220-
73-6  
0.0406   20.27±8.1 0.9±0.81    
Allopyranose, 5TMS 
derivative 
13.2
4 
217 1829 1859 862 NA >0.05       
Allofuranose, 
pentakis(trimethylsilyl
) ether 
13.3
6 
147 1853 1877 785 NA >0.05       
Unknown  13.6
1 
73/117/129 NA 1904 NA NA 0.0018   82.93± 
11.28 
  2.05± 0.97 
Palmitic Acid, TMS 
derivative 
13.7
7 
73/132/129/ 
313 
 S 935 55520-
89-3 
>0.05       
Galacturonic acid, 
5TMS derivative 
14.0
4 
75 1943 1924 729 NA >0.05       
Unknown 14.2
1 
131 NA 1932 NA NA >0.05   47.15± 
41.17 
   
Unknown  14.2
5 
73/145/311 NA 1934 NA NA  0.0078   70.10±16.23   1.26±0.85 
Unknown 14.4
2 
117 NA 1942 NA NA >0.05   63.22±58.62    
Unknown 14.4
7 
117/327 NA 1944 NA NA 0.0002p   71.71±10.89   1.91±0.94 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Unknown  14.9
4 
117/129/339 NA 1966 NA NA 0.0014   27.91±7.39   1.31±0.87 
Unknown 15.1
4 
117/129/145/ 
341 
NA 1975 NA NA  >0.05   11.09± 7.51    
9-Hexadecenoic 
acid, TMS derivative 
(palmitoleic acid) 
15.8 55/75/145 2027 2006 701 NA 0.0048   85.75±23.12   1.02± 0.83 
Unknown  17.3 55 NA 2075 NA NA >0.05       
Methyl 2-acetamido-
2-deoxy-3-O-methyl-
a-D-
galactopyranoside, 
2TMS 
17.9
4 
73/117 2134 2105 660 56196-
89-5  
0.0037   88.07± 
16.92 
  1.42± 0.87 
6,9-Octadecadiynoic 
acid, methyl ester 
18.8
7 
77 2112 2148 637 56847-
03-1  
>0.05       
Unknown 19.0
0 
73/117 NA 2154 NA NA <0.0001P   326.66± 
19.57 
  2.5± 1.04 
Cholesterol, TMS 
derivative 
23.0
6 
129/329/368  S 912 1856-
05-9  
>0.05   20.85± 
12.10 
   
KI: Kovat indices; S: Identified using standards; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 
1.14x10-3 (0.05 divided by 44 analyzed metabolites). 
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 Figure 23: Boxplots from the metabolites important for the separation between DU145 (PCa cells) and PNT2 (normal cells), after univariate analysis. 
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Table 17: List of metabolites selected in PLS-DA of LNCaP (PCa cells) vs PNT2 (normal cells) (VIP>1) as potentially important for discrimination between 
PCa and normal cell lines 
Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Unknown  4.56 69/140 NA 983 NA NA 0.0001p    70.35± 
22.44 
   1.82± 0.94 
Ethanolamine, 2TMS 
derivative 
5.08 102/147 1021 1027 890 17165-
52-5  
<0.0001p  89.19± 
17.26 
  3.47±1.28  
Lactic Acid, 2TMS 
derivative 
5.43 73/147  S 927 17596-
96-2  
<0.0001p    55.39± 7.88   3.83±1.36 
L-Alanine, 2TMS 
derivative 
5.94 116/147/190  S 935 27844-
07-1 
0.0171    24.11± 9.88    1.13± 0.85 
Glycine, 2TMS 
derivative 
6.14 102/147/204  S 950 7364-
42-3 
0.0042    118.14 ± 
20.13 
   1.57 ± 0.91 
ß-Alanine, 2TMS 
derivative 
6.9 102/176 1190 1186 899 17891-
86-0  
<0.0001p    87.83 ± 
21.39   
   2.73± 1.12 
2-Butenoic acid, 2-
[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 
6.96 73/147 1186 1192 793 55590-
70-0 
>0.05    20.13 ± 
14.41 
    
3-Hydroxyisovaleric 
acid, 2TMS 
derivative 
7.1 73/131 1216 1202 937 55124-
90-8 
<0.0001p    3161.67 ± 
34.43 
    2.40± 1.04 
L-Valine, 2TMS 
derivative 
7.17 144/218  S 920 7364-
44-5  
<0.0001p    71.40± 
10.70 
  3.92± 1.38 
Urea, 2TMS 
derivative 
7.43 
 
73/147 1249 
 
1219 
 
921 18297-
63-7  
>0.05    8.39 ± 7.20     
L-Leucine, 2TMS 
derivative 
7.94 
 
102/158 
 
 S 931 7364-
46-7 
<0.0001P    51.55±9.06    2.97 ± 1.16 
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
L-Proline, 2TMS 
derivative 
8.01 73/142/216  S 909 7364-
47-8  
>0.05         
Unknown 8.54 147/204 NA 1277 NA NA  0.0321   93.47± 25.21   1.07± 0.84 
p-Toluic acid, TMS 
derivative 
8.64 65/119/193 1282 1282 818 NA >0.05  16.04± 
10.59   
     
L-Threonine, 2TMS 
derivative 
8.77 73/117/130  S 737 7536-
82-5  
0.0445   27.58± 
14.13  
 0.88±0.82   
Glycerol, 3TMS 
derivative 
8.92 103/147/205 1289 129 789 6787-
10-6 
0.0004p    58.18± 
15.77 
  1.97±0.97  
L-Aspartic acid, 
3TMS derivative 
9.93 100  S NA NA >0.05 25.32±22.2        
L- Glutamine, 3TMS 
derivative 
10.73 73/75/246  S 570 70591-
28-5 
<0.0001P   108.67± 
12.83 
  2.29± 1.03 
Phenylalanine, 
2TMS derivative 
10.84 73/147/218  S 876 2899-
52-7  
0.0036 42.45±13.45    1.59±0.91    
1,2-Benzisothiazol-
3-amine, TMS 
derivative 
11.7 207 1605 1637 626 NA >0.05     
Unknown  11.77 73 NA 1646 NA NA >0.05 40.90±32.77      
Ribofuranose, 
tetrakis(trimethylsilyl) 
ether  
12.09 73/147/217 1671 1690 864 NA 0.0004p 42.26±10.73   1.96±0.96    
Lyxofuranose, 
tetrakis(trimethylsilyl) 
ether 
12.15 73/147/217 1671 1898 859 NA <0.0001P 48.11±11.13    2.23±1.02    
Talofuranose, 
pentakis(trimethylsilyl) 
ether  
12.87 73/103/147/191 1823 1803 720 NA 0.0056 29.01±16.04    0.85±0.83    
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Name RT Characteristic 
ions 
KI from 
literature 
Experimental 
KI or 
standards 
MS-R 
match 
Cas 
number 
p value Variation % 
(uncertainty) 
Effect size 
(uncertainty) 
Sorbose, 5TMS 
derivative 
13.02 103/217 1867 1826 809 NA <0.0001P 64.31±10.68    3.41±1.26    
L-Tyrosine, 3TMS 
derivative 
13.06 73/100/218/280  S 923 51220-
73-6  
<0.0001P 44.38±9.74    2.28±1.03    
Allopyranose, 5TMS 
derivative 
13.24 217 1829 1859 862 NA >0.05     
Allofuranose, 
pentakis(trimethylsilyl) 
ether 
13.36 147 1853 1877 785 NA >0.05     
Unknown  13.61 73/117/129 NA 1904 NA NA <0.0001P   64.27± 7.16   2.80± 1.13 
Palmitic Acid, TMS 
derivative 
13.77 73/132/129/313  S 935 55520-
89-3 
0.0424   21.27± 8.34   0.95± 0.84 
Galacturonic acid, 
5TMS derivative 
14.04 75 1943 1924 729 NA >0.05       
Unknown  14.94 117/129/339 NA 1966 NA NA >0.05   15.5± 7.07    
Unknown 15.14 117/129/145/341 NA 1975 NA NA 0.0256   20.39± 7.37   1.02± 0.84 
Unknown  15.62 57/69/84/ NA 1997 NA NA <0.0001P   147.83± 10   3.53± 1.29 
Unknown  16.28 117 NA 2028 NA NA >0.05   25.39± 16.87    
Methyl 2-acetamido-
2-deoxy-3-O-methyl-
a-D-
galactopyranoside, 
2TMS 
17.94 73/117 2134 2105 660 56196-
89-5  
0.0050   374.03± 
35.88 
  1.57± 0.91 
13-Octadecenoic 
acid, TMS derivative 
19.72 69/75/117 2228 2187 634 NA <0.0001P   560.66± 
18.06 
  3.54± 1.29 
Cholesterol, TMS 
derivative 
23.06 129/329/368  S 912 1856-
05-9  
0.0004p   73.42± 14.39   1.58± 0.91 
 KI: Kovat Indices; S: Identified using standards; NA: not available; P Alterations remaining significant after Bonferroni correction, with cutoff p value of 1.37x10-3 (0.05 divided 
by 38 analyzed metabolites). 
	
	96	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 24: Boxplots from the metabolites important for the separation between LNCaP (PCa cells) and PNT2 (normal cells), after univariate analysis. 
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New PLS-DA models using only discriminant metabolites (Figure 25) was performed. To 
prove the robustness of the models, a MCCV validation was performed for all 
comparisons, using GC-MS full data but also using just the discriminant metabolites 
described before, was also performed new PLS-DA models using just these set of 
discriminant metabolites (Figure 25). The results of these validations proved that all 
created models are robust for the discrimination between PCa cell lines and normal cell 
line (Table 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: PLS-DA from PCa cell line vs normal cell line with the set of discriminant metabolites. A. 22RV1 
(PCa cells) (dark blue) vs PNT2 (normal cells) (green) (R2X=0.845; R2Y=0.962; Q2=0.947). B. PC3 (PCa 
cells) (light blue) vs PNT2 (normal cells) (green) (R2X=0.77; R2Y=0.932; Q2=0.895). C. DU145 (PCa cells) 
(red) vs PNT2 (normal cells) (green) (R2X=0.855; R2Y=0.903; Q2=0.864). D. LNCaP (PCa cells) (yellow) vs 
PNT2 (normal cells) (green) (R2X=0.814; R2Y=0.938; Q2=0.919). 
A B 
C D 
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Table 18: MCCV parameters of true and permuted classes obtained for derivatized metabolites 
when considering GC-MS full data and the set of discriminant compounds.  
Models 
True classes Permuted classes 
LV Q2 
CR 
(%) 
Sens. 
(%) 
Spec. 
(%) 
LV Q2 
CR 
(%) 
Sens
. (%) 
Spec. 
(%) 
GC-MS full data  
22RV1 vs PNT2 4 0.93 100 100 100 1 -0.22 45 45 45 
PC3 vs PNT2 1 0.87 98 95 100 1 -0.38 47 47 46 
DU145 vs PNT2 2 0.93 100 100 100 1 -0.26 47 47 47 
LNCaP vs PNT2 4 0.92 100 100 100 1 -0.25 47 45 49 
Set of discriminant compounds  
22RV1 vs PNT2 1 0.97 100 99 100 1 -0.30 48 48 47 
PC3 vs PNT2 2 0.93 100 100 100 1 -0.32 48 47 49 
DU145 vs PNT2 1 0.94 100 100 100 1 -0.30 47 47 47 
LNCaP vs PNT2 2 0.96 100 100 100 1 -0.27 49 47 50 
 
 
 
 
Discussion 
 
In this work, we revealed the potentiality of metabolome for discrimination different PCa 
cell lines from normal prostate cell line, which indicates that the metabolome may be a 
valuable source of biomarkers for PCa detection in the future. The results revealed 
metabolites significantly decreased in all PCa cell lines when compared with normal cell 
line, namely ethanolamine, lactic acid, L-valine, L-leucine, L-threonine, lyxofuranose, and 
L-tyrosine significantly increased in all PCa cell lines. However, considering different 
metabolites is possible to discriminate PCa with different aggressiveness, for example, 
glycerol is significantly decrease in low (LNCaP) and moderated (DU145) metastatic 
potential cell line (but not in in high metastatic cell line (PC3)) and methyl 2-acetamido-2-
deoxy-3-O-methyl-a-D-galactopyranoside is significantly increased in DU145 and in 
LNCaP but not in PC3; the significant increase of 2-butenoic acid levels and the significant 
decrease of erythrotetrofuranose levels are characteristic alterations of cell line with 
moderated metastatic potential (DU145); and the significant increase of palmitic acid, and 
13-octadecenoic acid are characteristic of LNCaP, a cell line with low metastatic potential. 
LV: no. of latent variables; Q2: median predictive power; CR: classification rate; sens.: sensitivity; 
spec.: specificity. 
	
	99	
	
It is also possible discriminate between androgen-responsive from androgen-
nonresponsive PCa cell lines, using urea, since this metabolite is significantly decreased 
in androgen-nonresponsive PCa cell lines (22RV1, PC3 and DU145); significant increase 
of palmitic acid, and (E)-13-octadecenoic acid are others characteristic of androgen-
responsive PCa cell line (LNCaP).     
All living cells have in common most of the biochemical pathways in the body, for 
example, metabolic pathways involving energy and amino acid catabolism occurs similarly 
in all cells. However, cancer cells have unique features, consequence of their extremely 
proliferative capacity and resistance to apoptosis and, therefore, most certainly have 
some metabolic pathways altered (enhanced or diminished) (23). This theory was 
evaluated in this work, and the results show, as expected, alteration in several metabolic 
pathways, mostly energetic metabolism, lipid metabolism or protein metabolism.    
As previously explained (see Chapter 1), the prostate cell has a unique metabolic profile, 
once one of the major functions of these cells is production and accumulation of citrate 
(components of the prostatic fluid) (71). Unlike other human cells, the prostate cell does 
not use, preferentially, citrate in Krebs cycle, for ATP production (aerobic ATP 
production)¸ even in the presence of oxygen, prostate cell produces ATP mainly by the 
glucose oxidation which leads to pyruvate production and, consequently, to lactate 
production. However, prostate cells that undergo neoplastic transformation lose this ability 
to citrate accumulation and use citrate for Krebs cycle (26, 72-74). This well described 
alteration may explain the reduction of the levels of lactate observed in this study.  
The significant increase in glutamine levels is another indicator of possible alterations in 
Krebs cycle related with PCa once, through glutaminolysis, delivers intermediates (α-
ketoglutarate) for the Krebs cycle. Glutamine is also important for lipogenesis (75, 76). 
The alteration in energetic metabolism, related with PCa, is also observed, in the 
significant levels alteration of several carbohydrates, namely ribofuranose, lyxofuranose, 
talofuranose, and sorbose, since carbohydrates can be used by cancer cells for energy 
production. The described alterations in carbohydrates were also observed in other 
metabolomics PCa studies (13, 66).  
Mucin are glycoconjugates, and the increase in their levels is associated with cancer, 
once these compounds are involved  in signaling cell growth and survival, inducing tumor 
progression (77). These important roles of mucin in cancer may explain the significant 
increase in the mucin fragment methyl 2-acetamido-2-deoxy-3-O-methyl-a-D-
galactopyranoside (78) observed in our study.  
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The alteration in sarcosine levels in PCa is one of the most studied metabolic alterations 
related with PCa and one of the most promising potential biomarkers for PCa (6). In this 
work, we were unable to confirm the significant increase of sarcosine levels related with 
PCa, however, a significant alteration in glycine levels was observed. Glycine is a 
precursor of sarcosine so the alteration of this metabolite may suggest alteration in the 
metabolic pathway involved in sarcosine synthesis. Glycine is also an important protein 
precursor and provide C2N subunit for purines synthesis (79).             
Beyond glycine, several other amino acids were altered in PCa samples, namely, alanine, 
valine, leucine, threonine, phenylalanine and tyrosine, which may indicate the increased 
protein synthesis. The increase in protein metabolism is essential to cancer cell maintain 
the elevated proliferative state. This metabolic alteration was previously focused in other 
metabolomics PCa studies (66, 80, 81).  
The urea cycle uses ammonia to produce urea, as urea is less toxic than ammonia. The 
main source of ammonia is the degradation of proteins and, as previously explained, 
cancer cells have increased requirement of proteins which may explain the decreased 
levels of urea in PCa cells observed in our study.  
Other important indicator of alteration in proteins metabolism observed in our study is the 
significant increase of 3-hydroxyisovaleric acid levels. This leucine metabolite has an 
important role in protein metabolism once 3-hydroxyisovaleric acid stimulates protein 
synthesis and prevents protein catabolism (82).   
The elevated cholesterol levels observed in PCa cells was previously described in other 
metabolic studies using prostatic tissue from PCa patients (13, 83). The PCa cells have 
the ability to synthetise cholesterol, furthermore, a study performed by Awad et al (2001) 
revealed that in vitro supplementation with cholesterol increase cell proliferation, 
migration, and invasion in PCa cell lines (84). The relevant role of cholesterol in PCa 
metabolism may be due to the increased need of membrane biosynthesis in cancer cells, 
the need of growth factor signaling and cholesterol may have an important role in 
castration resistance of PCa, once cholesterol can be converted in vivo to androgens (83).    
The alteration in lipid metabolism, particularly, on phospholipid membrane constituents 
assembly and catabolism, is confirmed by the significant decreased ethanolamine levels. 
Ethanolamine is one of the principal components of cellular membrane, once 
ethanolamine is the precursor and the degradation product of phosphatidylethanolamine 
(abundant phosphoglyceride of human cellular membrane). The alteration in ethanolamine 
levels in PCa cells was previously observed by other authors (85, 86).  Mintz et al (2008), 
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using radiolabel ethanolamine, demonstrated that PCa cells shown an increase in 
ethanolamine uptake when compared with normal prostate cells (principally in androgen-
responsive cells in presence of androgens) (85-87). Glycerol is another important 
metabolite involved in lipid metabolism, once glycerol is present in the composition of 
triglycerides and phospholipids. The catabolism of these lipids, to produce energy, leads 
to the formation of glycerol, and glycerol can also be converted to glucose (the principal 
cellular source of energy). Therefore, the dysregulation in glycerol levels is indicative of 
alteration in lipid metabolism and of the high energy demand characteristic of cancer cells, 
to sustain its high proliferation state (53-55).  
Significant alterations in organic acids, namely 13-octadecenoic acid and 2-butenoic acid, 
was also observed in our study, as well as in other PCa metabolomics studies (67, 69, 
88). Fatty acids can be produced by the β-oxidation of lipids to produce energy but can be 
involved in other cellular mechanisms, namely cell signaling and cellular membrane 
integrity, so the alteration in these metabolites indicates that cancer cells have alteration 
in energetic and lipid metabolism (67, 69, 88).  
In this study we also observed a significant increase in palmitic acid levels in PCa 
samples. The increase of palmitic acid levels, in plasma, was previously associated, in a 
prospective case-control study, with the risk of PCa (9). Palmitic acid is produced in vivo 
from other fatty acids and from de novo lipogenesis, so the significant increase of palmitic 
acid levels is indicative of alteration in lipid metabolism principally the increase in fatty acid 
synthesis (9). Besides palmitic acid, palmitoleic acid is another fatty acid significantly 
increases in PCa cells. 
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Conclusion and future perspectives 
 
Currently, PCa diagnostic is performed by using PSA as biomarker, however, this 
biomarker has low sensibility and specificity. These drawbacks have given rise to serious 
efforts to the discovery of new biomarkers, preferentially noninvasive, that have better 
specificity and sensitivity. A novel biomarker is required to be specific for PCa and not 
altered or expressed in other human tissues or in other diseases, which will bring major 
benefits for patient health. Since metabolic alterations are the last step in cellular 
response to diseases, metabolomics can be successfully used to discover new 
biomarkers for cancer. 
In this study, we evaluated the alterationsin prostate exometabolome, more specifically 
the volatilome (Chapter 3) and intrametaboloma (Chapter 4) caused by the cancer 
development, using different PCa cell lines with different aggressiveness and hormone 
dependent and hormone independent. The results prove that, in both approaches, 
metabolomics alterations are capable of discriminating the different cell lines, therefore is 
a powerful tool to discover new biomarkers for PCa.  
In the third Chapter of this work, we identified several altered VOCs related to PCa. Most 
of them were low molecular weight compounds such as ketones, aldehydes and organic 
acids, indicating alteration in lipid and energy metabolism of PCa cells. 
In this Chapter was performed a comparative analysis of VOCs in PCa and normal cell 
lines obtained at pH 7 and pH 2 and the results in both show some potential biomarkers 
for PCa were discover. In pH 7 the VOCs that stand out as potential biomarkers for PCa 
was pentadecan-2-one which was increased in all PCa cell lines when compared with 
normal cell line. It was also possible to discriminate PCa with different grades of 
aggressiveness using, 2,7-dimethyloctan-1-ol and 2-(1-4-methylcyclohex-3-en-1-
yl)propan-2-ol, which are significantly altered specifically in high metastatic potential cell 
line (PC3),  significant increase in decan-1-ol levels is a characteristic alteration of cell line 
with moderated metastatic potential (DU145) and the significant alteration of 3-methylbut-
3-en-2-ol, 1-methoxypropan-2-yl acetate and 1,4-xylene levels is characteristic of cell line 
with low metastatic potential (LNCaP). Moreover, was also possible the discrimination 
between androgen-responsive cell lines from androgen-nonresponsive cell lines using 
3,7-dimethyloct-7-en-1-ol, since this metabolite is just significantly decreased in the 
androgen-nonresponsive cell lines (PC3, DU145 and 22RV1). In the results of the 
comparative analysis of VOCs in PCa and normal cell lines obtained at pH 2 the VOCs 
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that stand out were, cyclohexanone, 4-methylheptan-2-one, 2-methylpentane-1,3-diol, 4-
methylbenzaldehyde, 1-(3,5-dimethylfuran-2-yl)ethanone, methyl benzoate, nonanoic acid 
and decanoic acid which were significantly altered in all PCa cell lines when compared 
with normal cell line. It was also possible to discriminate PCa with different grades of 
aggressiveness using 2-ethoxy-2-methylbutane, hexanoic acid, 1-phenylmethanol, 2,4-
dimethylheptan-1-ol, benzoic acid, and 6-pentyloxan-2-one, are significantly decreased 
specifically in high metastatic potential cell line (PC3) and, 1-ethoxypentane, is 
significantly decreased specifically in moderated and low metastatic potential cell line 
(DU145 and LNCaP, respectively). Moreover, was also possible the discrimination 
between androgen-responsive cell lines from androgen-nonresponsive cell lines using 4-
methylpent-3-en-2-one and 1-phenylethanol can discriminate androgen-responsive cell 
lines from androgen-nonresponsive cell lines, these metabolites are just significantly 
decreased in the androgen-nonresponsive cell lines (PC3, DU145 and 22RV1). 
The integration of VOCs in specific metabolic pathways is still very difficult, needing more 
studies to accomplish this goal. Moreover, it was also evaluated the influence of pH in the 
volatilome. Acidification of the samples markedly influences it (e. g. detection of organic 
acids) but the quality of the PCA and PLS-DA models produced were not markedly 
different.    
The results of the evaluation of alterations in intrametaboloma were concordant with the 
results of the evaluation of volatiloma, in both approach, the results reveal alterations in 
lipid and energy metabolism of PCa cells. Alteration in protein metabolism was also 
observed in intrametaboloma. The alteration in these metabolic pathways can be 
explained by the well-known features of cancer cells, namely, their extremely proliferative, 
growth and migration capacity, and resistance to apoptosis. To sustain these elevated 
proliferation rates, the energy demand increases, as well as the protein synthesis. 
Alterations in lipid metabolism have also an important paper in the sustain of these 
elevated proliferation rates, once intercellular signaling are dependent on increased lipid 
biosynthesis, as well as, the increased cellular membrane synthesis is dependent on 
increased lipid biosynthesis and lipids also can be used for the cell to produce energy. 
The discriminative metabolites include ethanolamine, lactic acid, L-valine, L-leucine, L-
threonine, lyxofuranose, and L-tyrosine, metabolites significantly altered in all PCa cell 
lines when compared with normal cell line; significant decreased in glycerol levels and the 
significantly increased in methyl 2-acetamido-2-deoxy-3-methyl-galactopyranoside levels 
is characteristic of low (LNCaP) and moderated (DU145) metastatic potential cell line (but 
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not in in high metastatic potential cell line (PC3); the significant increase of 2-butenoic 
acid levels and the significant decrease of erythrotetrofuranose levels are characteristic 
alterations of cell line with moderated metastatic potential (DU145); and the significant 
increase of palmitic acid, and 13-octadecenoic acid are characteristic of LNCaP, a cell line 
with low metastatic potential. It is also possible discriminate between androgen-
responsive from androgen-nonresponsive PCa cell lines, using urea, since this metabolite 
is significantly decreased in androgen-nonresponsive PCa cell lines (22RV1, PC3 and 
DU145); significant increase of palmitic acid, and 13-octadecenoic acid are others 
characteristic of androgen-responsive PCa cell line (LNCaP).      
Up to date and according to the scientific literature, the most promising biomarker for PCa 
is sarcosine. In our work, once we not have available sarcosine standard, the formal 
identification of these metabolite was not accomplish, so we were unable to confirmed the 
value of sarcosine as PCa biomarker. However, we observed significant alteration in 
glycine levels and once sarcosine occurs as an intermediate product in the synthesis and 
degradation of this amino acid, we can conclude that this metabolic pathway is altered in 
consequence of PCa.  
The evaluation of these latter compounds (aminoacids, sugars, fatty acids and steroids) 
has the advantage to be easier to relate alterations in these metabolites with known 
metabolic pathways. Allowing the discover of potential biomarkers for PCa but also, 
allowing a better understand of which are the most important metabolic pathways altered 
in consequence of cancer development and progression and, consequently, may permit 
the discover of new therapeutic targets and the development of new therapeutic 
approaches. However, the study of the alterations in exometaboloma has the advantage 
of being potentially easier to translate these results for real samples, like urine, once these 
metabolites are secreted by cells.   
One of the advantages of metabolomics is that it allows improve the sensibility and 
specificity of biomarkers by using not just one metabolite but a panel of several 
metabolites, so it is possible with the interaction from results of different studies to achieve 
better discriminant capability.  
One limitation of the present study is that some compounds were not identified using 
standards, and despite, our best effort to correctly identify these metabolites, the formal 
identification of compounds is only accomplished by using standards. 
It is important to emphasize that for a possible use in the clinical practice is mandatory to 
prove the translability of results for real samples. Once it is practically impossible to 
	108	
	
simulate complex cell–cell and cell–matrix interactions in cell cultures of prostate cancer 
and these interactions are very important for metabolic alterations that happen with tumor 
progression, so the translability of results for real samples is not guaranteed. 
It is also necessary to develop more work with the objective of better understand the 
cellular source and the metabolic pathways responsible for the production and 
consumption of the VOCs.  
Despite the limitation of the study, the results reveal the potential of metabolomics, in 
both, extra and intracellular, approaches to discriminated between groups (PCa vs normal 
prostate cell lines), which may lead to the identification of new biomarkers for PCa. 
However, further studies are still needed to confirmed our results, and find out an 
inexpensive, noninvasive, sensible and specific biomarker for prostate cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	109	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. 	 References	
	110	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	111	
	
References   
 
1.	 Ferlay	J,	Soerjomataram	I,	Dikshit	R,	Eser	S,	Mathers	C,	Rebelo	M,	et	al.	Cancer	incidence	
and	mortality	worldwide:	sources,	methods	and	major	patterns	in	GLOBOCAN	2012.	International	
journal	of	cancer	Journal	international	du	cancer.	2015;136(5):E359-86.	
2.	 Rigau	M,	 Olivan	M,	 Garcia	M,	 Sequeiros	 T,	Montes	M,	 Colas	 E,	 et	 al.	 The	 present	 and	
future	 of	 prostate	 cancer	 urine	 biomarkers.	 International	 journal	 of	 molecular	 sciences.	
2013;14(6):12620-49.	
3.	 Roberts	MJ,	Schirra	HJ,	Lavin	MF,	Gardiner	RA.	Metabolomics:	a	novel	approach	to	early	
and	noninvasive	prostate	cancer	detection.	Korean	journal	of	urology.	2011;52(2):79-89.	
4.	 Trock	 BJ.	 Application	 of	 metabolomics	 to	 prostate	 cancer.	 Urologic	 oncology.	
2011;29(5):572-81.	
5.	 Schalken	 J,	 Dijkstra	 S,	 Baskin-Bey	 E,	 van	 Oort	 I.	 Potential	 utility	 of	 cancer-specific	
biomarkers	 for	 assessing	 response	 to	 hormonal	 treatments	 in	 metastatic	 prostate	 cancer.	
Therapeutic	advances	in	urology.	2014;6(6):245-52.	
6.	 Sreekumar	 A,	 Poisson	 LM,	 Rajendiran	 TM,	 Khan	 AP,	 Cao	 Q,	 Yu	 J,	 et	 al.	 Metabolomic	
profiles	 delineate	 potential	 role	 for	 sarcosine	 in	 prostate	 cancer	 progression.	 Nature.	
2009;457(7231):910-4.	
7.	 Khalid	T,	Aggio	R,	White	P,	De	Lacy	Costello	B,	Persad	R,	Al-Kateb	H,	et	al.	Urinary	Volatile	
Organic	Compounds	for	the	Detection	of	Prostate	Cancer.	PloS	one.	2015;10(11):e0143283.	
8.	 Giskeodegard	GF,	Hansen	AF,	Bertilsson	H,	Gonzalez	SV,	Kristiansen	KA,	Bruheim	P,	et	al.	
Metabolic	 markers	 in	 blood	 can	 separate	 prostate	 cancer	 from	 benign	 prostatic	 hyperplasia.	
British	journal	of	cancer.	2015;113(12):1712-9.	
9.	 Crowe	FL,	Allen	NE,	Appleby	PN,	Overvad	K,	Aardestrup	 IV,	 Johnsen	NF,	et	al.	Fatty	acid	
composition	of	plasma	phospholipids	and	risk	of	prostate	cancer	in	a	case-control	analysis	nested	
within	the	European	Prospective	Investigation	into	Cancer	and	Nutrition.	The	American	journal	of	
clinical	nutrition.	2008;88(5):1353-63.	
10.	 Kline	EE,	Treat	EG,	Averna	TA,	Davis	MS,	Smith	AY,	Sillerud	LO.	Citrate	concentrations	 in	
human	seminal	fluid	and	expressed	prostatic	fluid	determined	via	1H	nuclear	magnetic	resonance	
spectroscopy	 outperform	prostate	 specific	 antigen	 in	 prostate	 cancer	 detection.	 The	 Journal	 of	
urology.	2006;176(5):2274-9.	
11.	 Serkova	NJ,	Gamito	EJ,	 Jones	RH,	O'Donnell	C,	Brown	JL,	Green	S,	et	al.	The	metabolites	
citrate,	myo-inositol,	and	spermine	are	potential	age-independent	markers	of	prostate	cancer	in	
human	expressed	prostatic	secretions.	The	Prostate.	2008;68(6):620-8.	
12.	 McDunn	JE,	Li	Z,	Adam	KP,	Neri	BP,	Wolfert	RL,	Milburn	MV,	et	al.	Metabolomic	signatures	
of	aggressive	prostate	cancer.	The	Prostate.	2013;73(14):1547-60.	
13.	 Jung	 K,	 Reszka	 R,	 Kamlage	 B,	 Bethan	 B,	 Stephan	 C,	 Lein	 M,	 et	 al.	 Tissue	 metabolite	
profiling	identifies	differentiating	and	prognostic	biomarkers	for	prostate	carcinoma.	International	
journal	of	cancer	Journal	international	du	cancer.	2013;133(12):2914-24.	
14.	 Vaz	CV,	Alves	MG,	Marques	R,	Moreira	PI,	Oliveira	PF,	Maia	CJ,	et	al.	Androgen-responsive	
and	 nonresponsive	 prostate	 cancer	 cells	 present	 a	 distinct	 glycolytic	 metabolism	 profile.	 The	
international	journal	of	biochemistry	&	cell	biology.	2012;44(11):2077-84.	
15.	 Kaushik	AK,	Vareed	SK,	Basu	S,	Putluri	V,	Putluri	N,	Panzitt	K,	et	al.	Metabolomic	profiling	
identifies	 biochemical	 pathways	 associated	with	 castration-resistant	 prostate	 cancer.	 Journal	 of	
proteome	research.	2014;13(2):1088-100.	
	112	
	
16.	 Aoun	F,	Peltier	A,	van	Velthoven	R.	A	comprehensive	review	of	contemporary	role	of	local	
treatment	 of	 the	 primary	 tumor	 and/or	 the	metastases	 in	metastatic	 prostate	 cancer.	 BioMed	
research	international.	2014;2014:501213.	
17.	 Dimakakos	 A,	 Armakolas	 A,	 Koutsilieris	 M.	 Novel	 tools	 for	 prostate	 cancer	 prognosis,	
diagnosis,	and	follow-up.	BioMed	research	international.	2014;2014:890697.	
18.	 Caini	 S,	 Gandini	 S,	 Dudas	 M,	 Bremer	 V,	 Severi	 E,	 Gherasim	 A.	 Sexually	 transmitted	
infections	and	prostate	cancer	risk:	a	systematic	review	and	meta-analysis.	Cancer	epidemiology.	
2014;38(4):329-38.	
19.	 Doolan	G,	Benke	G,	Giles	G.	An	update	on	occupation	and	prostate	cancer.	Asian	Pacific	
journal	of	cancer	prevention	:	APJCP.	2014;15(2):501-16.	
20.	 Mandair	 D,	 Rossi	 RE,	 Pericleous	 M,	 Whyand	 T,	 Caplin	 ME.	 Prostate	 cancer	 and	 the	
influence	 of	 dietary	 factors	 and	 supplements:	 a	 systematic	 review.	 Nutrition	 &	 metabolism.	
2014;11:30.	
21.	 Abrate	A,	Lughezzani	G,	Gadda	GM,	Lista	G,	Kinzikeeva	E,	Fossati	N,	et	al.	Clinical	use	of	[-
2]proPSA	 (p2PSA)	 and	 its	 derivatives	 (%p2PSA	 and	 Prostate	 Health	 Index)	 for	 the	 detection	 of	
prostate	cancer:	a	review	of	the	literature.	Korean	journal	of	urology.	2014;55(7):436-45.	
22.	 Link	 RE,	 Shariat	 SF,	 Nguyen	 CV,	 Farr	 A,	 Weinberg	 AD,	 Morton	 RA,	 et	 al.	 Variation	 in	
prostate	specific	antigen	results	from	2	different	assay	platforms:	clinical	impact	on	2304	patients	
undergoing	prostate	cancer	screening.	The	Journal	of	urology.	2004;171(6	Pt	1):2234-8.	
23.	 Aboud	OA,	Weiss	RH.	New	opportunities	from	the	cancer	metabolome.	Clinical	chemistry.	
2013;59(1):138-46.	
24.	 Monteiro	 MS,	 Carvalho	 M,	 Bastos	 MdL,	 Pinho	 PG.	 Potentiality	 of	 volatile	 organic	
compounds	to	discriminate	patients	with	cancer	by	using	chemometric	tools.	 	 Identification	and	
Data	Processing	Methods	in	Metabolomics.	Future	Science	Book	Series:	Future	Science	Ltd;	2015.	
p.	166-84.	
25.	 Cuperlovic-Culf	M,	Barnett	DA,	Culf	AS,	 Chute	 I.	 Cell	 culture	metabolomics:	 applications	
and	future	directions.	Drug	discovery	today.	2010;15(15-16):610-21.	
26.	 Halama	A.	Metabolomics	in	cell	culture--a	strategy	to	study	crucial	metabolic	pathways	in	
cancer	 development	 and	 the	 response	 to	 treatment.	 Archives	 of	 biochemistry	 and	 biophysics.	
2014;564:100-9.	
27.	 Zhang	A,	Sun	H,	Xu	H,	Qiu	S,	Wang	X.	Cell	metabolomics.	Omics	:	a	journal	of	integrative	
biology.	2013;17(10):495-501.	
28.	 Keshari	KR,	Sriram	R,	Van	Criekinge	M,	Wilson	DM,	Wang	ZJ,	Vigneron	DB,	et	al.	Metabolic	
reprogramming	and	validation	of	hyperpolarized	13C	lactate	as	a	prostate	cancer	biomarker	using	
a	human	prostate	tissue	slice	culture	bioreactor.	The	Prostate.	2013;73(11):1171-81.	
29.	 Schmidt	 K,	 Podmore	 I.	 Current	 Challenges	 in	 Volatile	 Organic	 Compounds	 Analysis	 as	
Potential	Biomarkers	of	Cancer.	Journal	of	biomarkers.	2015;2015:981458.	
30.	 Shirasu	M,	 Touhara	 K.	 The	 scent	 of	 disease:	 volatile	 organic	 compounds	 of	 the	 human	
body	related	to	disease	and	disorder.	Journal	of	biochemistry.	2011;150(3):257-66.	
31.	 Li	J,	Peng	Y,	Liu	Y,	Li	W,	Jin	Y,	Tang	Z,	et	al.	Investigation	of	potential	breath	biomarkers	for	
the	early	diagnosis	of	breast	cancer	using	gas	chromatography-mass	spectrometry.	Clinica	chimica	
acta;	international	journal	of	clinical	chemistry.	2014;436:59-67.	
32.	 Poli	D,	Goldoni	M,	Corradi	M,	Acampa	O,	Carbognani	P,	Internullo	E,	et	al.	Determination	
of	aldehydes	 in	exhaled	breath	of	patients	with	 lung	cancer	by	means	of	on-fiber-derivatisation	
SPME-GC/MS.	 Journal	 of	 chromatography	 B,	 Analytical	 technologies	 in	 the	 biomedical	 and	 life	
sciences.	2010;878(27):2643-51.	
	113	
	
33.	 Leunis	N,	Boumans	ML,	Kremer	B,	Din	S,	Stobberingh	E,	Kessels	AG,	et	al.	Application	of	an	
electronic	nose	 in	 the	diagnosis	of	head	and	neck	cancer.	The	Laryngoscope.	2014;124(6):1377-
81.	
34.	 Kumar	S,	Huang	J,	Abbassi-Ghadi	N,	Spanel	P,	Smith	D,	Hanna	GB.	Selected	ion	flow	tube	
mass	 spectrometry	 analysis	 of	 exhaled	 breath	 for	 volatile	 organic	 compound	 profiling	 of	
esophago-gastric	cancer.	Analytical	chemistry.	2013;85(12):6121-8.	
35.	 Abaffy	 T,	 Moller	 MG,	 Riemer	 DD,	 Milikowski	 C,	 DeFazio	 RA.	 Comparative	 analysis	 of	
volatile	 metabolomics	 signals	 from	 melanoma	 and	 benign	 skin:	 a	 pilot	 study.	 Metabolomics.	
2013;9(5):998-1008.	
36.	 Altomare	DF,	Di	Lena	M,	Porcelli	F,	Trizio	L,	Travaglio	E,	Tutino	M,	et	al.	Exhaled	volatile	
organic	 compounds	 identify	 patients	 with	 colorectal	 cancer.	 The	 British	 journal	 of	 surgery.	
2013;100(1):144-50.	
37.	 Mochalski	P,	Sponring	A,	King	J,	Unterkofler	K,	Troppmair	J,	Amann	A.	Release	and	uptake	
of	volatile	organic	compounds	by	human	hepatocellular	carcinoma	cells	(HepG2)	in	vitro.	Cancer	
cell	international.	2013;13(1):72.	
38.	 Monteiro	M,	Carvalho	M,	Henrique	R,	Jeronimo	C,	Moreira	N,	de	Lourdes	Bastos	M,	et	al.	
Analysis	 of	 volatile	 human	 urinary	 metabolome	 by	 solid-phase	microextraction	 in	 combination	
with	gas	chromatography-mass	spectrometry	for	biomarker	discovery:	application	in	a	pilot	study	
to	discriminate	patients	with	renal	cell	carcinoma.	European	journal	of	cancer.	2014;50(11):1993-
2002.	
39.	 Fu	XA,	Li	M,	Knipp	RJ,	Nantz	MH,	Bousamra	M.	Noninvasive	detection	of	lung	cancer	using	
exhaled	breath.	Cancer	medicine.	2014;3(1):174-81.	
40.	 Amal	 H,	 Ding	 L,	 Liu	 BB,	 Tisch	 U,	 Xu	 ZQ,	 Shi	 DY,	 et	 al.	 The	 scent	 fingerprint	 of	
hepatocarcinoma:	 in-vitro	 metastasis	 prediction	 with	 volatile	 organic	 compounds	 (VOCs).	
International	journal	of	nanomedicine.	2012;7:4135-46.	
41.	 Arasaradnam	RP,	McFarlane	MJ,	Ryan-Fisher	C,	Westenbrink	E,	Hodges	P,	Thomas	MG,	et	
al.	Detection	of	colorectal	cancer	(CRC)	by	urinary	volatile	organic	compound	analysis.	PloS	one.	
2014;9(9):e108750.	
42.	 Kumar	 S,	Huang	 J,	 Cushnir	 JR,	 Spanel	 P,	 Smith	D,	Hanna	GB.	Selected	 ion	 flow	 tube-MS	
analysis	of	headspace	vapor	 from	gastric	content	 for	 the	diagnosis	of	gastro-esophageal	cancer.	
Analytical	chemistry.	2012;84(21):9550-7.	
43.	 de	Meij	TG,	Larbi	IB,	van	der	Schee	MP,	Lentferink	YE,	Paff	T,	Terhaar	Sive	Droste	JS,	et	al.	
Electronic	nose	 can	discriminate	 colorectal	 carcinoma	and	advanced	adenomas	by	 fecal	 volatile	
biomarker	analysis:	proof	of	principle	study.	International	journal	of	cancer	Journal	international	
du	cancer.	2014;134(5):1132-8.	
44.	 Steve	Smith	PW,	Jemma	Redding,	Norman	M.	Ratcliffe,	and	Chris	S.	J.	Probert.	Application	
of	 Similarity	 Coefficients	 to	 Predict	 Disease	 Using	 Volatile	 Organic	 Compounds.	 IEEE	 SENSORS	
JOURNAL.	2010;10:92	-	6.	
45.	 Wang	JH,	Byun	J,	Pennathur	S.	Analytical	approaches	to	metabolomics	and	applications	to	
systems	biology.	Seminars	in	nephrology.	2010;30(5):500-11.	
46.	 Lenz	EM,	Wilson	ID.	Analytical	strategies	in	metabonomics.	Journal	of	proteome	research.	
2007;6(2):443-58.	
47.	 Márcia	 Sá	M,	Márcia	 C,	Maria	 de	 Lourdes	B,	 Paula	Guedes	de	P.	 Potentiality	 of	 volatile	
organic	 compounds	 to	 discriminate	 patients	 with	 cancer	 by	 using	 chemometric	 tools.		
Identification	and	Data	Processing	Methods	in	Metabolomics.	Future	Science	Book	Series:	Future	
Science	Ltd;	2015.	p.	166-84.	
	114	
	
48.	 Mastrangelo	A,	 Ferrarini	 A,	 Rey-Stolle	 F,	Garcia	 A,	 Barbas	 C.	 From	 sample	 treatment	 to	
biomarker	 discovery:	 A	 tutorial	 for	 untargeted	metabolomics	 based	 on	GC-(EI)-Q-MS.	 Analytica	
chimica	acta.	2015;900:21-35.	
49.	 Pluskal	 T,	 Castillo	 S,	 Villar-Briones	 A,	 Oresic	 M.	 MZmine	 2:	 modular	 framework	 for	
processing,	 visualizing,	 and	 analyzing	 mass	 spectrometry-based	 molecular	 profile	 data.	 BMC	
bioinformatics.	2010;11:395.	
50.	 Berben	 L,	 Sereika	 SM,	 Engberg	 S.	 Effect	 size	 estimation:	 methods	 and	 examples.	
International	journal	of	nursing	studies.	2012;49(8):1039-47.	
51.	 Graca	G,	Duarte	 IF,	Barros	AS,	Goodfellow	BJ,	Diaz	SO,	Pinto	 J,	et	al.	 Impact	of	prenatal	
disorders	 on	 the	 metabolic	 profile	 of	 second	 trimester	 amniotic	 fluid:	 a	 nuclear	 magnetic	
resonance	metabonomic	study.	Journal	of	proteome	research.	2010;9(11):6016-24.	
52.	 Marcias	G,	Erdmann	E,	Lapouge	G,	Siebert	C,	Barthelemy	P,	Duclos	B,	et	al.	Identification	
of	 novel	 truncated	 androgen	 receptor	 (AR)	 mutants	 including	 unreported	 pre-mRNA	 splicing	
variants	 in	 the	 22Rv1	 hormone-refractory	 prostate	 cancer	 (PCa)	 cell	 line.	 Human	 mutation.	
2010;31(1):74-80.	
53.	 Wishart	 DS,	 Tzur	 D,	 Knox	 C,	 Eisner	 R,	 Guo	 AC,	 Young	 N,	 et	 al.	 HMDB:	 the	 Human	
Metabolome	Database.	Nucleic	acids	research.	2007;35(Database	issue):D521-6.	
54.	 Wishart	 DS,	 Jewison	 T,	 Guo	 AC,	Wilson	M,	 Knox	 C,	 Liu	 Y,	 et	 al.	 HMDB	 3.0--The	Human	
Metabolome	Database	in	2013.	Nucleic	acids	research.	2013;41(Database	issue):D801-7.	
55.	 Wishart	DS,	Knox	C,	Guo	AC,	Eisner	R,	Young	N,	Gautam	B,	et	al.	HMDB:	a	knowledgebase	
for	the	human	metabolome.	Nucleic	acids	research.	2009;37(Database	issue):D603-10.	
56.	 Dunja	 Zimmermann	 MH,	 Mary	 Pat	 Moyer,	 Jurgen	 Nolte,	 and	 Jorg	 Ingo	 Baumbach.	
Determination	 of	 volatile	 products	 of	 human	 colon	 cell	 line	 metabolism	 by	 GC/MS	 analysis.	
Metabolomics.	2007;3:13-7.	
57.	 Sponring	A,	Filipiak	W,	Ager	C,	Schubert	J,	Miekisch	W,	Amann	A,	et	al.	Analysis	of	volatile	
organic	compounds	(VOCs)	in	the	headspace	of	NCI-H1666	lung	cancer	cells.	Cancer	biomarkers	:	
section	A	of	Disease	markers.	2010;7(3):153-61.	
58.	 Wojciech	 F,	 Pawel	M,	 Anna	 F,	 Clemens	 A,	 Raquel	 C,	 Davis	 CE,	 et	 al.	 A	 compendium	 of	
volatile	organic	compounds	(VOCs)	released	by	human	cell	lines.	Curr	Med	Chem.	2016.	
59.	 Filipiak	 W,	 Sponring	 A,	 Mikoviny	 T,	 Ager	 C,	 Schubert	 J,	 Miekisch	 W,	 et	 al.	 Release	 of	
volatile	 organic	 compounds	 (VOCs)	 from	 the	 lung	 cancer	 cell	 line	 CALU-1	 in	 vitro.	 Cancer	 cell	
international.	2008;8:17.	
60.	 Davies	 MP,	 Barash	 O,	 Jeries	 R,	 Peled	 N,	 Ilouze	 M,	 Hyde	 R,	 et	 al.	 Unique	 volatolomic	
signatures	of	TP53	and	KRAS	in	lung	cells.	British	journal	of	cancer.	2014;111(6):1213-21.	
61.	 Haick	 H,	 Broza	 YY,	 Mochalski	 P,	 Ruzsanyi	 V,	 Amann	 A.	 Assessment,	 origin,	 and	
implementation	of	breath	volatile	cancer	markers.	Chemical	Society	reviews.	2014;43(5):1423-49.	
62.	 Hakim	 M,	 Broza	 YY,	 Barash	 O,	 Peled	 N,	 Phillips	 M,	 Amann	 A,	 et	 al.	 Volatile	 organic	
compounds	 of	 lung	 cancer	 and	 possible	 biochemical	 pathways.	 Chemical	 reviews.	
2012;112(11):5949-66.	
63.	 Zhang	Y,	Gao	G,	Liu	H,	Fu	H,	Fan	J,	Wang	K,	et	al.	 Identification	of	volatile	biomarkers	of	
gastric	cancer	cells	and	ultrasensitive	electrochemical	detection	based	on	sensing	interface	of	Au-
Ag	alloy	coated	MWCNTs.	Theranostics.	2014;4(2):154-62.	
64.	 Wallqvist	 A,	Monks	 A,	 Rabow	AA,	 Thanki	 N,	 Shoemaker	 RH,	 Covell	 DG.	Mining	 the	NCI	
screening	database:	explorations	of	agents	involved	in	cell	cycle	regulation.	Progress	in	cell	cycle	
research.	2003;5:173-9.	
65.	 Peng	G,	Hakim	M,	Broza	YY,	Billan	S,	Abdah-Bortnyak	R,	Kuten	A,	et	al.	Detection	of	lung,	
breast,	colorectal,	and	prostate	cancers	from	exhaled	breath	using	a	single	array	of	nanosensors.	
British	journal	of	cancer.	2010;103(4):542-51.	
	115	
	
66.	 Struck-Lewicka	W,	Kordalewska	M,	Bujak	R,	Yumba	Mpanga	A,	Markuszewski	M,	Jacyna	J,	
et	 al.	 Urine	 metabolic	 fingerprinting	 using	 LC-MS	 and	 GC-MS	 reveals	 metabolite	 changes	 in	
prostate	cancer:	A	pilot	study.	Journal	of	pharmaceutical	and	biomedical	analysis.	2015.	
67.	 Wu	H,	Liu	T,	Ma	C,	Xue	R,	Deng	C,	Zeng	H,	et	al.	GC/MS-based	metabolomic	approach	to	
validate	 the	 role	 of	 urinary	 sarcosine	 and	 target	 biomarkers	 for	 human	 prostate	 cancer	 by	
microwave-assisted	derivatization.	Analytical	and	bioanalytical	chemistry.	2011;401(2):635-46.	
68.	 Kwak	 J,	 Gallagher	M,	 Ozdener	MH,	Wysocki	 CJ,	 Goldsmith	 BR,	 Isamah	 A,	 et	 al.	 Volatile	
biomarkers	from	human	melanoma	cells.	Journal	of	chromatography	B,	Analytical	technologies	in	
the	biomedical	and	life	sciences.	2013;931:90-6.	
69.	 Zang	X,	Jones	CM,	Long	TQ,	Monge	ME,	Zhou	M,	Walker	LD,	et	al.	Feasibility	of	detecting	
prostate	 cancer	 by	 ultraperformance	 liquid	 chromatography-mass	 spectrometry	 serum	
metabolomics.	Journal	of	proteome	research.	2014;13(7):3444-54.	
70.	 Pereira	 DM,	 Vinholes	 J,	 de	 Pinho	 PG,	 Valentao	 P,	 Mouga	 T,	 Teixeira	 N,	 et	 al.	 A	 gas	
chromatography-mass	 spectrometry	multi-target	method	 for	 the	 simultaneous	analysis	of	 three	
classes	of	metabolites	in	marine	organisms.	Talanta.	2012;100:391-400.	
71.	 Costello	 LC,	 Franklin	 RB.	 Concepts	 of	 citrate	 production	 and	 secretion	 by	 prostate.	 1.	
Metabolic	relationships.	The	Prostate.	1991;18(1):25-46.	
72.	 Costello	 LC,	 Franklin	 RB.	 Prostatic	 fluid	 electrolyte	 composition	 for	 the	 screening	 of	
prostate	cancer:	a	potential	solution	to	a	major	problem.	Prostate	cancer	and	prostatic	diseases.	
2009;12(1):17-24.	
73.	 Pertega-Gomes	 N,	 Baltazar	 F.	 Lactate	 transporters	 in	 the	 context	 of	 prostate	 cancer	
metabolism:	what	do	we	know?	International	 journal	of	molecular	sciences.	2014;15(10):18333-
48.	
74.	 Ramautar	R,	Berger	R,	van	der	Greef	J,	Hankemeier	T.	Human	metabolomics:	strategies	to	
understand	biology.	Current	opinion	in	chemical	biology.	2013;17(5):841-6.	
75.	 Lucarelli	G,	Rutigliano	M,	Galleggiante	V,	Giglio	A,	Palazzo	S,	Ferro	M,	et	al.	Metabolomic	
profiling	 for	 the	 identification	 of	 novel	 diagnostic	markers	 in	 prostate	 cancer.	 Expert	 review	 of	
molecular	diagnostics.	2015;15(9):1211-24.	
76.	 Wang	Q,	Hardie	RA,	Hoy	AJ,	van	Geldermalsen	M,	Gao	D,	Fazli	L,	et	al.	Targeting	ASCT2-
mediated	glutamine	uptake	blocks	prostate	cancer	growth	and	tumour	development.	The	Journal	
of	pathology.	2015;236(3):278-89.	
77.	 Kufe	 DW.	 Mucins	 in	 cancer:	 function,	 prognosis	 and	 therapy.	 Nature	 reviews	 Cancer.	
2009;9(12):874-85.	
78.	 Kohata	 K,	 Abbas	 SA,	Matta	 KL.	 Synthetic	mucin	 fragments:	methyl	 3-O-(2-acetamido-2-
deoxy-beta-D-galactopyranosyl-beta-D-	 3-O-(2-acetamido-2-deoxy-3-O-beta-D-galactopyranosyl-	
beta-D-glucopyranosyl)-beta-D-galactoyranoside.	 pyranosyl)-beta-D-galactopyranoside.	
Carbohydrate	research.	1984;132(1):127-35.	
79.	 Cernei	N,	Heger	Z,	Gumulec	J,	Zitka	O,	Masarik	M,	Babula	P,	et	al.	Sarcosine	as	a	potential	
prostate	 cancer	 biomarker--a	 review.	 International	 journal	 of	 molecular	 sciences.	
2013;14(7):13893-908.	
80.	 Miyagi	Y,	Higashiyama	M,	Gochi	A,	Akaike	M,	Ishikawa	T,	Miura	T,	et	al.	Plasma	free	amino	
acid	 profiling	 of	 five	 types	 of	 cancer	 patients	 and	 its	 application	 for	 early	 detection.	 PloS	 one.	
2011;6(9):e24143.	
81.	 Teahan	O,	Bevan	CL,	Waxman	J,	Keun	HC.	Metabolic	signatures	of	malignant	progression	
in	 prostate	 epithelial	 cells.	 The	 international	 journal	 of	 biochemistry	 &	 cell	 biology.	
2011;43(7):1002-9.	
82.	 Eley	HL,	Russell	ST,	Baxter	JH,	Mukerji	P,	Tisdale	MJ.	Signaling	pathways	initiated	by	beta-
hydroxy-beta-methylbutyrate	to	attenuate	the	depression	of	protein	synthesis	in	skeletal	muscle	
	116	
	
in	 response	to	cachectic	stimuli.	American	 journal	of	physiology	Endocrinology	and	metabolism.	
2007;293(4):E923-31.	
83.	 Thysell	E,	Surowiec	I,	Hornberg	E,	Crnalic	S,	Widmark	A,	Johansson	AI,	et	al.	Metabolomic	
characterization	 of	 human	 prostate	 cancer	 bone	 metastases	 reveals	 increased	 levels	 of	
cholesterol.	PloS	one.	2010;5(12):e14175.	
84.	 Awad	 AB,	 Fink	 CS,	 Williams	 H,	 Kim	 U.	 In	 vitro	 and	 in	 vivo	 (SCID	 mice)	 effects	 of	
phytosterols	 on	 the	 growth	 and	 dissemination	 of	 human	 prostate	 cancer	 PC-3	 cells.	 European	
journal	of	cancer	prevention	:	the	official	journal	of	the	European	Cancer	Prevention	Organisation.	
2001;10(6):507-13.	
85.	 Zhou	 X,	 Mao	 J,	 Ai	 J,	 Deng	 Y,	 Roth	 MR,	 Pound	 C,	 et	 al.	 Identification	 of	 plasma	 lipid	
biomarkers	for	prostate	cancer	by	lipidomics	and	bioinformatics.	PloS	one.	2012;7(11):e48889.	
86.	 Swanson	 MG,	 Keshari	 KR,	 Tabatabai	 ZL,	 Simko	 JP,	 Shinohara	 K,	 Carroll	 PR,	 et	 al.	
Quantification	 of	 choline-	 and	 ethanolamine-containing	 metabolites	 in	 human	 prostate	 tissues	
using	1H	HR-MAS	total	correlation	spectroscopy.	Magnetic	resonance	in	medicine	:	official	journal	
of	the	Society	of	Magnetic	Resonance	in	Medicine	/	Society	of	Magnetic	Resonance	in	Medicine.	
2008;60(1):33-40.	
87.	 Mintz	 A,	Wang	 L,	 Ponde	 DE.	 Comparison	 of	 radiolabeled	 choline	 and	 ethanolamine	 as	
probe	for	cancer	detection.	Cancer	biology	&	therapy.	2008;7(5):742-7.	
88.	 Saylor	PJ,	Karoly	ED,	Smith	MR.	Prospective	study	of	changes	in	the	metabolomic	profiles	
of	 men	 during	 their	 first	 three	 months	 of	 androgen	 deprivation	 therapy	 for	 prostate	 cancer.	
Clinical	 cancer	 research	 :	 an	 official	 journal	 of	 the	 American	 Association	 for	 Cancer	 Research.	
2012;18(13):3677-85.	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
